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ABSTRACT 
 
IMPROVEMENT OF RELEASE CRITERIA FOR IMMEDIATE RELEASE SOLID 
DOSAGE FORMS 
 
 
 
 
By 
Phillip Douglas Lunney 
August 2012 
 
Dissertation supervised by James K. Drennen, Ph.D. 
 Herewith are presented the results of an investigation the statistical power 
of USP compendial release tests and recommended alternatives. 
The U.S. drug supply chain, formerly protected by a closed distribution network, 
is now threatened by the legal and illegal importation of drug products. Whereas quality 
can never be inspected into final products, compendial release standards may represent 
the only valid assessment that products of dubious origin would receive. Reliable tests for 
content uniformity and dissolution are required to protect the safety of the supply chain. 
A study was designed to test the hypothesis that existing compendial tests for content 
uniformity and dissolution would protect the supply chain against substandard and 
counterfeit drugs if basic field tests failed. 
  
 v 
Compendial tests for content uniformity and dissolution were evaluated for 
statistical power using simulation studies. The results revealed that the revised content 
uniformity test, based on tolerance analysis, was subject to an unacceptable level of 
consumers’ risk. The Bergum method proved to be an excellent secondary standard for 
product assessment and is recommended as an alternative to the USP method. 
Simulations with the USP dissolution test revealed significant weaknesses and 
inconsistencies in the test structure. Theoretical models and power assessments 
confirmed that the coverage specification of the dissolution test was an unacceptably high 
50% coverage with 50% confidence. 
A Bayesian D-optimal design program was used to investigate alternative 
methods to improve the coverage capability of the USP dissolution test. The result of this 
program was the identification of two alternatives to the existing USP procedure. The 
first alternative is based on the addition of attribute coverage tests to stages 2 and 3 of the 
USP test, whereas the second alternative is based on the concept of tolerance analysis. 
Validation studies confirmed that both alternatives significantly improved the 
statistical power of the USP dissolution test without increasing the sample size or 
modifying the current three-stage procedure. The attribute test is non-parametric and 
behaves similarly to the existing USP with improved coverage, whereas the continuous 
alternative is more sensitive and is consistent with the recent revisions to the content 
uniformity test. 
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Chapter 1 
 
 
Overview of Compendial Methods 
 
 
1.1 Introduction 
 
The United States benefits from one of the safest drug supply chains in the world. 
This high level of safety was attained through the combined efforts of pharmaceutical 
manufacturing excellence, federal regulatory oversight, and a “closed” distribution 
system that ensure that high standards of safety and efficacy in U.S. pharmaceutical 
products.  
The closed distribution system resulted from massive consolidation among the 
global pharmaceutical producers and wholesale distributors of U.S. pharmaceutical 
products. Between 1975 and 2000, the number of wholesale distributors decreased from 
approximately 200 to fewer than 50. In 2004, the top three of these wholesalers 
accounted for 88% of the entire wholesale drug market [1].  
The safety of the supply chain, however, is now facing new threats, mainly 
through the importation of drug products [2]. In 2003, Congress passed the Medicare 
Prescription Drug, Improvement, and Modernization Act (MMA). One of the provisions 
of the law is that it required the Secretary of the Department of Health and Human 
Services (HHS) to conduct a study on the importation of drugs from foreign supply 
  
 2 
sources. Legalized importation of drugs could create an opening in this closed system and 
pose a threat to the safety of the supply chain. 
The HHS Task Force recognized four categories of “imported drugs”, with 
potentially increasing levels of associated risk. These include: 
1. Drugs manufactured in a foreign FDA-inspected facility with adherence to FDA 
approval standards. 
2. Drugs “re-imported” into the country by the manufacturer under proper controls after 
having been originally manufactured and approved in the U.S.. 
3. Imported drugs manufactured in a foreign facility that also manufactures the U.S.-
approved version. 
4. Unapproved drugs produced in foreign facilities that the FDA has not inspected and 
therefore, has no knowledge or experience with the facility. 
 
 
1.2 The Global Threat of Counterfeit and Substandard Drugs 
 
The risk associated with the importation of drugs from foreign suppliers is the 
accidental or deliberate introduction products of poor or unknown quality into the U.S. 
supply chain, as is currently prevalent in developing countries [3]. Poor drug quality can 
result from poor manufacturing practices, counterfeiting, or inappropriate storage in 
extreme conditions of heat, moisture, or light [4]. 
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The World Health Organization has established two classes of dangerous drugs, 
counterfeit and substandard medicines [5]. A counterfeit drug is “deliberately and 
fraudulently mislabeled with respect to identity and/or source,” whereas substandard 
drugs are genuine medicines produced by legitimate manufacturers that do not meet the 
quality specifications or standards claimed by the producers. Thus, a counterfeit drug is 
always the result of a criminal intention, whereas a substandard drug may be the result of 
poor manufacturing practices or quality control procedures. 
Surveillance studies of poor drug quality in Asia [6] have found that substandard 
products could: 
 Contain no active ingredient, but harmless inactives. 
 Contain harmful or poisonous substances. 
 Be unregistered in the country where it is sold. 
 Have been registered inadvisably by a weak regulatory agency. 
 Have been an otherwise suitable product distributed past its expiration 
date. 
The established characteristics of counterfeit drugs include [7]: 
 Subpotency or super-potency. 
 No active ingredient. 
 Harmful or cross-reactive impurities. 
 No traceability. 
 Unsuitable processing or packaging conditions. 
The scale of counterfeiting activity is difficult to assess, but it has been estimated 
that up to 15% of all drug products are fake, and that this figure exceeds 50% in parts of 
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Africa and Asia [3]. The FDA estimates that counterfeit drugs comprise approximately 
10% of the global medicine market with annual sales in excess of US$ 35 billion [3]. 
Recent research reports indicate that nearly 97% of all international drug products made 
in China are counterfeited by local Chinese companies in spite of protection of these 
products under foreign patent laws [4]. 
The consequences of using poor quality drugs are severe [4]. The primary victims 
of poor quality drugs are the patients, whose health and lives are put at risk when they 
take medicines without the safeguards provided by legitimate pharmaceutical production 
and regulatory control. These products have been associated with serious health 
implications such as treatment failure, adverse reactions, drug resistance [8], and 
increased morbidity and mortality [9-10]. Legitimate manufacturers also suffer, 
particularly from counterfeit products, both in terms of lost revenue and through damage 
to the reputation of the company and its products. 
Several factors have been identified as contributors to the proliferation of fake and 
substandard drugs in developing countries [4]. These include the absence of a strong 
national drug regulatory authority, the lack of protection for intellectual property, weak 
enforcement of existing enforcement codes, and the high cost and erratic supply of 
medicines, which drives demand for these products. 
Additional conditions which threaten the global drug supply chain are the lack of 
control of drugs for export and within free trade zones and trading of pharmaceutical 
products through intermediate countries or trading houses. Pharmaceuticals for export are 
not regulated by many exporting countries to the same standard as those manufactured 
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for domestic use, and counterfeiters are able to introduce fakes into distribution through 
relabeling and repackaging. 
The World Health Organization has made recommendations for consumers of 
drugs, governments, manufacturers and health care professionals to ensure a stable 
supply of safe drugs [11]. Implementation of these recommendations, however, would 
require substantial cultural and legislative changes in the regions where the drug supply is 
currently at greatest risk. The United States Pharmacopeia has recommended field testing 
and sampling of products across the distribution chain as an element of routine quality 
surveillance [4]. 
 
 
1.3 Renewed Importance of Routine Sampling and Testing 
 
Whereas the emphasis of modern manufacturing practices, such as PAT, is on 
prevention of defects through advanced process understanding, as opposed to detection, 
sampling and physical testing could play a significant role in reducing the risk associated 
with opening the pharmaceutical supply chain to imported products. The requirements for 
such a test would include high sensitivity for detecting defective products with a 
reasonable sample size regardless of the distribution of the underlying lot characteristics. 
This latter requirement is particularly important, since product produced in an unknown 
facility without regulatory oversight could not reasonable be expected to display normal 
distributions of quality characteristics. Instead, for these materials, the normal 
distribution would probably be an exceptional occurrence. The threat is that products 
either produced under unknown conditions or released at barely acceptable levels of 
quality standards will enter the commercial U.S. supply chain. 
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Various strategies are now being considered to counter this threat, such as radio 
frequency identification tagging of raw materials used in processing and final products 
distributed to wholesalers. Whereas these technologies are an effective deterrent against 
counterfeit versions of branded drugs, they are not likely to be cost effective for generic 
products. Thus, increased testing of products for quality and safety, especially those 
arriving at a U.S. point of entry, will likely be required in addition to any other solutions 
implemented to counter this threat. 
The United States Pharmacopeia has recommended basic quality control tests that 
could be implemented as a minimum standard to detect substandard and counterfeit drugs 
[12]. These basic tests include: 
 Visual inspection of dosage forms, packaging, coloration, shapes, and 
labeling. 
 A simplified disintegration test of tablets and capsules to assess 
deficiencies related to solubility and availability. 
 Qualitative analysis for active ingredients using simple reagents that 
change color upon exposure to the drug. 
 Thin layer chromatography assays for a crude estimate of a drug’s 
potency. 
Counterfeit drug makers, however, have improved their products to a level that 
would likely render these simple tests ineffective. Table 1.1 is a reproduction of a table 
contained in the Health and Human Services report on drug importation [2] and contains 
the results of tests performed on materials represented and sold as “FDA approved” 
prescription drugs from a bogus internet pharmacy.
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Table 1.1 Test Results for Counterfeit Prescription Drugs obtained from an Internet 
Pharmacy 
 Drug Function  
Test Sleep Aid Statin 
Erectile 
Disfunction 
Drug Present Pass Pass Pass 
Potency Fail Fail Fail 
Dissolution Pass Fail Fail 
Purity Pass Fail Fail 
 
Note that all counterfeit products sampled by the FDA contained the active 
ingredient but failed on other criteria. If these results are representative of counterfeit 
products, then a simple field test to detect the presence or absence of active ingredients 
would not be an effective screening tool for suspect materials. At a minimum, tests for 
content uniformity and dissolution would be required for this purpose. 
 
 
1.4 USP-NF Standards 
 
The United States Pharmacopeial Convention, Inc. or “USP” is the publisher of 
the United States Pharmacopeia-National Formulary (USP-NF). The first USP document 
was published in 1820 and began as a “recipe” book to promote uniformity in drugs that 
were generally available in the United States at that time [13]. Currently, the USP-NF is 
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published annually and updated with two supplements between publications. The purpose 
of the USP-NF is to provide a single standard for medicines used in the United States to 
ensure product uniformity and quality. 
The Federal Food, Drug and Cosmetic Act (FDCA) recognized the USP-NF as 
the official compendia of the United States [14]. The FDCA states that drugs in the 
United States included in the USP-NF must adhere to compendial standards for quality, 
purity, and strength. USP Chapter <905> addresses the assessment of content uniformity, 
whereas Chapter <711> defines the requirements for dissolution of immediate release 
solid oral dosage forms.  
 
 
1.5 Compendial Tests for Content Uniformity 
 
Content uniformity is one test in a series of tests in a therapeutic product 
specification that assesses the quality of a batch. Content uniformity testing is intended to 
assure that the strength of a therapeutic product remains within specified acceptance 
limits [15]. Prior to 2007, several different approaches were applied to content uniformity 
by various agencies. The two basic classes of content uniformity tests consisted of 
parametric and non-parametric protocols. 
Parametric protocols assume a distribution of underlying product quality, usually 
a normal distribution, whereas nonparametric methods do not assume a product 
distribution. The assumption of normality of the underlying distribution includes 
distributions that can be transformed to a form approaching normality, such as through a 
logarithmic transformation of the raw data. 
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The objective of the parametric tests is to construct a statistical tolerance interval 
and utilize it to predict what percentage of the batch falls within a certain interval for a 
given level of certainty. Three decisions are required to assess content uniformity using a 
tolerance interval approach:  
1. The acceptable tolerance limits with respect to a target specification, such as 85-
115% of the label claim.  
2. The minimum proportion “p” of the batch that should fall between these limits, e.g., 
90%, also known as the “coverage” specification.  
3. The degree of confidence needed to reach a decision or “confidence level,” typically 
95%. 
For non-parametric approaches, conformance is determined by the count of assay values 
that fall within a specified acceptance region, irrespective of the actual values. At least 
nine draft or regulatory non-parametric approaches to content uniformity were 
inexistence in 2002 [15], including two procedures in the USP-NF. The advantage of the 
parametric approach over non-parametric methods is that it makes an inference about 
batch quality based on all of the observations, as opposed to the individual sample values. 
Parametric methods are thus statistical generalizations, similar to the process capability 
metrics employed to assess process capability. 
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A characteristic of all parametric and non-parametric methods in use up to 2002 
was that they were two-stage tests. If the results were initially positive in the first stage or 
tier of testing, the testing stopped with a passing result. The initial stages of the multiple 
tier tests were considered as interim analyses [15], a viewpoint that probably evolved 
from similar strategies used to control the Type I error rate for clinical trials [16-17].  
Content uniformity tests also included a “safety net” or a test for outliers. The 
safety net was a provision that precluded any single dose from exceeding an extended 
label claim. In addition to the acceptance criteria of 85-115%, USP<905> included a 
safety net of 75-125% at both tiers for most dosage forms. These safety limits have been 
criticized and compared to “zero-tolerance” criteria used in quality control inspection 
plans [18]. The arguments presented here are that zero-tolerance specifications do not 
ensure or improve quality, but merely compound the existing testing and regulatory 
burdens of the pharmaceutical manufacturing industries. 
A driving force for standardization of content uniformity testing resulted from the 
International Conference on Harmonization [19]. The Japanese Pharmacopeia adopted a 
parametric content uniformity “test by variables” in 1996 [20] and petitioned the USP to 
consider it in the harmonization process [21]. The parametric test by variables was based 
on the tolerance interval concept and was based on the test statistic 
ksXM           (1.1) 
where M is the label claim for content uniformity, X  and s are the mean and standard of 
the data collected from stages 1 and 2, and k was the tolerance factor. The value of k was 
dependent on the stage of the test, having a value of 2.2 for stage 1 and 1.9 for stage 2. 
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The USP adopted this concept but modified the Japanese criteria to align producer 
and consumer risks to the existing USP method [19, 22-23]. The revised USP method for 
content uniformity became official on January 1, 2007 through the Sixth Interim Revision 
Announcement to USP29-NF24 in Pharmacopeial Forum [24]. The revised content 
uniformity test is illustrated in Figure 1.1. 
Stage 1 Criterion Stage 2 Criteria 
Assay 10 units. The result is “pass” if the 
following acceptance criterion is met: 
(otherwise “fail”) 
Assay 20 additional units. The result is  
„pass” if for all 30 units, the following 
two criteria are met: (otherwise “fail”)  
1. 14.2 LsXMAV   1. 10.2 LsXMAV   
2.  
 
 MLX
MLX
01.021
01.021
max
min


and 
Where M = reference value, s=standard deviation, X = content uniformity sample mean, 
Xmin and Xmax are the observed minimum and maximum values. 
Default values for L1 and L2 are 15.0 and 25.0, respectively. 
Reference Value Determination, M 
Target Claim, % of LC 
ObservedX  ,% of LC M 
5.98  98.5 
5.1015.98  X  X  
 
5.101  
>101.5 101.5 
5.98  98.5 
TX 5.98  X  
 
      >101.5 
>T T 
 
 
 
Figure 1.1 Revised USP Content Uniformity Test 
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The probability details of the test structure will be discussed in Chapter 3 as part 
of the simulation study. Basically, the revised protocol consists of two stages, the first 
requiring a sample size of 10 units. The second stage, if required, requires 20 additional 
units. No rational basis exists for these sample sizes other than historical precedence. A 
common statistical rule of thumb, however, is that a minimum of 30 individual values are 
necessary to estimate the population parameters (mean and standard deviation) for a 
normal distribution.  
The test statistic for the revised content uniformity test is an “Acceptance Value” 
AV that is based on the tolerance interval concept introduced by the Japanese 
Pharmacopeial Forum. A passing result is obtained at stage 1 if the sum of the absolute 
difference between the observed mean and reference value M form an interval that is less 
than or equal to 2.4 standard deviations of the acceptance value L1.  
The manufacturer can specify the value of L1 in a monograph submission, but the 
test default value is 15. Note that this default value represents the 15% interval that 
formed the previous content uniformity stage 1 acceptance criteria, 85-115%. Similarly, 
the L2 default value for stage 2 represents the span of the previous safety net limits, 75-
125%.  
The values for the mean and standard deviation are based on the first 10 values 
for stage 1, but all 30 values are used for stage 2. Thus, the revised test makes maximum 
use of the collected data. 
The value of M, used as a reference for calculation of the tolerance, depends on 
the target claim for the drug and the observed mean. If the label claim for the product is 
less than 101.5, then M becomes the observed mean if it falls between 98.5-101.5%. If 
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the observed mean exceeds 101.5, M assumes the maximum reference value of 101.5. 
Alternatively, if the observed mean is less than 98.5% of the label claim, M assumes a 
minimum value of 98.5%. If the label claim for content uniformity exceeds 101.5%, then 
the minimum and maximum values of M are 98.5% and the label claim T, respectively. 
A final noteworthy feature of the revised content uniformity test is that it retains 
the safety net provision in a slightly modified form. Thus, no individual unit may be less 
than or greater than 25% of the reference value, assuming a default value of L2 equal to 
25. 
In comparison to previous versions, the current USP content uniformity test is 
rather complex. The USP issued an official computer program, based on Microsoft Excel, 
to facilitate implementation of the revised method [25]. 
 
 
1.6 Dissolution  
 
Dissolution rate is defined as the amount of drug substance that goes into solution 
per unit time under standardized conditions of liquid-solid interface, temperature and 
media composition [26]. In addition to being a compendial release requirement, 
dissolution testing is important as a tool for formulation development and routine control 
of the manufacturing process. 
Dissolution testing evolved from the disintegration test, an early compendial 
requirement to ensure that solid dosage forms would dissolve effectively in the 
alimentary tract. Disintegration tests became official in the United States Pharmacopeia 
in 1950 following general acceptance of the principle that a solid dosage form must first 
disintegrate into small aggregates prior to absorption [27]. The approved apparatus for 
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the disintegration test consisted of six vertical tubes, approximately one inch in diameter, 
arranged in a rack with a 10-mesh screen at one end. 
In a typical disintegration test, six tablets were placed in the vertical tubes and 
were agitated in a reciprocating motion while immersed in water or simulated gastric 
fluid at 37 
◦
C. Mechanical agitation of the assembly with a plastic “hammer” was 
employed to facilitate the disintegration process. A disintegration test was considered 
successful if no visible mass from the tablet remained on the 10-mesh screen after a 
specific period of time, such as 30 minutes for ordinary immediate release tablets. 
By the early 1960s, it was recognized that disintegration was only indirectly 
related to drug bioavailability and product performance, and that a more discriminating 
test was needed for immediate-release solid dosage forms [27]. The mechanism for 
dissolution, or the process through which the active ingredient became available for 
absorption, was proposed to proceed through the mechanism outlined in Figure 1.2 [28]. 
 
Figure 1.2 Mechanism for Drug Release from a Solid Dosage Form 
Aggregates or 
Granules 
Fine Particles 
Solid Dosage Form 
Dissolution Absorption 
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The mechanism proposed in Figure 1.2 illustrates a multi-step process in which 
the solid dosage form breaks apart to form aggregates or granules less than 2 microns in 
diameter. This step is followed by the formation of fine particles generally less than 0.25 
microns in diameter. The initial stage of this mechanism for dissolution corresponds to 
the rate of disintegration and explains why a test for disintegration does not necessarily 
provide any indication of bioavailabilty. The transport of the active ingredient from the 
solid phase into the aqueous solution can occur at any of these stages, but is favored by 
the increase of surface area that follows disintegration of the dosage form. This is 
explained by the equation for steady state dissolution through a diffusion-controlled 
mechanism proposed by Noyes and Whitney in 1897, expressed as equation 1.2, 
 CC
Vh
DS
dt
dC
s          (1.2) 
where t is time in seconds, D is the diffusion coefficient in cm
2
/sec, S is the surface area 
of the drug in cm
2
, V is the volume of solution in cm
3
, h is the theoretical film thickness 
in cm, representing the resistance of drug to dissolution, Cs is the aqueous solubility of 
the drug in g/cm
3
 measured under the conditions of the dissolution environment, and C is 
the concentration of the drug in the bulk solution in g/cm
3
. According to equation 1.2, the 
rate of dissolution is favored as the dosage form disintegrates and increases the exposed 
surface area for mass transport of the drug into solution. 
The term represented by the difference between the aqueous solubility of the drug 
and its concentration in solution at time t, Cs –C, represents the concentration “driving 
force” for mass transfer. Thus, highly soluble drugs would be expected to dissolve faster 
than drugs with lower solubility. If the aqueous solubility of the drug is so high such that 
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a single tablet would not likely produce a measurable change in the drug concentration in 
the bulk solution, then “sink” conditions are considered to apply [26]. Under these 
conditions, the expression representing the steady state dissolution simplifies to 
sC
Vh
DS
dt
dC
         (1.3) 
Sink conditions are approximated when the volume of the solution is 5 to 10 times 
greater than the amount corresponding to a saturated solution [26].  
For a specified solid oral dosage form, the dissolution procedure is the primary 
quality control tool in the absence of an in vitro-in vivo correlation [29]. Dissolution, 
however, doesn’t necessarily correlate to bioavailabilty or bioequivalence unless these 
links have been established scientifically [30]. A drug can exhibit high aqueous solubility 
but experience resistance in crossing tissue boundaries of the gastrointenstinal tract. 
Thus, the permeability of the drug is also an important consideration for bioavailabilty of 
an immediate release solid dosage form. 
The Biopharmaceutics Classification System (BCS) was proposed as a basis for 
setting in vitro dissolution specification and can also provide a basis for predicting the 
likelihood of achieving a successful in vivo-in vitro correlation [31]. The four BCS 
classes correspond to 
 Case 1: High solubility – high permeability drugs. 
 Case 2: Low solubility – high permeability drugs. 
 Case 3: High solubility – low permeability drugs. 
 Case 4: Low solubility – low permeability drugs. 
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Under this classification system, the solubility of a drug is determined by 
dissolving the highest unit dose in 250 ml of buffer adjusted to pH between 1.0 and 8.0. 
A drug is considered highly soluble if the dose/solubility volume of solution are less than 
or equal to 250 mL [32]. Drugs are considered highly-permeable when the extent of 
absorption is greater than 90% in the absence of documented instability in the 
gastrointestinal tract or if high permeability has been established experimentally. 
The utility of the BCS system is that it can be used to establish dissolution 
specifications for oral solid dosage forms. The BCS suggests that for case 1 drugs, 85% 
dissolution in 0.1N HCl in 15 minutes can ensure that the bioavailabilty of the drug is not 
limited by dissolution, but instead, gastric emptying [32]. The basis for this assertion is 
that the mean gastric residence time is 15-20 minutes under fasting conditions. Similar 
considerations may also apply to some case 3 drugs. If the dissolution rate, however, is 
significantly longer than 15 minutes, a dissolution profile with multiple time points in 
multimedia is recommended. 
The expectation for case 2 drugs is that the dissolution rate will be the limiting 
step in the drug absorption process, and an in vitro-in vivo correlation should be possible. 
A dissolution profile in multiple media is recommended to establish dissolution 
specifications for case 2 drugs. 
With respect to drugs of high solubility but low permeability (case 3), 
permeability is the expected rate controlling step and a limited IVIC may be possible, 
depending on the relative rates of dissolution and intestinal transport. The expectation for 
case 4 drugs is that the development of a suitable oral dosage form and reasonable 
dissolution specifications would present significant challenges. 
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The FDA guidance describes three categories of dissolution test specification for 
immediate release drug products, including a single point specification for highly soluble 
and rapidly dissolving drug products, two-point specifications for slowly dissolving or 
poorly water soluble drug products, and a dissolution profile comparison to support 
product sameness under SUPAC related changes and waivers for bioequivalence 
requirements [32]. The single-point specification was recommended as a routine quality 
control test and would serve the purpose of developing a test for detecting substandard or 
counterfeit drugs in the distribution chain for immediate release solid oral dosage forms.  
 
 
1.7 Compedial Dissolution Tests for Solid Oral Immediate Release 
Dosage Forms 
 
Monographs in the USP describe the necessary conditions to assess dissolution 
against a release standard criterion. In a typical test, dosage forms would be placed in a 
USP dissolution apparatus and samples withdrawn at specified intervals. The amount of 
material released is usually determined by analytical comparison against a standard. The 
most common method employed for dissolution test analysis is UV spectroscopy. The 
results are interpreted through comparison of the ultimate amount released to the 
specification limit Q, which defines the minimum amount required for a successful 
outcome. As compared to the content uniformity test, which has both upper and lower 
specifications for acceptance, the dissolution specification for an immediate release solid 
oral dosage form is a single lower specification limit. 
Similar to the content uniformity test, the USP method for assessing dissolution 
has been revised several times since its introduction in USP XIX in 1975 [33]. The 
original test was a simple two-stage attribute test with six tablets at each stage, but was 
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revised to a three-stage procedure in 1980 [34]. Whereas the original procedure measured 
acceptance strictly in terms of the lower acceptance limit “Q”, the revised three-stage 
method introduced a critical performance requirement of “Q+5%” at stage 1, a safety net 
limit “Q-15%” at stages 2 and 3, and a comparison of the average dissolution rate at 
stages 2 and 3 to the lower limit, Q. A second safety net limit, “Q-25%”, was added to 
stage 3 of the test in 1990 [35]. 
The current US Pharmacopoeia Chapter <711> includes two procedures for 
dissolution testing of immediate release solid dosage forms, a “Unit Sample” or short 
form and a “Pooled Sample” procedure [36]. The pooled sampling became an official 
method in USP 23 Seventh Supplement with the goal of reducing resource requirements 
of the test without a loss of quality assurance of the method. The Unit Sample procedure 
was selected as the basis for this investigation. The procedure for the unit sample method 
is summarized in Table 1.2. 
 
Table 1.2 Acceptance Table for USP Dissolution <711> Unit Sample Procedure 
 
Stage 
 
Number 
Tested 
 
Acceptance Criteria 
S1 6 Each unit not less than Q + 5%. 
S2 6 Average of 12 units (S1 + S2) is equal to or greater than Q, 
and no unit is less than Q - 15%. 
S3 12 Average of 24 units (S1 + S2 + S3) is equal to or greater 
than Q, not more than two units are less than Q - 15%, 
and no unit is less than Q - 25%. 
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Each stage is performed sequentially until a positive result is achieved or until the 
test ultimately fails at stage 3. In contrast to content uniformity, the multiple samples of 
six units have a rational basis. A typical laboratory apparatus for dissolution testing is 
constructed to perform six replicates of the test simultaneously [26]. 
Chapter <711> does not include a description of the statistical basis for the 
procedures or statistical power curves for the individual stages and overall test, although 
these may be available in the future [37]. The stage 1 attribute test and mean tests for 
stages 2 and 3 were introduced to ensure coverage, i.e., a requirement that a minimum 
percentage the material under consideration meets or exceeds the minimum specification 
for dissolution, Q. The remaining attribute tests employed in stages 2 and 3 were intended 
to detect skewness and extreme values.  
The USP monographs specify the equipment and conditions required for testing 
an immediate release dosage form [36]. The original device approved for dissolution 
testing in 1970 was a basket-stirred-flask test apparatus [27]. This device was 
recommended by the USP-NF Joint Panel on Physiological Availability, formed in 1967 
and 1968, and officially became known as “Apparatus I.” Typical conditions for a 
dissolution test using Apparatus I were a water bath temperature between 36.5-37.5 
◦
C, 
900 mL of media, with basket stirring at 100 revolutions per minute [26]. 
Apparatus 1 required the dosage forms to be placed in the rotating basket, which 
were constructed of 40-mesh, 316 stainless steel wire. The basket was intended to 
constrain the dosage form in order to provide a consistent solid-liquid interface, but 
proved troublesome for dosage forms that formed gummy deposits, which clogged the 
basket, or disintegrated to produce small aggregates capable of passing through the mesh. 
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In these cases, the solid-liquid interface was not reproducible, and the solids were 
exposed to varying hydrodynamic conditions as they floated in the media or deposited on 
the bottom of the flask [26]. 
As would be expected from the Noyes-Whitney equation, dissolution rates varied 
throughout the vessel and produced inconsistent results. This was due to the lack of a 
consistent surface area for dissolution, and the likelihood that suspended particles were 
exposed to non-laminar flow conditions, under which the dissolution rate was no longer 
diffusion controlled, but instead, was increased by turbulent flow within the media in the 
immediate vicinity of the rotating basket [26]. Thus convection, as opposed to diffusion, 
became the dominant mechanism for dissolution for dosage forms which produced 
suspended aggregates. 
Apparatus 2 was introduced to address these issues and became official in 1978 
[27]. Apparatus 2 is a simple modification of Apparatus 1, with the rotating basket 
replaced by a paddle. The advantage of the paddle over the basket is that a disintegrating 
dosage form will produce a reproducible surface area at the bottom of the flask, resulting 
in a reproducible dissolution test. Turbulence is avoided by using a slower rotation rate, 
typically 50 revolutions per minute. 
The USP discouraged the proliferation of test apparatuses beyond the basket and 
paddle [27], but others were introduced to accommodate the development of novel 
dosage forms unsuitable for the basket or paddle methods, such as extended release 
tablets, delayed release tablets, low solubility-high permeability drugs, and novel drug 
release devices, such as transdermal patches. 
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Seven test apparatuses are officially recognized for dissolution testing in Chapter 
<724> of the current USP, “Drug Release” [36]. The FDA, however, strongly 
recommends the use of Apparatus 1 or 2 for immediate release solid oral dosage forms, 
unless they are shown to be unsatisfactory [32]. 
 
 
1.8 Compendial Tests and Release Standards  
 
The USP procedures are not statistical sampling plans, as typically employed in 
clinical trials, but instead represent protocol sampling schemes [38]. In a statistical 
sampling plan, the objective is to characterize a population of interest through statistical 
tests of hypotheses. Determination of the appropriate sample necessary to achieve 
statistical characterization of the population of interest would vary depending upon the 
requirements and objectives of the study. Statistical sampling plans used in surveillance 
and routine sampling are discussed further in section 1.9. 
Protocol sampling plans are designed for decision purposes, and regulations 
specify the sample size and decision process in advance. Once established, a protocol test 
is considered indisputable, regardless of its true underlying statistical power. Protocol 
tests are also referred to as “singlet tests” [39]. 
The characteristics that confirm the USP tests as protocol sampling schemes are 
evident in Figure 1.2 for content uniformity and Table 1.2 for dissolution. The sample 
sizes are thus fixed in advance for each stage with no provision for modification. Further, 
neither scheme provides any details on how these samples should be collected, such as at 
random from a lot under test or in a stratified fashion to capture characteristics at the 
beginning, mid-point and end of the batch. 
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The final confirmation of the USP methods as protocol tests is evident from the 
decision made with respect to the lot. If the sample fails, the lot fails and is rejected [39]. 
If a lot is tested multiple times and fails only once, the lot is again rejected. The 
compendial test is purely a “fitness for use” decision, as opposed to a quality assurance 
assessment [18, 39].  
If there is confusion about the role of compendial tests in quality control, the 
introduction to the revised content uniformity test probably contributed to this state. The 
revision appears to detail a statistical assessment of a lot under test, and not a single 
specimen [40].  
Whereas the compendial tests are required for legal release of materials, 
manufacturers are responsible to develop internal specifications for release. Bergum [41-
43] developed a procedure to construct internal release acceptance criteria for multiple 
stage tests and applied it to the existing USP content uniformity and dissolution 
protocols. The basis of the method, which can be applied to any multiple stage procedure, 
estimates the lower bound probability for acceptance through 
1. Assuming an underlying distribution for the population under investigation. 
2. Specifying a desired passing level and confidence desired for that level of 
coverage, and 
3. Estimating the maximum probability of passing each stage using the specified 
criteria for coverage and confidence for a given sample size. 
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A typical specification for the application of Bergum’s method is a 95% lower 
bound for the probability of passing the test with 95% confidence for a sample size of 30. 
In this case, a successful outcome would be interpreted as follows: the manufacturer 
would be 95% confident of passing repeated multiple stage tests in 95% of all attempts. 
For the case of a lower bound of 95% with 90% confidence, the manufacturer would be 
90% confident of passing 95% of all future tests. Thus, Bergum’s method is a prediction 
of the ultimate outcome of repeated tests based on a single sample. 
The outcome of the Bergum method is an internal release standard based on the 
sample in terms of the mean and maximum allowable standard deviation or coefficient of 
variation. 
The computational requirements of Bergum’s method are demanding, and 
Bergum used SAS to compile tables of acceptance standards for the USP content 
uniformity and dissolution tests [44]. Microsoft Excel versions of Bergum’s method were 
introduced by Cholayudth, initially for content uniformity in 2004 [45] followed by 
dissolution in 2006 [46], extending the capability for the implementation of the method to 
a much broader audience. 
The revision of the content uniformity test, however, has affected this status. 
Bergum updated his method to reflect changes to the method [47]. Cholayudth has since 
updated the Excel program, although it has not yet been validated [48]. 
Regardless of the difference between internal release standards, which are 
optional, and compendial release standards, which are required, the compendial tests will 
serve an important function in protecting the drug supply chain. For a drug product of 
dubious origin or intentional adulteration, the compendial tests may be the only valid 
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independent assessment these products would receive. Thus, the compendial methods 
need to have as much statistical power as possible without overburdening the testing 
requirement for industry or regulatory agencies. 
 
 
1.9 Statistical Sampling Plans for Surveillance and Routine Quality 
Assurance  
 
Whereas the compendial content uniformity and dissolution tests do not specify 
sampling requirements for testing, the FDA strongly encourages statistical sampling 
methods, and it is highly likely that most manufacturers voluntarily comply with this 
request [49]. The USP has also issued guidelines for drug sampling, with particular 
emphasis on securing statistically valid samples for surveillance testing of drug quality 
[50]. 
The application of appropriate sampling procedures is the cornerstone of 
statistical inference, a process through which observations from a sample are extended to 
a general population of observations under the premise that the sample “represents” or 
reflects the population under study. A sample that does not represent the population under 
study produces estimates that are biased and potentially misleading with respect to that 
population. 
The introduction of techniques to enable valid generalizations based on samples 
for populations that would otherwise be too large to characterize through direct 
observation have significantly improved the efficiency and quality of research in both the 
physical and social sciences. The burden of the process, however, lies in obtaining valid 
samples upon which to base inferences. 
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The sampling techniques utilized in sampling of drug products for surveillance 
and quality control include: 
 Convenience samples. 
 Random samples. 
 Representative samples. 
 Stratified samples. 
Convenience sampling is a technique whereby a drug sample for testing is 
obtained directly through ordinary channels, such as a local pharmacy, without any 
attempt to categorize the parent population from which the sample came [51]. In the case 
of a prescription obtained from a local pharmacy, the larger population would be 
represented by the entire lot of product, which may contain 1 or 2 million tablets. 
Whereas the individual prescription came from the parent lot and is a sample from it, this 
single prescription may not be representative of the quality of the entire lot. 
Convenience samples are considered biased and would not likely produce valid 
inferences for a population of tablets. Convenience sampling has been used, however, in 
many studies of counterfeit and substandard drugs [51]. The FDA utilized convenience 
samples when it ordered branded products through an internet pharmacy [2].  
A random sample, collected under conditions such that each member of a 
population under study has an equal chance of being selected for observation, is generally 
used in inferential statistics. The advantage of a random sample over a convenience 
sample is that it is less likely to be biased, and thus, more representative of the population 
under investigation. Random samples have been recommended for surveillance studies of 
drug quality [51]. An example of a random sample for drug quality assessment at the 
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distributor level would be a sample of 30 units taken at large from a warehouse where 
drugs in transit are stored. A single dosage unit would be selected from each package for 
qualitative and quantitative analysis. 
Representative and stratified samples are utilized to assess drug quality at the 
manufacturing level [49]. Dosage forms are typically produced in a continuous filling 
process, which can be sampled periodically to capture a history of the lot from the start of 
the production process to its end. A representative sample would consist of a single tablet 
collected at 30 intervals throughout the dosage form production process. The sample is 
not strictly random, but is more likely to characterize the entire lot than a sample 
collected strictly at random. 
 An alternative approach that a manufacturer may choose to provide additional 
details about the variability of the process over time is stratified sampling. In this case, 
two dosage forms might be collected over 15 time periods to provide a measure of 
process variability during the production process. A measure of process variability is 
provided by the range of the individual measurements collected at the same time interval, 
i.e., the difference between the maximum and minimum values. 
 
 
1.10 Overall Summary and Hypothesis  
 
Clearly, the safety of the drug supply chain is at risk from both counterfeit drugs, 
intentionally introduced by criminal elements, and substandard drugs, which are 
produced by legitimate manufacturers but still pose a threat to the public health. The 
basic quality tests proposed for field surveillance purposes by the USP [12] would not 
detect sophisticated counterfeit products or substandard drugs. Compedial methods for 
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content uniformity and dissolution have been recommended for final assessment of drug 
quality for those cases in which the basic tests are inconclusive [4].The compendial 
methods for content uniformity, however, have not been evaluated for this purpose. The 
statistical basis of the dissolution test is unknown, and its history suggests that statistical 
power was not even a consideration in its design [27]. Indeed, the basis for approval of 
dissolution at stage 1 with a sample of six was “to allow products with optimum in vitro 
performance to pass with a minimum of testing.” 
The hypothesis of this dissertation, stated as a null hypothesis, is that the existing 
USP standards for content uniformity and dissolution, for immediate release solid oral 
dosage forms, are effective in identifying product lots with high levels of non-conforming 
units. The alternative hypothesis is that these procedures are not effective, and thus, 
alternatives are required to protect the supply chain. 
Testing the effectiveness of these procedures using physical methods would 
require considerable resources and thousands of chemical tests. Thus, the only reasonable 
alternative to test these methods is through computer simulation. 
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Chapter 2 
 
 
Simulating the Performance of the Compendial Tests 
 
 
2.1 Introduction 
 
One approach to investigating the statistical power of the content uniformity and 
dissolution is to model the expected behavior of the test and its individual stages directly 
from probability theory. The Bergum method is one example of this approach, but other 
models have been developed along a similar path. 
Chow et. al. [52] developed alternative lower probability bounds for both content 
uniformity and dissolution that were demonstrated to have some superior properties to the 
Bergum method when compared to estimated values obtained through simulation. These 
lower bounds, however, were also obtained through assumption of a normal probability 
distribution. The authors concluded that simulation was too slow and complex to be 
useful for establishing internal release standards. The model for content uniformity was 
not updated by these authors following its revision by the USP. 
Wang [53] introduced a detailed model for the dissolution test that invoked a 
normal distribution and developed a mathematical model to estimate the probability of 
passing the USP test. The prediction from the Wang model is not a lower probability 
bound as provided by the models of Bergum and Chow, but instead is an actual 
prediction of passing the overall dissolution test. The model’s accuracy was dependent on 
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the variability of the population under consideration, and produced biased predictions 
once the standard deviation exceeded a value of 7. 
The Wang model required estimation of an integral function, and thus required 
advanced mathematical software for implementation. This author also considered 
simulation a difficult procedure for estimation of internal specifications. 
Monte Carlo simulation [54] was applied in the testing, but not development of 
these models. But Monte Carlo simulation has several advantages over statistical 
modeling in terms of understanding the statistical power of the compendial methods. First 
of all, Monte Carlo simulation does not require any assumptions about the characteristics 
of the distribution under investigation. Secondly, Monte Carlo simulation can elucidate 
the interactions among stages in multiple stage tests, a consideration that is ignored in 
most models from statistical theory. 
Interaction among stages is a possible outcome from multiple comparisons using 
the same data [16, 55]. The data collected in stage 1 of content uniformity, and in stages 
1, and 2 in dissolution testing, are used in the final stage if the prior results do not 
produce a passing test. The characteristics of these samples, which failed the previous test 
criteria, could likely impact the final outcome in a way that could only be observed 
empirically. 
The barrier to implementing a Monte Carlo simulation of the USP tests was to 
find the right platform that could exploit the public domain computational tools recently 
made available through the efforts of Bergum, Cholayudth and the USP. 
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2.2 Monte Carlo Simulation with Crystal Ball 
 
Crystal Ball version 7.3 was selected as the simulation engine for investigating 
the power of the compendial tests [56]. The software includes a set of applications for 
predictive modeling, optimization, and Monte Carlo simulation. The advantage of Crystal 
Ball over alternative approaches, such as building simulations in commercially available, 
proprietary software, is that it is a spreadsheet-based application that functions as an add-
in for Microsoft Excel. Therefore, the validated spreadsheets for content uniformity and 
the Bergum Method could be incorporated directly as part of the simulation. 
The program includes sub-routines to automatically tabulate any desired results. 
This feature was considered especially useful for tabulating results form individual stages 
of the test simulations, which provide an opportunity to develop powerful interpretations 
and predictive models of the results. 
With respect to its Monte Carlo simulation capability, Crystal Ball utilizes a 
Multiplicative Congruential Generator with a period of length or 2,147,483,646. The 
cycle of random numbers does not repeat until after several billion trials [57]. The 
program also includes options to automatically terminate a simulation in response to 
meeting a predetermined convergence requirement, such as no appreciable change in the 
standard error of the mean between successive trials. This feature was not used in any of 
these simulations, since a balanced estimate of precision was desired for trial 
comparisons. Instead, the trials were run a sufficient number of times to ensure that the 
standard error approached zero to four decimal places, typically 10,000 trials. 
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2.3 Categories of Simulations  
 
Three general types of simulation were executed in this project, depending on the 
objective of the investigation. Each category is described in detail in the following 
sections.  
2.3.1 Simulations with Small Discrete Distributions 
Initial simulations were performed with discrete artificial lots comprised of 
20,000 to 60,000 individual values for content uniformity or dissolution. These lots are 
only considered small with respect to actual pharmaceutical lots, which may contain 
1,000,000 to 2,000,000 tablets [39]. The relatively small size of these artificial 
distributions permitted simulations to be executed rapidly, thus permitting a large number 
of individual populations to be screened. 
From a sampling standpoint, a distribution of tens of thousands of individual 
values is relatively large in comparison to the sample size required for testing, a 
maximum of 30. Thus, the screening results can be considered conservative estimates as 
compared to experiments with full sized lots, since any sample size limitations 
discovered for lots of 60,000 would only be magnified with lots consisting of millions of 
individuals. 
The use of discrete distributions did create an issue with respect to duplicate 
samples, which was successfully addressed by including a sub-routine to search for 
duplicate sample numbers. Samples containing duplicates were discarded for simulation 
purposes. Discrete distributions were constructed to test specific features of the 
compendial methods, particularly their response to non-normal distributions. The 
distributions were created using the random number generators in Microsoft Excel, and 
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each was thoroughly characterized using JMP version 8.0 [58]. The characteristics of 
each distribution tested will be presented in context with the discussion of the simulation 
results.  
2.3.2 Simulations with Built-in Probability Functions 
Crystal Ball includes a number of built-in probability distributions, which 
effectively represent lots of infinite size. These features were used in combination with 
experimental designs conducted to investigate improvements to the USP dissolution test. 
The distributions utilized included normal, beta distributions [59], and uniform 
distributions. A discussion of why these distributions were chosen, and how they could 
arise in practice is presented in Chapter 3 using a common tablet production process as an 
example. 
2.3.3 Simulations with Large Discrete Distributions 
The final validation of a proposed modification of USP <711> was completed 
with a discrete lot containing 1,800,000 values, intended to represent a realistic product 
lot. In this case, the simulator was able to overcome the row limitation of Excel using a 
programming tool. 
Microsoft Excel is limited to approximately 66,000 rows of data, so this also 
represents the maximum size of a discrete lot using a simple vertical lookup function. 
This limitation was overcome in the dissolution final validation series by expanding the 
database horizontally, with each column representing a sub-lot of the parent population. 
The validation lots contained 30 columns of 60,000 dissolution values to produce a parent 
lot with 1,800,000 individual values. 
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In these simulations, Crystal Ball generated a random number for both the sub-lot 
(range 1-30) and tablet number (1-60,000). The database function “VLOOKUP” was 
used to populate the test spreadsheet with the corresponding values. The procedure is 
illustrated in Figure 2.1. 
 
Figure 2.1 Column Expansion Procedure for incorporating large discrete lots 
 
Figure 2.1 demonstrates how the size limitations of Excel were overcome in the 
validation series. The expansion of the database from a single column of 60,000 unique 
values to 30 columns of random numbers overcame the limitation of the Micrsoft Excel 
spreadsheet through the application of a horizontal lookup sub-routine. In this case 
illustrated in Figure 2.1, Crystal Ball generated random tablet and sub-lot numbers of 
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30,733 and 8, respectively. The database function “VLOOKUP” returned a value 
corresponding to the observation in row number 30,733 and column 8, respectively. This 
corresponded to the value of 80.43 which was returned to populate the compendial test 
spreadsheet. 
The disadvantage of this procedure, however, was that it significantly slowed the 
execution speed of the simulation. For this reason, the procedure was reserved only for 
final validation series. 
 
 
2.4 General Considerations 
 
In the initial stage of this project, spreadsheet versions of USP content uniformity 
and dissolution were created and validated against literature values. The validated 
spreadsheet representing the test was copied and used repeatedly for each simulation. 
Databases of discrete lot values, if required, were linked to the compendial spreadsheets 
through relational formulas. 
The USP does not provide guidance on sampling for these tests in the 
monographs. If the simulation was based on discrete lots, a random sample was generated 
based on the maximum number of observations required. For content uniformity, a 
sample of 30 observations was selected at once. The first 10 observations were used as 
the values for stage 1, and the remaining 20 were subsequently used for stage 2, if 
necessary. 
For dissolution testing, a random sample of 24 values was generated at once, and 
the first 6 were tested as Stage 1. Observations 7-12 were treated as stage 2 values, and 
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observations 13-24 were tested as stage 3. Unless otherwise specified, testing was 
terminated at the earliest stage indicating a passing result.
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Chapter 3 
 
 
Simulation Studies for Content Uniformity Tests 
 
 
3.1 Introduction 
 
The original content uniformity test was considered a singlet test, which once 
performed, resulted in a single attribute classification of the material under investigation: 
“pass” or “fail.” Theoretically, the procedure could be repeated an infinite number of 
times with a single failure resulting in possible material recalls or regulatory action. The 
revised procedure’s statistical tolerance concept, however, appears to be intended as an 
inference about the composition range of the material under test.  
A characteristic of the two-stage testing procedure is that the test proceeds to 
stage 2 only if it fails stage 1. Thus, it is possible to pass the test at the first stage based 
on a sample of 10 units, but the test cannot produce a failure unless the combined sample 
of 30 units fails both stages of the test. This presumably skews the test towards favoring 
the producer, increasing risk to the consumer, since there are two ways to pass the test but 
only one outcome that produces a failing result. 
This simulation study was designed to investigate the statistical power of the 
revised content uniformity test against the various types of distributions likely to be 
encountered in practice. Simultaneously, Bergum’s revised acceptance limit procedure 
for 95% probability and 95% confidence was performed as a parametric standard for 
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comparison purposes. In this case, the Bergum method represents a post-release 
evaluation of whether a lot should have been released. 
The simulations were conducted with small, discrete lots of size N=20,000 to 
permit rapid evaluation of as many distributions as possible. The effect of the population 
size relative to the sample size was discussed previously in Section 2.3.1, “Design of a 
Compendial Simulator Tool.” 
Figure 3.1 illustrates the flow chart upon which the simulation was based. The 
process initiated with the selection of a random sample (n=30) from the synthetic lot 
under investigation. The relatively small lot sizes of 20,000 units resulted occasionally in 
duplicate tablet selections, which could not occur in actual practice through random 
sampling without replacement. Thus, a sub-routine was introduced in the sampling phase 
to test the sample validity. Only valid samples without duplicates were submitted for 
stage 1 testing. 
Two tests were performed in stage 1 of the simulation. The first ten tablets were 
processed under the conditions of the revised content uniformity test. A passing result at 
this point was recorded as a “pass,” and the procedure was terminated. Simultaneously, 
the entire sample of 30 units was tested against Bergum’s lot acceptance criteria for 95% 
lower bound and 95% confidence. The revised spreadsheet of Cholyaduth [48] was 
considered for the assessment using the Bergum Method, but was not used due to its un-
validated status. Instead, a table of recently published results for Bergum’s revised 
method [47] representing the desired lower bound and confidence limit was created and 
used for this portion of the test. The Bergum method was not applied in stages, but only 
to the complete sample of 30 observations. 
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The process flow diagram in Figure 3.1 details how the USP simulations were 
conducted. Testing was terminated at Stage 1 if a passing result was observed. Otherwise, 
samples failing stage 1 of the USP test were passed on to stage 2 for final assessment 
using all 30 observations. The final results of each test were tabulated by the Crystal Ball 
application. 
The USP compendial spreadsheet was not included in the simulation, but was 
used to validate the accuracy of the simulator calculations. 
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Figure 3.1 Flow Chart for the Simulation Study 
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3.2 Distributions Selected for Testing 
 
Effective simulation studies for investigating compendial procedures (content 
uniformity or dissolution) need to be based on material characteristics that represent solid 
dosage forms that are likely to be found in pharmaceutical production environments. 
Typically, the normal distribution is selected for this purpose since it is prevalent in 
nature and is a commonly invoked assumption in statistical practice. Actual tablet lots, 
however, could deviate significantly from this assumption. 
Consider the example of a simple powder mixture for direct compression, 
consisting of a minor proportion of active ingredient, with the majority of the formulation 
consisting of a binder, a filler, and a disintegrate. Prior to compression, the formulation 
components would require mechanical mixing.  
Successful mixing of fine pharmaceutical powders is a difficult unit operation and 
perfect homogeneity, as would be possible in the preparation of liquids, is unattainable 
[28]. Instead, it is only possible to achieve a maximum degree of randomness with 
respect to the individual components of the mixture.  
Even if optimal mixing is achieved, the uniformity of the mixture will not be 
perfect, but would vary slightly throughout the composition of the powder bed. In this 
case, the slight differences in the powder bed composition would be expected to produce 
minor and random differences in the observed content uniformity and dissolution 
characteristics of the table. The minor, random changes in composition would likely 
produce a normal distribution of content uniformities and dissolution upon repeated 
testing. 
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If the mixing process is not quite optimal, but instead is conducted such that the 
material is slightly under or over mixed, non-random segregation of the active ingredient 
would exist in the powder bed. In this case, repeated testing would likely reveal a 
departure from normality correlated to the extent of over or under mixing. In this case, a 
skewed distribution of derived properties would be expected for the tablets. Distributions 
that are skewed towards higher or lower values distributions are typically represented by 
lognormal or beta distributions.  
Note that an optimally mixed powder formulation, if allowed to remain at static 
equilibrium for a prolonged period following mixing, would also produce skewed 
distributions if the density differences between the components are significant [28]. In a 
production environment, exposure to vibration from the operation of machinery would 
promote this segregation process.  
If the powder is severely under-mixed, it is likely that the active ingredient would 
be concentrated to a large extent in the vicinity of the mixer into which it was introduced, 
and to a much lesser extent elsewhere throughout the bed. This would likely produce two 
populations of tablets with respect to compendial testing, including a group of tablets 
consisting of low active and high excipient proportions and a contrasting group, 
containing high active and relatively low excipent proportions. 
The expected behavior of a severely under mixed powder blend is a bimodal 
distribution with respect to content uniformity and dissolution. Bimodal distributions can 
also result from blending of discrete tablet formulations with different compositions. The 
bimodal distribution can be considered a special case of the beta distribution in which the 
characteristic parameters defining the distribution, α and β, are equal [59]. 
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If the formulation and mixing processes are poorly controlled such that a broad or 
random distribution of content uniformities are observed, the manufacturer may resort to 
an on-line measurement process to sort and reject tablets that are outside the specification 
range of the compendial test, such as 85-115% of label claim. This scenario would result 
in a distribution of content uniformity and dissolution characteristics that fully occupy the 
specification window to roughly an equal extent, or a uniform distribution. 
In a manufacturing process, the uniform distribution usually results from manual 
inspection and sorting operations. In pharmaceutical products, the uniform distribution 
represents a product of poor quality, inasmuch as the probability of getting a barely 
acceptable dosage form is just as likely as receiving one meeting the label claim. 
For the content uniformity tests, a series of distributions representing normal, 
lognormal, bimodal, and uniform distributions were created to challenge the test 
procedures. An example of each is presented in Figure 3.2. All of the artificial 
distributions share the target label claim of 100%, an upper label claim of 110%, and a 
lower label claim of 90%. 
The target claim of 100% represents an ideal case for content uniformity that a 
counterfeit or substandard drug producer would strive for through post production unit 
operations, such as blending of off-target materials. The revised method, however, would 
not necessarily penalize producers that fell short of this goal. The M parameter or 
reference value becomes the observed mean if it falls between 98.5 to 101.5%. The M 
value becomes 98.5% or 101.5%, however, if the observed mean falls below or above 
these limits, respectively [24]. Thus, shifts in the mean from the target claim would not 
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cause a failure with the revised method unless a substantial proportion of the product is 
outside of the tolerance limits defined by L1 and L2. 
 
 
Figure 3.2 Examples of Test Distributions for the Content Uniformity Simulation 
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The normal distribution is considered to be representative of high quality 
materials manufactured under carefully controlled conditions. For this simulation, 
however, the variability of the lots was increased to produce an increasing level of 
defects, from approximately 0 to 32%. The characteristics of the normal distributions 
tested are presented in Table 3.1 and are arranged in order of increasing non-conformity 
with respect to compendial limits. 
A “defect” corresponds to an observation with a content uniformity outside the 
label claim of 85-115% or beyond the safety net level of 75-125%. Inasmuch as the 
normal distribution is symmetrical, the proportions of non-conforming values as 
measured against either specification are roughly equal. 
Table 3.1 Lot Characteristics of Simulated Normal Distributions  
Population Mean 
Standard 
Deviation 
Maximum 
Value 
Minimum 
Value 
Below 
Label 
Claim, % 
Above 
Label 
Claim, % 
Total 
Defect 
Level, % 
I 100.02 3.39 118.24 86.37 0.17 0.14 0.31 
II 100.00 4.99 120.05 81.29 2.13 2.23 4.36 
III 100.06 6.03 123.05 42.78 4.68 5.11 9.78 
IV 100.00 6.99 128.07 73.81 7.74 7.53 15.27 
V 100.08 8.04 130.73 23.71 10.37 10.89 21.26 
VI 100.01 8.93 136.08 67.50 13.07 13.33 26.40 
VII 99.98 10.09 136.68 4.63 16.22 15.98 32.19 
 
The lognormal distribution is a commonly observed deviation from the normal 
and was selected to investigate the sensitivity of the tolerance interval to extreme values. 
The characteristics of the artificial lots are presented in Table 3.2. The lognormal 
distributions created for this simulation were constructed to challenge the upper and 
lower specifications equally. The skewness of the distribution was also designed to 
challenge the revised content uniformity assumption of normality. 
  
 46 
Table 3.2 Lot Characteristics of Simulated Lognormal Distributions  
Population Mean 
Standard 
Deviation 
Maximum 
Value 
Minimum 
Value 
Below 
Label 
Claim, 
% 
Above 
Label 
Claim, % 
Total 
Defect 
Level, % 
VII 100.04 2.49 110.55 91.07 0.01 0.00 0.01 
VI 100.17 5.03 121.18 62.08 1.78 2.98 4.76 
III 100.18 6.07 124.62 56.43 3.96 5.59 9.55 
II 100.33 7.99 137.82 74.91 9.17 11.69 20.86 
IV 100.39 9.12 162.07 42.39 12.08 14.33 26.40 
V 100.43 9.67 166.47 68.33 13.77 16.06 29.83 
I 100.60 10.13 146.84 38.53 14.35 17.49 31.83 
 
The characteristics of the bimodal distributions appear in Table 3.3. The bimodal 
distributions were included to present extreme values at both label claim limits and to 
represent one possible form of product tampering, “lot blending.” In this scenario, 
finished tablets from two or more non-conforming lots that would otherwise be destroyed 
are instead selectively blended to produce a final lot with “nominally” acceptable 
characteristics.  
A defining characteristic of the bimodal distribution is the relatively low 
proportion of units representing the mean value, which, in this case, is the 100% label 
claim. Bimodal distributions are often mistaken for normal distributions with tests from 
small samples.
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Table 3.3 Lot Characteristics of Simulated Bimodal Distributions 
 
Population 
Mean, 
μ1 
 Mean, 
μ2 
Standard 
Deviation, 
σ1,2 
 Test 
Lot 
Mean 
 Test Lot 
Standard 
Deviation 
Maximum 
Value 
Minimum 
Value 
Total 
Defect 
Level, 
% 
IX 95.00 105.00 3.00 99.97 5.70 110.00 90.00 0.00 
VIII 95.00 105.00 3.00 99.97 5.81 115.37 83.78 4.72 
I 95.00 105.00 3.40 99.97 6.02 116.75 82.28 7.03 
II 95.00 105.00 4.00 99.96 6.37 118.82 80.03 10.52 
III 95.00 105.00 4.50 100.04 6.73 121.51 77.71 13.24 
V 93.00 107.00 3.40 99.98 7.79 118.98 60.58 18.93 
VII 92.50 107.50 3.40 100.04 8.19 125.74 79.44 22.38 
VI 92.00 108.00 3.40 100.00 8.67 121.63 75.58 27.54 
 
The final distributions selected for study, the uniform distributions, are presented 
in Table 3.4. In manufacturing quality control, the uniform distribution represents a 
material of low quality, since there is approximately twice the amount of material just 
meeting the label claims as there is representing the target, 100%. For the purposes of this 
study, the uniform distributions represent the most severe departure from the assumption 
of normality.  
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Table 3.4 Lot Characteristics of Simulated Uniform Distributions 
 
Population Mean 
Standard 
Deviation 
Maximum 
Value 
Minimum 
Value 
Below 
Label 
Claim, 
% 
Above 
Label 
Claim, 
% 
Total 
Defect 
Level, 
% 
I 99.98 5.77 90.00 109.99 0.00 0.00 0.00 
II 99.99 6.30 124.91 75.20 1.00 1.00 2.00 
III 100.00 6.81 124.91 75.20 2.00 2.00 4.00 
IV 100.01 7.28 124.91 75.20 3.00 3.00 6.00 
V 100.02 7.67 124.91 75.20 4.00 4.00 8.00 
VI 100.05 8.07 124.99 75.20 5.00 5.00 10.00 
VII 100.04 9.29 124.99 75.07 8.50 8.50 17.00 
IX 100.05 10.05 124.99 75.07 11.00 11.00 22.00 
X 100.02 10.54 124.99 75.07 12.50 12.50 25.00 
 
 
3.3 Simulation Procedure 
 
The simulations were conducted by specifying 12,000 runs for each test 
distribution, which typically produced over 11,000 valid trials. Probability calculations 
were constructed directly from the Crystal Ball reports. A sample calculation is illustrated 
in Figure 3.3. Figure 3.3 contains a summary of the stage 1 compendial test for lognormal 
distribution III from Table 3.2.  
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Figure 3.3 Stage 1 Summary for Lognormal Distribution III 
 
In this case, the 12,000 simulation trials produced in 11,742 valid samples of 30 
observations for stage 1 testing. These samples passed stage 1 and thus the revised 
content uniformity test 6,469 times, equivalent to a probability of passing stage 1 
PS1 =55.093%         (3.1) 
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The 5,273 samples that failed stage 1 were subsequently tested at stage 2, the 
results of which are illustrated in Figure 3.4.  
 
Figure 3.4 Stage 2 Summary for Lognormal Distribution III 
 
These results indicate that 91.58% (4,829) of the samples that failed stage 1 
subsequently passed stage 2. The probability of a sample at random passing stage 2 given 
that it failed stage 1 is given by equation (3.2) as 
%126.41
742,11
829,4
2 PS        (3.2) 
The overall probability of passing the USP revised content uniformity is the sum 
of these two probabilities, 
 96.219%21  PSPSPpass        (3.3) 
The complement of Ppass is the probability of failing the revised test, 
 3.781%219.96000.100 failP       (3.4) 
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The probability calculations for Bergum’s method are based on the first stage only 
for the entire sample of 30 units and are represented by the equations (3.5) and (3.6). 
%100
total
trials
pass
N
passn
BergumP       (3.5) 
%100
total
trials
fail
N
failn
BergumP       (3.6) 
 
 
3.4 Simulation Results 
 
The tabulated summary of results for the normal distributions is presented in 
Table 3.5. Technically, none of these lots should have passed the inspection tests, since 
all contain tablets exceeding both the upper and lower label claims of 90% and 110%, 
respectively. A graphical display of the final results, plotted as a function of the 
percentage of non-conforming tablets, is presented in Figure 3.5. 
The curves form a familiar pattern for statistical power curves common in quality 
control applications. If 90% power is desired for correct rejection of lots containing 
defects, it is clear that the revised USP method does not achieve this performance level 
until the percentage of defects exceeds 25%, whereas Bergum’s method attains this level 
below 5% defects. 
 
  
 
5
2
 
Table 3.5 Summary of Simulation Results, Normal Distributions 
Population 
Total 
Defect 
Level, % 
% Pass 
Stage I 
% Fail 
Stage 1 
% Pass 
Stage II 
% Fail 
Stage 
II 
Probability 
of Passing, 
% 
Probability 
of Failing, 
% 
No of 
Simulation 
Trials 
Bergum 
% Pass 
Bergum 
% Fail 
I 0.31 99.82 0.18 100.00 0.00 100.00 0.00 11,723 93.32 6.69 
II 4.36 84.86 15.14 99.44 0.06 99.92 0.01 11,732 7.30 92.70 
III 9.78 56.54 43.46 93.24 6.76 97.06 2.94 11,746 0.55 99.45 
IV 15.27 32.55 67.45 63.06 36.94 75.08 24.92 11,724 0.03 99.97 
V 21.26 16.06 83.94 24.99 75.01 37.04 62.96 11,731 0.00 100.00 
VI 26.40 8.45 91.55 7.94 92.06 15.72 84.28 11,769 0.00 100.00 
VII 32.19 3.59 96.41 1.67 98.33 5.20 94.80 11,750 0.00 100.00 
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Figure 3.5 Performance Summary for Normal Distributions 
  
 
5
4
 
0.00
20.00
40.00
60.00
80.00
100.00
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00
P
a
ss
 P
ro
b
a
b
il
it
y
, 
%
Percent Non-conforming
% Pass Stage I
% Pass Stage II
LSL USLTarget
70 80 90 100 110 120 130
 
Figure 3.6 USP Performance of Normal Distributions by Stage 
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Figure 3.6 details the individual results for both stages of the USP method for the 
normal distributions. In this case, the defect percentage is plotted as a function of the 
probability of passing the individual stages. Note that after the 10% defect level, stage 2 
controls the overall test result, since the majority of samples fail stage 1. The proportion 
of samples passing stage 2 remains consistently high until the defect percentage 
approaches the 20% level. After this level, the power of stages 1 and 2 become 
essentially equal. 
The simulation results for the lognormal distributions are presented in Table 3.6 
and are graphically illustrated in Figures 3.7 and 3.8. As expected, these results were 
similar to those obtained for the normal distributions. An expectation from this series of 
simulations, however, was an increased sensitivity at stage 2 of the USP method for 
detecting outliers exceeding the maximum upper limit. This was not apparent from 
Figure 3.8, which details the results of the individual tests. 
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Table 3.6 Summary of Simulation Results, Lognormal Distributions 
Population 
Total 
Defect 
Level, % 
% Pass 
Stage I 
% Fail 
Stage 1 
% Pass 
Stage II 
% Fail 
Stage II 
Probability of 
Passing USP, % 
Probability of 
Failing USP, % 
No. of 
Trials 
Bergum 
% Pass 
Bergum 
% Fail 
VII 0.01 100.00 0.00     100.00 0.00 11,764 100.00 0.00 
VI 4.76 83.70 16.30 99.69 0.31 99.95 0.05 11,748 7.03 92.97 
III 9.55 55.09 44.91 91.58 8.42 96.22 3.78 11,742 0.32 99.68 
II 20.86 16.75 83.25 26.96 73.04 39.20 60.80 11,753 0.00 100.00 
IV 26.40 8.41 91.59 7.52 92.47 15.30 84.70 11,739 0.00 100.00 
V 29.83 5.63 94.37 3.01 96.99 8.48 91.52 11,714 0.00 100.00 
I 31.83 4.01 95.99 1.78 98.22 5.71 94.28 11,727 0.00 100.00 
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Figure 3.7 Performance Summary of Lognormal Distributions 
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Figure 3.8 USP Performance of Lognormal Distributions by Stage 
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Table 3.7 details the simulation results for the series of bimodal distributions, and 
the corresponding power curve is presented in Figure 3.9. Only the initial population 
tested contained a zero defect level and should have passed inspection, assuming non-
parametric bias in the assessments. Note that Bergum’s acceptance test failed all of these 
lots in all but a few cases. 
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Table 3.7 Simulation Results for Bimodal Distributions 
Population 
Total 
Defect 
Level, % 
% Pass 
Stage I 
% Fail 
Stage 1 
% Pass 
Stage II 
% Fail 
Stage II 
Probability of 
Passing USP, % 
Probability of 
Failing USP, % 
No. of 
Trials 
Bergum 
% Pass 
Bergum 
% Fail 
IX 0.00 67.85 32.15 100.00 0.00 100.00 0.00 11,734 0.03 99.97 
VIII 4.72 63.89 36.12 99.86 0.14 99.95 0.05 11,732 0.02 99.98 
I 7.03 54.24 45.76 98.86 1.14 99.48 0.52 11,735 0.00 100.00 
II 10.52 42.47 57.53 92.96 7.04 95.95 4.05 11,733 0.00 100.00 
III 13.24 33.30 66.70 78.12 21.88 85.41 14.59 11,739 0.00 100.00 
V 18.93 5.37 94.63 26.35 73.64 30.31 69.68 11,726 0.00 100.00 
VII 22.38 2.33 97.67 9.46 90.54 11.57 88.43 11,738 0.00 100.00 
VI 27.54 0.88 99.12 1.93 98.06 2.79 97.20 11,738 0.00 100.00 
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Figure 3.9 USP Performance of Bimodal Distributions 
  
  62 
The results for both stages 1 and 2 are presented in Figure 3.10. The results are 
consistent with the results from the previous simulations, which suggested that stage 2 
controls the overall result of the test until the defect level exceeds 15%. 
The USP content uniformity test passed this particular lot 100% of the time, 
providing evidence for the non-parametric bias of the tolerance interval concept. But as 
illustrated in the power curve for failing (Figure 3.9) the revised USP method did not 
become 90% effective in detecting the defective lots until the percentage of defects 
exceeded 20%. The Bergum results were not plotted in this case, since the result was 
essentially 100% failure for all bimodal distributions tested. 
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Figure 3.10 USP Performance for Bimodal Distributions by Stage 
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The simulation results for the uniform distributions are presented in Table 3.8. 
These uniform distributions were created form a parent distribution containing no defects 
(Population I) using the random number generator for uniform distributions in the 
Microsoft Excel data analysis toolkit. The rest of the series was created by “seeding” 
values symmetrically (with replacement) in the ranges from 75-89% and 111-125% into 
this parent population. 
 The results are similar to those for the bimodal distributions and demonstrate a 
contrast between the revised USP and Bergum’s method. Population I, which contained 
no defects, was accepted by the USP method and rejected by Bergum’s acceptance test in 
100% of these 11,035 simulation trials. Moreover, Bergum’s method rejected all sample 
lots representing uniform distributions. This was attributed to the assumption of 
normality with respect to the individual sample values. Random samples from these 
uniform distributions produced unacceptably large values for the sample standard 
deviation, a significant component of the Bergum acceptance criteria [47].  
The corresponding USP power curves for these distributions are presented in 
Figures 3.11 and 3.12. As was observed for all previous classes of distributions, stage 1 
of the revised USP method is responsible for the relatively poor sensitivity of the test. 
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Table 3.8 Simulation Results for Uniform Distributions 
Population 
Defect 
Level, % 
% Pass 
Stage I 
% Fail 
Stage 1 
% Pass 
Stage II 
% Fail 
Stage II 
Probability of 
Passing, % 
Probability of 
Failing , % 
No. of 
Trials 
Bergum % 
Pass 
Bergum 
% Fail 
I 0.00 65.18 34.82 100.00 0.00 100.00 0.00 11,035 0.00 100.00 
II 2.00 53.36 46.64 83.75 16.25 92.42 7.58 11,006 0.00 100.00 
III 4.00 44.12 55.88 66.22 33.78 81.12 18.88 11,042 0.00 100.00 
IV 6.00 35.91 64.09 48.13 51.87 66.76 33.24 10,977 0.00 100.00 
V 8.00 29.54 70.46 35.99 64.01 54.90 45.10 10,946 0.00 100.00 
VI 10.00 24.80 75.20 26.04 73.96 44.38 55.62 10,973 0.00 100.00 
VII 17.00 14.24 85.76 9.92 90.08 22.75 77.25 11,020 0.00 100.00 
IX 22.00 6.40 93.60 2.01 97.98 8.28 91.72 10,987 0.00 100.00 
X 25.00 4.49 95.51 1.11 98.88 5.56 94.44 10,909 0.00 100.00 
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Figure 3.11 USP Performance of Uniform Distributions  
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Figure 3.12 USP Performance of Uniform Distributions by Stage 
  
  68 
 
 
3.5 Conclusions 
 
The objective of this study was to explore the revised USP content uniformity test 
and Bergum’s Method as potential stand alone tests to assess the characteristics of 
materials manufactured under unknown conditions. Whereas the scope of this simulation 
was too limited to make definitive conclusions about the statistical properties of these 
procedures, the following insights were extracted from the results of the challenge 
distributions. 
1. The revised USP content uniformity test is relatively insensitive to detecting non-
conforming material. 
The test distributions contained significant proportions of non-conforming material, but 
these lots were not consistently rejected until the defect percentage exceeded 20%. The 
insensitivity of the test was attributed to the following characteristics of the test stages: 
2. The stage 1 sample size of 10 is too small to obtain a reasonable estimate of the 
population standard deviation, σ. 
3. A failure at stage 1 always results in a second opportunity to pass the test in stage 2. 
The limited power of the sample size of 10 was confirmed by tabulating the 
sample estimates of the values and comparing them to the true estimate during the 
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simulation. Considering the insensitivity of stage 1, a more reasonable procedure would 
be to stop testing if the lot failed at this point, as opposed to proceeding to stage 2. 
4. Stage 2 ultimately passes an unacceptable number of defective lots. 
The insensitivity of stage 2 to high defect percentages was a surprising result, 
since the procedure utilizes all 30 values, a sample size that proved highly effective with 
Bergum’s method. The problem appears to be that the calculated tolerance interval is too 
broad. As discussed in Chapter 1, the Japanese Pharmacopeia utilized k factors of 2.2 for 
stage 1 and 1.9 for stage 2 [20], which would produce tighter tolerance bands than the 
USP specifications of 2.4 and 2.0 for stages 1 and 2, respectively. 
For a fixed sample size, the tolerance analysis concept requires two specifications 
to establish the value of the factor k, a coverage specification, or desired interval to 
capture in terms of percentage of the total population, and a confidence level for that 
coverage [60-62]. Determining the exact specifications of the revised USP content 
uniformity test cannot be determined without knowledge of all three specifications. Based 
on the observed results against a range of possible distributions, however, the design 
specification appears to between 25 to 30% coverage. 
5. The revised USP content uniformity test increases robustness with respect to the 
shape of the underlying product distribution. 
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Although the method was relatively insensitive, it performed consistently regardless of 
the shape of the underlying distribution. Thus, the tolerance interval concept was 
definitely effective in this respect. 
6. Bergum’s method was highly effective in identifying defective materials. 
Although the method was too sensitive to the assumption of normality, as 
observed in the results for bimodal and uniform distributions, the method performed 
consistently well. In certain lots with high defect percentages, the test did not produce a 
single incorrect inference in over 11,000 simulation trials. 
As opposed to a singlet test that could theoretically performed repeatedly until a 
failing result is produced, a modification of Bergum’s method might be useful as a single 
test that would only be performed once to definitely assess material acceptability. 
Conceivably, other values for P or the confidence interval (such as 90% and 95%, 
respectively) would moderate the effect of the assumption of normality. 
In summary, the tolerance concept is a proven method to make valid inferences 
about a population of interest and forms the basis of many standard statistical tests, such 
as statistical process control. The sample size employed in stage 1 of the content 
uniformity test is too small to effectively estimate the population standard deviation and 
thus increases the Type II or consumers’ risk. 
Bergum’s method provides a prediction of how a lot would do against repeated 
content uniformity testing. Thus, it represents a secondary standard that is more powerful 
than the parent protocol and is an effective tool for pre-assessment or post assessment of 
the fitness for use.
  
  71 
 
 
Chapter 4 
 
 
Investigation of the Statistical Power of the Dissolution 
Test 
 
 
4.1 Introduction 
 
Dissolution testing is required by the FDA to insure that a drug product releases a 
specific percentage of active ingredient Q within a specified period of time, such as 80% 
of label claim within 45 minutes. As opposed to tests for content uniformity, which 
include upper and lower specification boundaries, dissolution has only a lower 
specification limit for immediate release solid oral dosage forms.  
Dissolution testing is an important consideration in establishing equivalence of a 
generic drug to its NDA standard or precedent. Drugs that fail the dissolution test do so 
either because they are formulated with insufficient drug to achieve sufficient 
concentrations against the lower specification, Q, or because the formulation matrix does 
not release the product effectively. 
 
 
4.2 Modeling the USP <711> 
 
Previous investigators have attempted to model the USP test for predictive 
purposes, and these models provide useful insights into the structure of the test. The 
challenges to developing a predictive model for the dissolution test are that the method 
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combines both attribute or “pass/fail” tests and tests for continuous variables in a 
sequential structure. Since testing is terminated once the test criteria for a given stage are 
met, conditional probabilities must also be considered. 
If an underlying distribution of predictable dissolution characteristics is assumed, 
then both the attribute and continuous tests can be modeled with continuous probability 
distributions, and a predictive lot acceptance model becomes feasible. Bergum [43] 
invoked the assumption of a normal distribution to estimate lower probability bounds for 
passing compendial dissolution and content uniformity tests. The same assumption was 
invoked by Chow et. al. [52] to develop alternative models for determination of lower 
bounds for USP-NF tests. 
Wang [53] proposed a model to estimate the probability of passing the sample 
unit test based on the assumptions that the underlying distribution of product distribution 
was normal with known mean μ and variance σ2. As discussed in the previous chapter 
concerning content uniformity, the assumption of normality is questionable, particularly 
when considering products of unknown origin. Nevertheless, Wang’s model provides 
some interesting insights into the nature of this procedure. 
The probability of passing the USP dissolution test is the union of the events of 
passing stages 1, 2, and 3 or 
)( 321 SSSPPpass         (4.1) 
The following events define the conditions that produce a passing result. The probability 
of passing the dissolution test at stage 1 is the probability of observing 6 results in which 
the measured dissolution is greater than or equal to “Q+5%”, or 
}6,...,1,5{1  iQyiPS        (4.2) 
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If the sample does not pass at stage 1, then 6 more dosage units are tested to 
produce a sample of 12. The probability of passing at stage 2 requires two conditions to 
be satisfied. No single unit may have a result less than “Q-15%”, and the average of the 
sample of all 12 observations must be greater than Q. In terms of probability theory, this 
is the intersection of the two events described by equation (4.3) 
}{}12,...,1,15{ 122 QyiQyPS i        (4.3) 
An unsuccessful outcome at stage 2 requires analysis of 12 additional units to 
produce a final sample of 24. Three conditions must be satisfied at this final stage. First 
of all, no more than 2 values can be less than Q-15%. Secondly, no single value may be 
less than Q-25%. Finally, the average of all 24 results must be at least equal to Q. From 
probability considerations, this can be expressed as the intersection of three events as 
presented in equation (4.4): 
     QyiQyQsyPS ii  243 24,...,1,2515'2    (4.4) 
The assumption of normality makes it possible to estimate in advance the 
proportion of tablets found at any distance from the target value Q using given values of 
the mean and standard deviation through the normal probability density function. 
Moreover, the sampling distribution for the mean can be used to estimate the probabilities 
that the mean is greater than Q for stages 2 and 3 respectively as, 
(P /()((1)12  QQy 12/ ))     (4.5) 
(P /()((1)24  QQy 24/ ))     (4.6) 
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4.3 Alternative approach to Modeling USP <711> on a distribution free 
basis 
 
If a normal distribution cannot be assumed, then it is not possible to estimate the 
probabilities associated with the attribute tests. This is an important consideration, 
inasmuch as materials posing a threat to the supply chain are not likely to present a 
normal distribution. Instead, procedures employed to mask or “blend off” non-
conforming products would likely result in skewed, uniform or even bimodal product 
distributions. 
From a “distribution free” viewpoint, it is conceivable that all of the attribute tests 
of chapter <711> can be approximated with a binomial probability mass function, 
 
  xnxx pp
xnx
n
P



 1
!!
!
  for x = 0,1,2,…n     (4.7) 
where n is the number of Bernoulli trials, x is the number of successes observed, and p is 
the proportion of units meeting the criteria of the attribute test. Furthermore, the tests 
involving comparisons of the stage average to the lower dissolution specification limit Q 
could be approximated with the sampling distribution of the mean, as utilized by Wang, 
through the central limit theorem, which states that the sampling distribution of averages 
from a non-normal population would be approximately normally distributed. 
These simple considerations makes it possible to estimate the probabilities 
associated with passing the individual stages and tests for any distribution based simply 
on the mean, standard deviation, and proportion of dissolutions meeting the “success” 
criteria of the Bernoulli trials. With respect to stage 1, if finding a tablet meeting or 
exceeding the criterion is considered a success, then passing the test is equivalent to the 
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probability of observing the discrete event that all six tablets pass. Thus, PS1 can be 
approximated with the function 
 661 55 1)(   QiQi yy ppSP        (4.8) 
in which 5Q
iy
p is the proportion of units with dissolutions greater than or equal to Q+5%, 
regardless of the shape of the underlying distribution. The assumption is that the tablets 
are chosen at random from a population large enough such that removal of the samples 
does not significantly affect 5Q
iy
p . 
Figure 4.1 is a graphical representation of the probability of passing stage 1 as a 
function of the lot quality characteristics, which in this case is represented by the 
proportion of dosage units equal to or greater than Q+5%. Under the binomial 
assumption, the probability of passing stage 1 does not attain 80% until the proportion of 
units with dissolutions greater than or equal to Q+5% exceeds 90%. Thus, passing stage 
1 simply due to chance would likely be a rare event, even for a lot with reasonable quality 
characteristics.  
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Figure 4.1 Binomial Approximation Probability of passing Stage 1 of USP <711> as a function of the proportion of 
units exceeding Q+5% 
  
  77 
Binomial distributions could also be applied to approximate the remaining 
attribute tests of stages 2 and 3. Figure 4.2 illustrates a power curve for the attribute test 
of stage 2. In this case, the acceptance curve represents the probability of finding no 
dissolutions less than Q-15% as a function of the proportion of units meeting that 
criterion. The attribute test of stage 2 rejects 90% of lots once the percentage of 
dissolutions equal to Q-15% approaches 20%. According to the central limit theorem, the 
sampling distribution for the mean for a sample size of 12 should also approximate the 
behavior for any distribution, assuming that the deviation from normality is not too 
severe. In this case, the probability of passing stage 2 could be approximated by the 
product or joint probability of the two events, passing the attribute test corresponding to 
Figure 4.2 and the mean test “μ ≥ Q”. This assumes independence of the two events, and 
it is more reasonable to measure this probability through simulation. 
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Figure 4.2 Binomial Approximation for the Attribute Test of Stage 2 USP <711> 
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Similar considerations apply to stage 3. Binomial distributions could be used to 
approximate power curves for the two attribute tests corresponding to observing no more 
than 2 yi’s<Q-15% and no yi<Q-25%, but the tests are not strictly independent. Further, it 
is not clear that the central limit theorem would apply to the average measured in stage 3, 
24y . Stage 3 is only conducted in practice if stage 2 produces an average less than Q and 
fails. Thus, the average measured at stage 3 would likely be biased to some extent by the 
inclusion of values from stage 2, since the average of the latter values would always be 
less than Q. 
 
 
4.4 Expected Outcomes for Non-normal Distributions 
 
In summary, it is difficult to predict how USP <711> would perform against non-
normal distributions. Whereas a passing outcome at stage 1 would be an unlikely 
occurrence for a lot with poor quality characteristics (Fig.4.1), a passing result at stage 2 
or 3 is possible as long as the average dissolution value is approximately equal to or 
slightly greater than Q. Tsong et. al. [63] performed simulation studies and found USP 
<711> to lack discriminating power. Specifically, the procedure passed lots with an 
unacceptably large percentage of dissolutions less than the lower specification as long as 
the lot average was approximately equal to Q. This was later confirmed for skewed 
distributions based on the beta probability density function [64]. 
Intuitively, Tsong’s observations can be interpreted using the simple modeling 
considerations presented previously. If the sampling distribution of the mean is a 
reasonable probability model for the continuous tests of USP <711>, then any 
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distribution with mean greater than Q will pass this portion of the test readily. Under 
these circumstances, the power or “beta” of the dissolution test would be determined by 
the attribute test elements. In practice, however, these outcomes cannot be predicted in 
advance and are best measured empirically through simulation. 
 
 
4.5 Summary of Hypotheses and Simulation Study Design 
 
The testable hypotheses of Chapter 4 are: 
1. The attribute tests of stages 1, 2, and 3 can be modeled without assuming a normal 
distribution with binomial probability distributions specific to each stage. 
2. The mean tests of stages 2 and 3 can be modeled without assuming an underlying 
distribution using the central limit theorem. 
3. The test stages will not be independent, since the results produced in the early stages 
will influence the outcome of later stages. 
These hypotheses were tested with simulation studies employed the same 
concepts used in investigating the compendial test for content uniformity (Chapter 3). A 
spreadsheet equivalent to the short form dissolution test was constructed using Microsoft 
Excel, and Crystal Ball version 7.3 was employed as the tool for simulation. A public 
domain Microsoft Excel spreadsheet was incorporated in the simulation to automatically 
calculate acceptance limits using Bergum’s method assuming a completely random 
sample [46]. Values of 80% and 90% were selected for the lower specification limit Q 
and simultaneous confidence interval, respectively. The probabilities of passing the USP 
test at both 90% and 95% confidence were evaluated and tabulated. 
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The simulation tool offers the capability of automatic random sampling for many 
common distributions, but artificial lots of size N=60,000 were used in this study to test 
specific features of the USP protocol. The shapes created included normal, skewed, 
bimodal and uniform distributions. 
The simulation executed the USP test exactly as would occur in actual physical 
testing. An initial sample of 24 units was selected totally at random from the parent 
population. A sub-routine validated the sample to ensure that no duplicate tablets were 
present. Upon confirmation of the sample integrity, the simulator performed the three 
stage dissolution test as described in Table 1.2. Testing was terminated if the lot passed at 
stages 1 or 2. Simultaneously, the results of each sample were assessed using the 
spreadsheet equivalent of Bergum’s method. Acceptance decisions were calculated for 
the sample based for 6, 12 and 24 tablets. The simulator tool tested each lot 20,000 times 
and tabulated the outcomes for both procedures. 
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4.6 Interpretation of Results 
 
Table 4.1 lists the minimum information that was recorded for each simulation 
run. The conditional probabilities at each stage of the procedure were measured to 
provide information about the relative strength of the individual stages. In addition to the 
conditional probabilities, the overall lot acceptance result (pass or fail) was tabulated 
independently.
Table 4.1 Event Space for Dissolution Simulations 
 
 
 
An example of the USP test results is presented in Figure 4.3 which represents a 
beta distribution skewed towards the lower limit Q of 80%. The interpretation of the 
outcomes for the individual stages is as follows. The simulation attempted 20,000 trials, 
which resulted in 19,900 valid samples. The remaining 100 samples were rejected and no 
Stage Result Event 
Description 
Outcome 
1 Pass Stage 1 PS1 Pass USP 
Dissolution 
1 Fail Stage 1 FS1 Advance to 
Stage 2 
2 Pass Stage 2 PS2 | FS1 Pass USP 
Dissolution 
2 Fail Stage 2 FS2 | FS1 Advance to 
Stage 3 
3 Pass Stage 3 PS3 | (FS1 FS2) Pass USP 
Dissolution 
3 Fail Stage 3 FS3 | (FS1 FS2) Fail USP 
Dissolution 
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testing was performed. Of the 19,900 valid samples tested, 2.809% passed stage 1. The 
samples that failed (19,341) were advanced to stage 2 for assessment, which resulted in a 
passing percentage of 52.06%. The failing samples (9,272) were submitted for Stage 3 
testing and passed 70.74% of the trials.
 
USP Stage Fail % Pass % N
1 97.19 2.81 19,900
2 47.94 52.06 19,341
3 29.26 70.74 9,272
Overall 13.63 86.37 19,900
Q
50 60 70 80 90 100 110
 
Figure 4.3 Sample simulation results for a skewed distribution 
 
The overall result presented in Figure 4.3 can be interpreted as follows. The 
probability of passing USP<711> is given by equation (4.1) 
)( 321 SSSPPpass         (4.1) 
The probabilities of passing the individual stages, as presented in Table 4.1 are 
 213121 || FSFSPSFSPSPSPpass       (4.9) 
 
    9719.04794.07074.09719.05206.002809.0 passP   (4.10) 
The resulting calculated value is 0.8637 or 86.37% passing, as indicated the “overall” 
outcome entry in Figure 4. 
The simulation tool was programmed to report details for all individual tests of 
the method, which were recorded in a laboratory notebook. Table 4.2 contains the details 
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for the individual tests for the skewed lot of Figure 4.3. These results clarify the overall 
results of the dissolution test. This particular lot, which had a true mean of 85.87% and 
standard deviation of 12.01, usually failed stage 1 because the proportion of values 
greater than 85% (Q+5%) was low (54.96%). 
According to the binomial approximation illustrated in Figure 4.1, this lot would 
only be expected to pass stage 1 for approximately 2.76% of all attempts, 
    661 5496.0)( 5QiypSP 0.0276     (4.11) 
Table 4.2 Detailed analysis of the performance of the skewed lot 
 
 
 
For each stage, the bold entries in Table 4.2 identify the controlling portion of the 
test. The example lot contained 5.11% of Q values less than 65%, which limited the 
theoretical pass probability of the Q-15% attribute tests of stages 2 and 3, to 53.3% and 
87.8%, respectively. Note that the expected and observed results for this simulated lot 
agree well for stages 1 and 2, but not stage 3. In this case, this is not evidence of failure 
of the modeling assumptions, but instead is due to the conditional probabilities measured 
USP Stage Fail % Pass % Expected Pass % N
1 97.19 2.81 2.76 19,900
2 Q-15 47.39 52.61 53.29 19,341
2 avg. ≥Q 4.55 95.45 95.66 19,341
2 47.94 52.06 50.98 19,341
3 Q-15 24.20 75.80 87.83 9,272
3 Q-25 8.21 91.79 94.58 9,272
3 avg. ≥Q 1.64 98.36 99.26 9,272
3 29.26 70.74 82.46 9,272
Overall 13.63 86.37 91.63 19,900
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in the simulation. Only samples failing earlier stages are passed on for additional testing, 
and these influence or skew the results of subsequent tests.  
This is illustrated in Table 4.3, which represents a repeat of the original 
simulation with each stage performed an equal number of times. The improvement 
between the measured and expected pass percentages resulted from removing the 
conditional probability considerations. 
Table 4.3 Example from Figure 4 with all tests replicated an equal number of 
times 
USP Stage Fail % Pass % Expected Pass % N
1 97.31 2.69 2.76 19,920
2 Q-15 46.60 53.40 53.29 19,920
2 avg. ≥Q 4.18 95.82 95.66 19,920
2 47.09 52.91 50.98 19,920
3 Q-15 12.14 87.86 87.83 19,920
3 Q-25 5.29 94.71 94.58 19,920
3 avg. ≥Q 0.68 99.32 99.26 19,920
3 15.78 84.22 82.46 19,920
Overall 13.32 86.68 91.64 19,920   
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4.7 Simulation Results With Normal Distributions 
 
Initial simulations were performed to determine the coverage and power provided 
by the coverage tests of stages 2 and 3 (hypothesis 2). Table 4.4 describes the 
characteristics and results of the first series of distributions subjected to simulated USP 
testing. The initial series tested (Series I) consisted of normal distributions of fixed 
standard deviation equal to 1.00. This resulted in product distributions free of the extreme 
values that would activate the stage 2 and 3 attribute tests, and thus, can only fail through 
the tests μStage2<Q and μStage3<Q. 
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Table 4.4 Simulation Results, Normal Distributions. Series I, 20,000 trials. Q=80% 
 
Mean 
Standard 
deviation 
Proportion<Q-
25 
Proportion<Q-
15 
Proportion 
< Q Proportion>Q+5 
Proportion 
Pass USP 
Stage 1 
Proportion 
Pass USP 
Stage 2 
Proportion 
Pass USP 
Stage 3 
Probability 
of 
Acceptance 
85.0 1.00 0.00 0.00 0.00 0.502 0.015 1.000  1.000 
84.0 1.00 0.00 0.00 0.00 0.159 0.000 1.000  1.000 
83.0 1.00 0.00 0.00 0.00 0.022 0.000 1.000  1.000 
82.0 1.00 0.00 0.00 0.02 0.024 0.000 1.000  1.000 
81.0 1.00 0.00 0.00 0.16 0.000 0.000 1.000 1.000 1.000 
80.5 1.00 0.00 0.00 0.31 0.000 0.000 0.957 0.892 0.995 
80.3 1.00 0.00 0.00 0.40 0.000 0.000 0.801 0.630 0.926 
80.0 1.00 0.00 0.00 0.50 0.000 0.000 0.495 0.252 0.622 
79.8 1.00 0.00 0.00 0.60 0.000 0.000 0.186 0.047 0.225 
79.5 1.00 0.00 0.00 0.69 0.000 0.000 0.042 0.003 0.045 
79.0 1.00 0.00 0.00 0.84 0.000 0.000 0.000 0.000 0.000 
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The power curve for the simulation series is presented in Figures 4.4 and 4.5, the 
latter of which details the results for each stage. The results from these simulations 
suggest that the effective coverage of the mean tests is approximately 50%. As the 
proportion of dissolutions less than Q approaches 0.50, the probability of acceptance falls 
from 93% at P<Q equal to 0.40 to 62% at P<Q equal to 0.50. When P<Q becomes 0.60, 
the acceptance level falls to 23%, representing the statistical power or beta of the USP 
procedure for this series. 
The results illustrated in Figure 4.5 reveal a significant shortcoming of the 
coverage test based on the mean, namely that the stage 2 test is consistently weaker than 
stage 3. This would be expected from examination of equations (4) and (5), since the 
larger sample size at stage 3 improves precision in the estimation of the mean. The 
consequence, however, is that the Type II error rate is relatively high at stage 2 and 
would likely lead to false inferences, assuming that the remaining attribute tests do not 
compensate for the lack of sensitivity, Thus, a distribution with P<Q equal to 0.5 will 
pass stage 2 approximately 50% of all cases, but would fail stage 3 and hence the overall 
test approximately at a rate of 75% in repeated testing. 
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Figure 4.4 Power Curve for Normal Distribution Series I 
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 Figure 4.5 Power Curve for Individual Stages of Normal Series I 
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Table 4.5 presents the results of a second series of normal distributions with 
similar means to those in the first series but with standard deviations equal to 2. The 
power curves for this series are presented in Figures 4.6 and 4.7. The increase in 
variability had no impact on the power of the mean test, except that it changed the 
proportion of dissolutions less than Q with respect to the first series. Thus the two groups 
of distributions can be considered a single series that differ significantly only the 
proportion of dissolutions less than Q. 
Mean
Standard 
deviation
Proportion
<Q-25
Proportion
<Q-15
Proportion 
< Q
Proportion
>Q+5
 Proportion 
Pass USP 
Stage 1
 Proportion 
Pass USP 
Stage 2
 Proportion 
Pass USP 
Stage 3
Probability 
of 
Acceptance
87.0 2.01 0.00 0.00 0.00 0.840 0.346 1.000 1.000 1.000
85.0 2.00 0.00 0.00 0.01 0.503 0.015 1.000 1.000 1.000
84.0 2.01 0.00 0.00 0.02 0.309 0.001 0.999 1.000 1.000
83.0 2.01 0.00 0.00 0.07 0.159 0.000 0.999 1.000 1.000
82.0 2.01 0.00 0.00 0.16 0.066 0.000 0.999 1.000 1.000
81.0 2.01 0.00 0.00 0.31 0.022 0.000 0.955 0.879 0.995
80.5 2.00 0.00 0.00 0.39 0.013 0.000 0.821 0.640 0.936
80.3 2.00 0.00 0.00 0.45 0.008 0.000 0.670 0.443 0.816
80.3 2.01 0.00 0.00 0.45 0.009 0.000 0.656 0.421 0.801
80.0 2.01 0.00 0.00 0.50 0.006 0.000 0.494 0.247 0.619
79.8 2.01 0.00 0.00 0.55 0.004 0.000 0.332 0.123 0.414
79.5 2.01 0.000 0.000 0.597 0.003 0.000 0.190 0.044 0.226
79.0 2.01 0.00 0.00 0.69 0.001 0.000 0.043 0.003 0.046
78.0 2.01 0.00 0.00 0.84 0.000 0.000 0.000 0.000 0.000  
 
Table 4.5 Results of Simulation, Normal Distributions. Series II, 20,000 trials. Q=80% 
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Figure 4.6 Power Curve for Normal Distribution Series II 
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Figure 4.7 Power Curve for Individual Stages of Normal Series II 
  
  94 
 
 
4.8 Interpretation of the Coverage Tests 
 
The results from the investigation of the coverage component of USP <711> 
using normal distributions support an interpretation of the test as a special case of a one-
sided tolerance interval. 
One-sided tolerance tests are typically specified to provide coverage against a 
single upper or lower specification limit. The tolerance interval is of the form 
KsX           (4.12) 
where s is the standard deviation and K is a tolerance factor for a one-sided interval 
assuming a normal distribution. Note that this is not the same tolerance factor used for the 
revised content uniformity test (k), although the two tolerance factors share a common 
origin. For content uniformity, the value k is an unspecified tolerance factor for a two-
sided interval. 
Tsong et. al. [64] proposed, but did not investigate, a test statistic for dissolution 
based on a one-sided tolerance interval. The suggested test statistic was alternative to the 
current mean test of the form 
 sKQX Pr         (4.13) 
The decision to accept the lot at any stage would result if the observed mean was greater 
than the test statistic, Q+K*s. Tsong cited Faulkenberry and Daley [65] and proposed the 
use of the non-central t distribution for the determination of the tolerance factor K. For N-
1 degrees of freedom and 95% confidence, where N is the sample size, K can be 
determined from the expression 
NzNNtK p /%)95,,1( )1(        (4.14) 
  
  95 
in which )1( pzN   is the non-centrality parameter for the desired coverage 1-p. 
The current mean tests of USP <711> can thus be considered a special case of a 
one-sided tolerance interval with K equal to zero, 
QsKQX Stage 3,2        (4.15) 
The tolerance interval concept was designed to ensure coverage, i.e., that a certain 
percentage of a distribution (e.g., 90%) is captured within an interval with a certain level 
of confidence. In equation (4.14), coverage corresponds to the z factor used to determine 
the value of t from the non-central t-distribution. For 50% coverage, z becomes zero, and 
the non-central t-distribution reduces to the standard t distribution. The confidence level 
is determined for this special case by the percentiles of the t-distribution.  
For K=0, t must also be zero, which corresponds to the 50
th
 percentile of the 
standard t-distribution. Thus, considered in terms of tolerances, the mean tests employed 
in USP <711> correspond to a one-sided tolerance test with 50% coverage and 50% 
confidence. As a consequence, any product distribution with μ>Q will likely pass the 
mean tests of USP <711>. 
The results presented previously in Figures 4.4.through 4.7 support this deduction. 
The series normal distributions presented here, which were specially designed to test only 
the coverage elements of USP <711>, do not begin to fail until the percentage less than Q 
exceeds 50%. This explains, of course, Tsong et.al.’s observation that the USP method 
lost discriminating power as the mean approached the specification value Q [63]. 
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4.9 Interaction Between the Coverage Tests at Stages 2 and 3 
 
Table 4.6 presents the expected outcomes for stages 2 and 3 of Normal Series I 
and II as calculated form equations (4.5) and (4.6), respectively. 
Table 4.6 Calculated Outcomes for Stages 2 & 3, Normal Series I & II 
Series Mean
Standard 
deviation
Proportion 
< Q
Expected 
Pass USP 
Stage 2
Expected 
Pass USP 
Stage 3
I 79.000 1.000 0.841 0.000 0.000
I 79.500 1.000 0.691 0.042 0.007
I 79.750 1.000 0.597 0.193 0.110
I 80.000 1.000 0.500 0.500 0.500
I 80.250 1.000 0.403 0.807 0.890
I 80.500 1.000 0.312 0.958 0.993
I 81.000 1.000 0.157 1.000 1.000
I 82.000 1.000 0.023 1.000 1.000
I 83.000 1.000 0.000 1.000 1.000
I 84.000 1.000 0.000 1.000 1.000
I 85.000 1.000 0.000 1.000 1.000
II 77.993 2.009 0.841 0.000 0.000
II 78.990 2.010 0.691 0.041 0.007
II 79.493 2.009 0.597 0.191 0.108
II 79.750 2.010 0.550 0.333 0.271
II 79.993 2.009 0.500 0.495 0.493
II 80.250 2.010 0.452 0.667 0.729
II 80.260 2.000 0.449 0.674 0.738
II 80.530 2.000 0.394 0.821 0.903
II 81.000 2.010 0.314 0.958 0.993
II 81.993 2.009 0.160 1.000 1.000
II 82.993 2.009 0.068 1.000 1.000
II 83.993 2.009 0.023 1.000 1.000
II 85.007 1.997 0.006 1.000 1.000
II 86.993 2.009 0.000 1.000 1.000  
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The results are presented graphically in Figure 4.8. The results show that the 
expected values determined from the models agree well for stage 2, but are biased low for 
stage 3. These results were interpreted as a consequence of the stepwise testing 
procedure. As the mean approaches Q, samples in stage 2 begin to fail the mean test. This 
introduces a bias that must be overcome by the third sample of 12 collected at stage 3. 
For example, a lot with true mean of 80 and standard deviation equal to 2 will fail the 
mean test in 50% of all cases. If the observed mean at stage 2 is less than Q by an amount 
δ, then the third sample collected must present an average greater than or equal to the 
average from stage 2 plus δ to pass the test. This probability would be more relevant to a 
modification of equation (4.5) as opposed to (4.6), namely 
(P /()((1)2413   QQy 12/ ))    (4.16) 
Thus, failure at stage 2 introduces a non-random bias that must be overcome by 
the sample of stage 3. Thus, if a sample from the aforementioned lot produced a result of 
79.0 at stage 2, the sample from stage 3 must be greater than or equal to 81.0 to pass the 
USP mean test, a result which would only occur in ~ 5% of all cases according to 
equation (4.16). 
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Figure 4.8 Expected versus Actual values for Normal Distribution Series I & II  
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4.10 Final Simulations with Normal Distributions 
 
Table 4.7 presents the results of simulations with normal distributions designed to 
test hypothesis 1 by exploring the characteristics of the attribute tests at stages 1, 2, and 3 
independently of the mean tests. The results are listed with respect to increasing 
proportion of values less than Q-15%. The characteristics of these distributions are such 
that they permit investigation of the attribute tests of all three stages of USP <711>. Note 
that the means of these distributions are all greater than Q, which should minimize 
interference from the mean tests for coverage. 
The results from Table 4.7 for stage 1 are presented in Figure 4.9. In this case, the 
observed values were expressed as percentages in order to provide clarity. The solid line 
represents computations of Equation (4.8), which agree well with observed values. The 
results support the extraordinary power of stage 1 of USP <711> presented in Figure 4.1. 
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Table 4.7 Final Simulations with Normal Distributions, Q=80%. Results of 20,000 trials 
 
Mean 
Standard 
deviation 
Proportion< 
Q-25 
Proportion< 
Q-15 
Proportion 
< Q Proportion>Q+5 
Proportion 
Pass USP 
Stage 1 
Proportion 
Pass USP 
Stage 2 
Proportion 
Pass USP 
Stage 3 
Probability 
of 
Acceptance 
84.0 1.0 0.000 0.000 0.000 0.159 0.000 1.000  1.000 
80.5 1.0 0.000 0.000 0.311 0.000 0.000 0.957 0.892 0.995 
84.0 2.0 0.000 0.000 0.023 0.309 0.001 0.999 1.000 1.000 
84.0 5.0 0.000 0.000 0.213 0.422 0.006 0.995 0.835 0.999 
80.5 5.0 0.000 0.001 0.462 0.183 0.000 0.630 0.383 0.771 
84.0 10.0 0.002 0.029 0.348 0.459 0.009 0.671 0.799 0.935 
80.5 10.0 0.006 0.062 0.482 0.328 0.001 0.350 0.355 0.588 
84.0 12.6 0.011 0.065 0.376 0.467 0.011 0.425 0.493 0.712 
83.9 15.1 0.027 0.104 0.397 0.472 0.011 0.258 0.249 0.449 
80.5 12.6 0.021 0.109 0.486 0.361 0.002 0.211 0.214 0.382 
80.4 15.1 0.046 0.152 0.488 0.384 0.004 0.127 0.094 0.212 
83.9 20.1 0.075 0.172 0.423 0.479 0.010 0.103 0.052 0.158 
80.4 20.1 0.102 0.220 0.491 0.413 0.005 0.049 0.017 0.070 
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Figure 4.9 Expected versus observed values for Stage 1 expressed as percentages 
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The predicted and actual results expected for stage 2 are presented in Figure 4.10, 
which includes the expected value for the attribute test plotted as a reference line. The 
reference line was calculated from Equation (4.7) and represents the probability of 
finding no tablets less than Q-15% in a sample of 12 with the proportion of these tablets 
given by the values in column four in Table 4.7. 
The expected value for acceptance at stage 2 is the product of the probabilities for 
the attribute test and the mean test given by Equation (4.5), assuming that the two events 
are independent. The multiplicative law of probability [66] states that the probability of 
the intersection of two events A and B is 
  )|()( ABPAPBAP         (4.16) 
If the events A and B are independent, then 
  )()( BPAPBAP         (4.17) 
The multiplicative law applies to any number of independent events, but would 
not likely apply beyond stage 2, due to the conditional probability considerations of the 
dissolution test.
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Figure 4.10 Predicted versus actual values from Stage 2 
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The expected results agree with the observed values until the percentage of 
dissolutions less than Q-15% approaches 6.0%, after which the attribute test seems to 
control the test outcome at stage 2. The agreement between actual and expected values is 
less for distributions with mean approaching Q. This is likely a limitation of the 
assumption of independence between the probability tests. 
Proposed power curves for the attribute tests of stage 3 are presented in Figure 
4.11. Both tests can be approximated with binomial distributions. The probability of 
finding no more than two values less than Q-15% can be estimated with a cumulative 
binomial distribution with 24 trials, whereas the probability of finding no values less than 
Q-25% corresponds to the expression 
24
2525 )1()3(   QyQ ipSP        (4.18) 
The x-axis of Figure 11 corresponds to the proportion nonconforming for either 
test, either pyi<Q-15 for the first attribute test or p yi<Q-25 for the latter. Note that these 
proportions are related through the expression, 
2515   QyQy
ii
pp         (4.19) 
since a value less than Q-25% is necessarily, of course, also less than Q-15%. 
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Figure 4.11 Attribute Power Curves for Stage 3. Proportion nonconforming refers to the proportion of values less than 
Q-15 or  Q-25 
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Table 4.8 reproduces a portion of Table 4.7 including only those elements 
relevant to stage 3. In this table, the results of the individual predictions for each test of 
stage 3 are compared to the observed values. The observed values represent the actual 
conditional probabilities measured in the simulation, and would not be expected to 
conform to the simple prediction assuming independence of the tests. These results, 
however, correctly project the trend expected for these distributions at stage 3. On the 
basis of the mean test alone, all of these distributions would be expected to pass USP 
<711>. But as the proportion of values less than Q-15% and Q-25% increases, the 
attribute tests interact and control the overall results. 
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Table 4.8 Expected results for Stage 3 versus observed values 
Mean 
Standard 
deviation 
Proportion 
<Q-25 
Proportion 
<Q-15 
Proportion 
 < Q 
Stage 3 
Expeced 
Q-15 
Stage 3 
Expected 
Q-25 
Stage 3 
Expected 
μ<Q 
Overall 
Expected 
Stage 3 
Proportion 
Pass USP 
Stage 3 
84.0 1.0 0.000 0.000 0.000 . . . . . 
84.0 2.0 0.000 0.000 0.023 1.000 1.000 1.000 1.000 1.000 
84.0 5.0 0.000 0.000 0.311 1.000 0.998 1.000 0.998 0.892 
80.5 1.0 0.000 0.000 0.213 1.000 1.000 0.992 0.992 0.835 
84.0 10.0 0.002 0.029 0.348 0.969 0.957 0.973 0.903 0.799 
80.5 5.0 0.000 0.001 0.376 1.000 0.998 0.681 0.680 0.493 
84.0 12.6 0.011 0.065 0.462 0.795 0.773 0.939 0.577 0.383 
80.5 10.0 0.006 0.062 0.482 0.816 0.876 0.590 0.422 0.355 
83.9 15.1 0.027 0.104 0.397 0.537 0.517 0.900 0.250 0.249 
80.5 12.6 0.021 0.109 0.486 0.505 0.598 0.571 0.173 0.214 
80.4 15.1 0.046 0.152 0.488 0.272 0.327 0.558 0.050 0.094 
83.9 20.1 0.075 0.172 0.423 0.193 0.154 0.831 0.025 0.052 
80.4 20.1 0.102 0.220 0.491 0.076 0.075 0.542 0.003 0.017 
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4.11 Simulations with Non-Normal Distributions 
 
The simulations executed with normal distributions provided valuable insight into 
the characteristics of the three stage dissolution test. Simulations with non-normal 
distributions were conducted to test the robustness of these insights and to provide 
specific information about the attribute tests. Simulations were conducted with uniform, 
bimodal and beta distributions. 
Table 4.9 contains the results of simulations conducted with a series of uniform 
distributions. This series was based on a parent uniform distribution with minimum and 
maximum values of 80 and 100%, respectively. Non-conforming values ranging from 50 
to 79% were added randomly in sequence to create distributions consisting of 0 to 50% 
less than Q, as given in column 5 of Table 4.9. 
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Table 4.9 Results of simulations with Uniform Distributions. Q=80%. 20,000 trials 
Distribution Mean 
Standard 
deviation 
Proportion 
<Q-25 
Proportion
<Q-15 
Proportion 
< Q 
Proportio
n>Q+5 
Proportion 
Pass USP 
Stage 1 
Proportion 
Pass USP 
Stage 2 
Proportion 
Pass USP 
Stage 3 
Probability 
of 
Acceptance 
UD8010000 89.99 5.78 0.000 0.000 0.000 0.750 0.177 1.000  1.000 
UD8010005 88.82 7.74 0.002 0.021 0.050 0.711 0.131 0.759 0.839 0.966 
UD801007,5 88.24 8.55 0.003 0.033 0.075 0.694 0.113 0.651 0.765 0.927 
UD8010010 87.67 9.24 0.004 0.044 0.100 0.675 0.097 0.561 0.703 0.882 
UD8010015 86.47 10.31 0.006 0.066 0.150 0.639 0.070 0.423 0.567 0.768 
UD8010020 85.29 11.22 0.009 0.089 0.200 0.601 0.046 0.308 0.431 0.624 
UD8010030 82.92 12.47 0.012 0.133 0.300 0.522 0.021 0.172 0.230 0.376 
UD8010040 80.60 13.15 0.016 0.176 0.400 0.451 0.009 0.092 0.107 0.198 
UD8010050 78.24 13.43 0.042 0.220 0.500 0.307 0.002 0.045 0.036 0.081 
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The overall results together with the results by stage are presented graphically in 
Figure 4.12. Based on the considerations discussed previously, the results of this series 
would be expected to be determined by the attribute tests until the mean approaches Q. 
The expected values for stages 1 and 2 agree reasonably with observed values, as 
illustrated in Figures 4.13 and 4.14. 
Note that although stage 3 controls the overall acceptance, there is a gap between 
stage 2 and 3 acceptances that increases until the proportion of dissolutions less than Q 
approaches 0.30. 
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Figure 4.12 Results of Simulations with Uniform Distributions. Q=80%. 20,000 trials 
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Figure 4.13 Comparison of Expected to observed values for Stage 1. Uniform Series 
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Figure 4.14 Comparison of Expected to observed values for Stage 2. Uniform Series 
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Table 4.10 presents the expected values for stages 2 and 3 for this series and 
offers insight about the role of the Q-15% attribute tests. The expected results predict the 
trend of the observed results, which suggest that the attribute tests control the acceptance 
until the average approaches Q.  
The results of this table suggest that gap observed between stages 2 and 3 
acceptances in Figure 4.12 is due to a difference in statistical power between the Q-15% 
attribute tests. Thus, a lot with a given percentage of values less than Q-15% that 
normally would be rejected at stage 2 has a higher chance of acceptance at stage 3. For 
example, the percentage of values less than Q-15% equal to 8.89 would be accepted at 
stage 2 with a probability of 0.33, whereas the same proportion would be accepted at 
stage 3 with a probability of 0.64. This represents an inconsistency in the test. 
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Table 4.10 Expected values for Stage 2 attribute and Stage 3 trials 
Distribution Mean 
Standard 
deviation 
P< 
Q-25 
P< 
Q-15 
Predicted 
Pass 
Attribute 
Q-15  
Stage 2 
Predicted 
Pass 
Attribute 
Q-15 
 Stage 3 
Predicted 
Pass 
Attribute 
Q-25  
Stage 3 
Predicted 
Pass Mean 
Test  
Stage 3 
Expected 
Pass 
Stage 3 
Observed 
Acceptance 
Stage 3 
UD8010000 89.99 5.78 0.000 0.000 1.000 1.000 1.000 1.000 1.000  
UD8010005 88.82 7.74 0.190 2.130 0.772 0.986 0.955 1.000 0.942 0.839 
UD801007,5 88.24 8.55 0.310 3.310 0.668 0.956 0.928 1.000 0.888 0.765 
UD8010010 87.67 9.24 0.410 4.440 0.580 0.911 0.906 1.000 0.826 0.703 
UD8010015 86.47 10.31 0.580 6.590 0.441 0.792 0.870 0.999 0.688 0.567 
UD8010020 85.29 11.22 0.860 8.890 0.327 0.639 0.813 0.989 0.514 0.431 
UD8010030 82.92 12.47 1.210 13.303 0.180 0.364 0.747 0.875 0.237 0.230 
UD8010040 80.60 13.15 1.590 17.600 0.098 0.180 0.681 0.588 0.072 0.107 
UD8010050 78.24 13.43 4.184 21.967 0.051 0.077 0.359 0.260 0.007 0.036 
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A comparison of the power curves for the Q-15% attribute tests for stages 2 and 3 
are presented in Figure 4.15. The probability for stage 2 represents the probability of 
finding no values less than Q-15% in a sample of 12, whereas the curve for stage 3 
represents the cumulative probability of observing up to 2 non-conforming tablets in a 
sample of 24. The models suggest that the stage 3 attribute test for Q-15% is less 
discriminating than stage 2 for a given proportion of defects until the level approaches 
approximately 0.25. Beyond this point, the tests are equivalent. 
Although the USP dissolution test is not a statistical sampling plan, a reasonable 
expectation for any test is that it would increase in power with increasing sample size. 
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Figure 4.15 Power Comparison of the Q-15% Attribute Tests at Stages 2 and 3. The dashed arrow represents the loss 
of discrimination for the test from stage 2 to 3 at the 5% non-conformance level. 
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4.12 Simulations with Bimodal Distributions 
 
The final series for this discussion represent bimodal distributions. Bimodal 
distributions are a particular concern for the supply chain. Multi-modal distributions can 
result from undetected assignable causes, such as an unknown difference between two or 
more production units, or can result from intentional activity, such as blending. The two 
characteristics that distinguish the bimodal distribution include a scarcity of values at the 
mean and excessive variation. 
The characteristics of the bimodal distributions created for this simulation 
together with observed results from 20,000 trials are presented in Table 4.11. The 
distributions were created by mixing equal proportions of the parent distributions, whose 
properties are given in columns 2-4 of Table 4.11.
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Table 4.11 Simulations with Bimodal Distributions. Results from 20,000 trials. Q=80% 
 
Distribution μ1 μ2 1  Mean 
Standard 
deviation 
Proportion 
< Q-25 
Proportion 
< Q-15 
Proportion 
< Q 
Proportion 
> Q+5 
Pass 
Stage 
1, Pct 
Pass 
Stage 
2, Pct 
Pass 
Stage 
3, Pct 
Probability 
of 
Acceptance 
BD75853 75 85 3 3 80.00 5.83 0.0000 0.0003 0.4695 0.2508 0.0003 0.4995 0.2483 0.6284 
BD74863 74 86 3 3 79.99 6.71 0.0000 0.0006 0.5008 0.3135 0.0011 0.5033 0.2502 0.6280 
BD72883 72 88 3 3 80.01 8.54 0.0000 0.0045 0.4999 0.4227 0.0050 0.4809 0.2705 0.6232 
BD73873 73 87 3 3 79.99 7.61 0.0000 0.0019 0.5000 0.3733 0.0030 0.4882 0.2552 0.6199 
BD734873 73 87 4 3 79.99 7.84 0.0000 0.0114 0.4859 0.3740 0.0030 0.4640 0.2829 0.6168 
BD713883 71 88 3 3 79.49 9.01 0.0000 0.0114 0.5013 0.4200 0.0057 0.3913 0.2020 0.5171 
BD703883 70 88 3 3 78.99 9.48 0.0000 0.0245 0.5018 0.4200 0.0061 0.3016 0.1668 0.4216 
BD693883 69 88 3 3 78.49 9.96 0.0000 0.0468 0.5019 0.4200 0.0060 0.2150 0.1310 0.3219 
BD683883 68 88 3 3 77.99 10.44 0.0000 0.0798 0.5020 0.4200 0.0057 0.0952 0.0690 0.1625 
BD673883 67 88 3 3 77.50 10.93 0.0000 0.1263 0.5023 0.4209 0.0053 0.0474 0.0533 0.1030 
BD643883 64 88 3 3 75.99 12.37 0.0005 0.3127 0.5020 0.4200 0.0061 0.0083 0.0042 0.0185 
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This series was constructed to evaluate the modeling assumptions presented 
previously, such as the interaction between the mean and attribute tests at stages 2 and 3. 
To this end, detailed results were recorded for the individual test components. Based 
upon the modeling assumptions presented within this text, these distributions would be 
expected to fail stage 1, as observed, but pass the coverage test at stage 2. The results at 
stage 2 would be controlled by the attribute test once the proportion of dissolutions less 
than Q-15% exceeds 0.05. 
The results from Table 4.11 are plotted in Figure 4.16 by stage. The proportion 
less than Q-15% was used for a reference for comparison of the results. The passing 
results for stage 1 were negligible and were omitted for clarity. 
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Figure 4.16 Results for Bimodal Distributions by Stage 
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Detailed results for stages 2 and 3 are presented in Tables 4.12. and 4.13, 
respectively. The agreement between the expected and observed results for Table 4.12 is 
generally good. These distributions consistently failed stage 1, which eliminated the 
possibility for interaction between stages 1 and 2. Under these circumstances, equation 
(4.17) produced reasonable approximations for the observed values. 
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Table 4.12 Detailed results for Stage 2. Bimodal Distribution Series 
Distribution Mean 
Standard 
deviation 
Proportion 
< Q-25 
Proportion 
< Q 
Proportion 
< Q-15 
Expected 
Pass  
Q-15 
Stage 2 
Observed 
Pass  
Q-15 
Stage 2 
Predicted 
Pass μStage 2 
> Q 
Observed 
μStage 2 > 
Q 
Expected 
Stage 2 
Observed 
Stage 2 
BD75853 80.00 5.83 0.00 0.47 0.000 0.996 0.997 0.499 0.496 0.497 0.495 
BD74863 79.99 6.71 0.00 0.50 0.001 0.993 0.993 0.498 0.495 0.494 0.493 
BD72883 80.01 8.54 0.00 0.50 0.004 0.948 0.948 0.502 0.504 0.476 0.480 
BD73873 79.99 7.61 0.00 0.50 0.002 0.978 0.978 0.498 0.502 0.487 0.496 
BD734873 79.99 7.84 0.00 0.49 0.011 0.872 0.871 0.498 0.502 0.434 0.468 
BD713883 79.49 9.01 0.00 0.50 0.011 0.872 0.871 0.422 0.422 0.368 0.390 
BD703883 78.99 9.48 0.00 0.50 0.024 0.743 0.744 0.356 0.357 0.264 0.302 
BD693883 78.49 9.96 0.00 0.50 0.047 0.562 0.564 0.300 0.297 0.169 0.219 
BD683883 77.99 10.44 0.00 0.50 0.080 0.369 0.327 0.252 0.253 0.093 0.146 
BD673883 77.50 10.93 0.00 0.50 0.126 0.198 0.194 0.214 0.211 0.042 0.084 
BD643883 75.99 12.37 0.00 0.50 0.313 0.011 0.012 0.131 0.128 0.001 0.009 
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Table 4.13 Detailed results for Stage 3. Bimodal Distribution Series 
Distribution
Predicted 
Pass Q-15 
Stage 3
Observed 
Pass Q-15 
Stage 3
Predicted 
Pass Q-25 
Stage 3
Observed 
Pass Q-25 
Stage 3
Predicted 
Pass 
μStage 3 
>  Q
Observed 
Pass 
μStage 3 
>  Q
Expected 
Stage 3
Observed 
Stage 3
BD75853 1.000 1.000 1.000 1.000 0.499 0.252 0.499 0.252
BD74863 1.000 1.000 1.000 0.999 0.497 0.251 0.497 0.251
BD72883 1.000 1.000 1.000 0.999 0.502 0.275 0.502 0.275
BD73873 1.000 1.000 1.000 1.000 0.497 0.246 0.497 0.246
BD734873 0.998 0.995 1.000 1.000 0.497 0.279 0.496 0.279
BD713883 0.998 0.997 1.000 1.000 0.391 0.206 0.390 0.206
BD703883 0.980 0.974 1.000 1.000 0.301 0.166 0.295 0.165
BD693883 0.900 0.876 1.000 0.999 0.229 0.138 0.206 0.131
BD683883 0.701 0.658 1.000 0.999 0.173 0.116 0.121 0.098
BD673883 0.401 0.358 1.000 0.999 0.131 0.101 0.053 0.065
BD643883 0.009 0.007 0.987 0.987 0.056 0.051 0.000 0.004
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The results for stage 3 support the hypothesis that the coverage test is affected by 
the interaction between stages 2 and 3, as represented by equation (4.16). The predicted 
acceptance value based on the sampling distribution of the mean for an independent 
random sample of 24 units, equation (4.8), consistently over-estimates the observed 
value. The random sample of the additional 12 units collected at stage 3 must not only 
produce a mean greater than Q, but must also overcome the bias introduced, -δ, by the 
sample of 12 that failed stage 2. 
An alternative interpretation for the failure of equation (4.8) to predict observed 
results is that the assumption of normality is simply not valid under these conditions. 
Figure 4.17 illustrates the distribution of observed means for stages 2 and 3 for the 
distribution “BD734873” in Table 4.11. Whereas both distributions are approximately 
normally distributed, the distribution of means observed at stage 3 is shifted below the 
true mean and accounts for the lower than expected acceptance as predicted by equation 
(4.16). 
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Figure 4.17 Distribution of Observed Means at Stages 2 and 3 for BD734873 
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An interesting result extracted from Table 4.13 is the plot of predicted and 
expected values for the Q-15% attribute test at stage 3, presented in Figure 4.18.
The agreement between the expected and observed values is good and supports 
the proposed cumulative binomial distribution as a model for this test. The apparent lack 
of fit in the mid-range of the plot is likely due to the conditional structure of the test. 
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Figure 4.18 Expected versus Observed Results for the Stage 3 Q-15% Attribute Test 
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A final consideration concerning the coverage tests of USP 711 is that it favors 
distributions with increasing variability, as illustrated in Table 4.14. Note that this was 
observed in the results presented for the bimodal distribution in Tables 4.12 and 4.13. 
 Table 4.14 Detailed results for Stage 3. Bimodal Distribution Series 
μ  COV, %
Probability of 
Acceptance Stage 2 
Mean Test
Maximum Probability of 
Acceptance Stage 3 
Mean Test
78.5 0.1 0.1 0.000 0.000
78.5 0.5 0.6 0.000 0.000
78.5 1.0 1.3 0.000 0.000
78.5 2.0 2.5 0.005 0.000
78.5 5.0 6.4 0.149 0.071
78.5 10.0 12.7 0.302 0.231
78.5 12.5 15.9 0.339 0.278
78.5 15.0 19.1 0.365 0.312
78.5 20.0 25.5 0.398 0.357
78.5 30.0 38.2 0.431 0.403  
 
The results presented in Table 4.14 are based on Equations (4.5) and (4.6). For a 
given value of the mean, increasing variability, as measured by the standard deviation, 
improves the probability that a lot will pass the coverage portion of the acceptance test. 
This is contrary to current accepted quality principles, which stress both conformance to 
target and consistency.
 
 
4.13 Conclusions 
 
The results of this study support the following conclusions about the current USP 
dissolution procedure. 
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1. The attribute tests of the method can be modeled as Bernoulli trials with binomial 
distributions, whereas the mean tests can be approximated using the sampling 
distribution for a normal distribution based on sample sizes of 12 and 24. Thus, 
hypotheses 1 and 2 are confirmed. 
2. The models can be applied to any distribution, but the normal approximation for the 
mean becomes increasingly biased as the mean of the distribution approaches the 
lower specification Q.  
3. The models predict excellent statistical power for the stage 1 attribute test. The 
distribution of values greater than Q+5% must exceed 90% to achieve an 80% 
probability of acceptance. 
4. The Q-15% attribute test has good statistical power at stage 2 but is significantly 
weaker at stage 3 until the proportion of values less than Q-15% exceeds 0.25. 
5. The attribute test Q-25% has acceptable power, but is not a reliable detector of 
outliers or extreme values. The proportion of values less than Q-25 must be greater 
than 0.02 for less than 80% acceptance. 
6. The attribute tests at stage 3 interact in the sense that values less than Q-25% are also 
likely to fail the Q-15% criterion. This confirms hypothesis 3. 
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7. The coverage tests at stages 2 and 3 provide 50% coverage at 50% confidence and 
favor lots with high variability For any given value of the mean less than Q, a higher 
variance will increase the probability of acceptance. A likely consequence of these 
findings is a Type II error at stage 2, i.e., lots that would fail at stage 3 will pass at 
stage 2 due to a lack of sensitivity, as was observed in these simulations. 
8. The coverage tests interact to provide an increased failure rate as the mean 
approaches Q. 
The results for Bergum method for these distributions are included in the 
Appendix. In contrast to the content uniformity test, which has a sound statistical basis 
but a small sample size, the dissolution test is inconsistent with respect to the statistical 
power of the stages. Therefore, the Bergum method is acceptable as a secondary standard 
for content uniformity, but not dissolution. 
The final phase of this project was directed towards improving the statistical 
power of the dissolution test. Ideally, this would be accomplished through simple 
modifications to the existing procedure, which would improve the chances for acceptance 
by regulatory agencies and the pharmaceutical industry. The information obtained 
through simulation, that the current method lost power as the sample sizes increased, was 
the basis for investigating modifications to the current procedure. 
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Chapter 5 
 
 
Improving the USP <711> Dissolution Test 
 
 
5.1 Introduction 
 
The revision of the USP <509> content uniformity test resulted from reports 
published by the Japanese Pharmacopeia [20-21] and required approximately 10 years for 
implementation. The simulation results presented in Chapter 4 clearly demonstrate that 
the USP dissolution test also requires revision. The objective of this phase of the project 
was to produce a recommendation to improve the dissolution test based on the insights 
achieved from the simulation studies. 
Ideally, an improved dissolution test would possess the following characteristics: 
1. The revised test would build upon the existing test structure, in as much as possible, 
to facilitate acceptance. 
2. Suggested revisions would be based on sound statistical principles and compared 
comprehensively, as opposed to trial and error presumptions. 
3. The revision would be non-parametric and validated against a range of possible 
population distributions. 
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4. The test would be consistent with revisions to the content uniformity test with respect 
to coverage, if possible. 
 
 
5.2 Considerations for Improvement 
 
Based on the preceding list of characteristics and the knowledge gained through 
the previous simulation studies, it was determined that the stage 1 attribute test would be 
left in its present form. The power of this test makes it a highly improbable event that a 
lot with poor release characteristics would pass simply due to chance. Further, it is 
unlikely that any alternative test based on the mean of six units would offer any 
advantage over the simple attribute test due to the small sample size. 
Similarly, the Q-15% attribute test of stage 2 and the Q-25% attribute test of stage 
3 were demonstrated to be to be reliable and sufficiently powerful to remain in their 
current form. Instead, the opportunities for improvement for the tests lie in the stage 3 Q-
15% attribute test and the coverage (mean) tests for both stages 2 and 3. 
Figure 5.1 illustrates the power curves for possible modifications of the stage 3 
attribute test. The top and middle curves in Figure 5.1 represent the statistical power for 
the current stage 3 and stage 2 Q-15% attribute tests, respectively. As discussed in 
Chapter 4, the gap between these power curves represents a loss of power from stage 2 to 
3 for any given proportion of values, although the effect is more pronounced at the lower 
range of values. 
The second set of power curves represents two possible modifications to the 
existing attribute test. The first curve shows the improvement of power that occurs when 
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the maximum count of observations less than Q-15% is decreased from the current 
compendial value of 2 to 1, whereas the bottom power curve shows a change to “zero,” or 
no values less than Q-15%.
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Figure 5.1 Proposed Modifications to the Q-15% Attribute Test for Stage 3 
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The power curves permit a rational basis for selecting a possible alternative to the 
current standard. If the maximum value is changed from 2 to 1, the power gap between 
stages 2 and 3 decreases significantly in the range from 0 to 15% of proportions less than 
Q-15%. After this point, stage 3 becomes slightly more powerful than the corresponding 
stage 2 test. Therefore, this represents a reasonable alternative value for investigation.  
If the value is change to zero, however, stage 3 is considerably more powerful 
than stage 2 and would reject acceptable lots with non-conforming proportions of less 
than 10%, increasing the producers’ risk or Type II error. The maximum value of 1 is 
clearly the only viable alternative to the current standard. 
Two alternatives are available to improve the coverage portions of the dissolution 
test, including attribute tests in the form of maximum allowable counts of observations 
below Q, and tolerance tests as proposed by Tsong et. al. [64]. An attribute coverage test 
would offer the advantage of being a non-parametric test and would work equally well 
for any distribution, whereas a tolerance test would conceivably be more sensitive for 
distributions approaching normality. Another possibility is that a combination of attribute 
and tolerance formats would offer the best coverage for a revised test.  
The critical binomial distribution [66-67] was used to construct an appropriate 
attribute test for coverage for stages 2 and 3. The critical binomial distribution is 
commonly used to establish quality assurance standards based on attribute classifications. 
For a given number of Bernoulli trials and confidence level (alpha), the distribution 
returns the smallest value for which the cumulative binomial distribution is greater than 
or equal to a criterion value. For dissolution testing, the number of trials is fixed at values 
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equal to 12 and 24 for stages 2 and 3, respectively, and the criterion value is the desired 
level of coverage in terms of values less than Q. 
The values in table 5.1 were calculated using the built-in critical binomial 
distribution function in Microsoft Excel version 2002. As an example of the application 
of this table, consider the current coverage level of the USP dissolution test, 50% or 
P<Q=0.5. Using the information from Table 5.1, a maximum count of 4 values less than 
Q would be expected at 90% confidence, and only 3 at 95% confidence for stage 2 with a 
sample size of 12. Similarly, for stage 3, no more than 9 values less than Q would be 
expected at 90% confidence and no more than 8 would at 95% confidence for a sample 
size of 24. 
The critical value is a testable hypothesis concerning the assumed value of P<Q. 
If the observed number of values meeting the condition of success is greater than the 
critical value, then the null hypothesis that the proportion of values P<Q is the 
corresponding value in Table 5.1 is rejected at the confidence level corresponding to 
alpha. For example, if the proportion of values for P<Q is assumed to be 0.4 or 40%, 
then no more than 3 values less than Q would be expected at stage 2 for 90% confidence. 
A value of 4 would be evidence that the proportion of values less than Q is higher, 
perhaps 0.5 or 50% as listed in Table 5.1. 
Inasmuch as the critical value can only assume an integer value, the numbers 
presented in Table 5.1 approximately correspond to 90% and 95% confidence and are 
somewhat severe criteria. For this reason, values of 2 and 3 for 90% confidence were 
selected as alternative specifications for stage 2, whereas the more severe 95% values of 
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4 and 6 were chosen for stage 3. Table 5.1 suggests that this would improve the coverage 
specification Q from the current 50% level to the 60-70% range. 
 
Table 5.1 Values for the Critical Binomial Distribution  
alpha 0.10 0.05 0.10 0.05
Stage 2 2 3 3
Proportion P <Q Critical Value Critical Value Critical Value Critical Value 
0.1 0 0 1 0
0.2 1 0 2 2
0.3 2 1 4 4
0.4 3 2 7 6
0.5 4 3 9 8
0.6 5 4 11 10
0.7 6 6 14 13
0.8 8 7 17 16
0.9 9 9 20 19
 
 
 
 
5.3 Continuous Alternative for Coverage Based on Tolerance Intervals 
 
The previous discussion demonstrated some of the limitations of attribute testing, 
particularly for relatively small, fixed sample sizes such as those used in stage 2 of the 
dissolution test. An alternative proposed by Tsong et. al. [64] offers a more flexible 
alternative based on a continuous test of hypotheses. 
Tsong proposed and tested a three-stage alternative to the dissolution test that was 
based on an alpha spending concept, which forms the basis of some procedures for 
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conducting multi-tier clinical trials. As part of this discussion, an alternative technique 
based on a one-sided tolerance test was proposed as an alternative. 
Tsong recommended a one-sided tolerance test with 95% confidence based on the 
equation of Faulkenberry and Daley [65] that could be estimated by solving equation 
(4.14) for K, 
N
NzNt
K
P %)95,,1( )1( 
        (4.14) 
As stated previously in Chapter 4, t is the value of the non-central t-distribution 
with N-1 degrees of freedom and non-centrality parameter -√Nz(1-p). A table of one-sided 
tolerance values based on equation (4.14) is presented in Table 5.2. The values of K were 
calculated from the non-central t-distribution for 70%, 80%, and 90% coverage 
(percentage of values greater than Q) for 95% confidence using MATLAB [68]. The 
values listed in Table 5.2 are analogous to the tolerance factors utilized in the revised 
content uniformity test, except that they are for comparison to a lower specification only.  
 Table 5.2 Calculated Tolerance Factors for Dissolution Tests 
Stage Coverage Confidence Level, % K
2 70% 95 1.168
80% 95 1.593
90% 95 2.210
3 70% 95 0.937
80% 95 1.313
90% 95 1.853  
 
The application of the tolerance factor to dissolution testing is straightforward. 
Following the format of the content uniformity test, the decision to accept the lot at stages 
2 or 3 follows if QKsX  , where the average and standard deviation are based on the 
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combined stage 1 and 2 values (N=12) at stage 2 and all 24 measurements at stage 3. 
Note that two advantages of this methodology is that the tolerance factor is automatically 
adjusted as the sample size increases, and further, that the variability of the lot is included 
in the assessment. 
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5.4 Summary of Proposed Changes 
 
A summary of the alterations proposed for stage 2 of the USP dissolution test is 
presented in Figure 5.2. The highlighted areas represent the characteristics of the existing 
test. No change was proposed for the existing attribute test at stage 2, as illustrated in the 
left corner of Figure 5.2. The proposed tolerance and attribute coverage tests are 
presented to the right of the existing attribute test in Figure 5.2. 
 
No xi < Q-15%
No xi < Q test
No more than  2xi’s < Q
No more than  3xi’s < Q
or
or
and and
Denotes current USP standard
%70QKsX 
%80QKsX 
%90QKsX 
QX 
or
or
or
 
Figure 5.2 Proposed Modifications to the Dissolution Test, Stage 2 
The current coverage test for the USP method, corresponding to QX  , can also 
be considered equivalent to 50% coverage at 50% confidence. 
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The proposed modifications to stage 3 are presented in Figure 5.3. The changes to 
the stage 3 outlier test based on the Q-15% standard and the proposed coverage tests are 
illustrated, with highlight portions representing the current USP standard. No change was 
proposed for the Q-25% safety net attribute test at stage 3.  
No xi < Q test
No more than  4xi < Q
No more than  6xi < Q
No more than  2xi’s < Q-15%
No more than  1xi< Q-15%
%70QKsX 
%80QKsX 
%90QKsX 
QX 
or
or
or
or
or
or and and
Denotes current USP standard
 
Figure 5.3 Proposed Modifications to the Dissolution Test, Stage 3 
The proposed modifications describe a factor space for experimentation, 
presented in Table 5.3. The factor levels have been described such that an equivalent to 
the current USP test is included for each modification. For the attribute coverage tests, 
the USP “equivalents” defining the maximum number of values less than Q do not exist, 
but can be considered as “12” for stage 2 and “24” for stage 3. 
Table 5.3 Factor Space for Investigation 
Factor Levels Description
Stage 3 Q-15 Attribute Critical Value 2 1,2(USP)
Stage 2 Attribute Coverage Critical Value, xi<Q 3 2,3, "12"(USP)
Stage 3 Attribute Coverage Critical Value, xi<Q 3 3,4,"24"(USP)
Tolerance, Stages 2&3, 95% confidence 4 90%,80%,70% and "50%"(USP)
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Similarly, the existing USP coverage test based on the mean can be expressed as 
50% coverage at 50% confidence, a specification that corresponds to a tolerance factor of 
K=0. Establishing USP dissolution equivalents as part of the factor space incorporates the 
current method as a baseline for comparison for experimentation. 
The simulations performed with the USP dissolution test confirmed that there are 
significant interactions between stages 2 and 3 of this protocol, so an experimental 
approach capable of investigating interactions is absolutely required. The challenge to 
develop a suitable experimental design is that all factors are nominal, and typical 
approaches to reduce the number of experiments, such as fractional factorial experiments 
[69], are not applicable. 
The factorial space of all possible combinations of these variables includes 72 
trials, which if replicated 20,000 times would require 1,440,000 simulation trials. A full 
factorial design would be inefficient, since many trials would be dedicated to estimating 
effects that are not likely to be significant. The structure of the full factorial design is 
presented in Table 5.4. The factors have been coded as “A”, “B”, “C” and “D” in order of 
appearance in Table 5.3 for simplification. 
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 Table 5.4 Factor Effects of the Full Factorial Design 
Factor Effect
Degrees of 
Freedom Classification
A 1 Main Effect
B 2 Main Effect
C 2 Main Effect
D 3 Main Effect
AxB 2 Second Order Interaction
AxC 2 Second Order Interaction
AxD 3 Second Order Interaction
BxC 4 Second Order Interaction
BxD 6 Second Order Interaction
CxD 6 Second Order Interaction
AxBxC 4 Third Order Interaction
AxBxD 6 Third Order Interaction
AxCxD 6 Third Order Interaction
BxCxD 12 Third Order Interaction
AxBxCxD 12 Fourth Order Interaction
Total 71  
 
The degrees of freedom required to estimate a main effect for a factor is equal to 
the number of levels minus one. The degrees of freedom to estimate higher order terms, 
such as an interaction between two or more factors, is equal to the product of the degrees 
of freedom for each main effect. Thus, the three-factor or third order interaction 
representing AxBxC requires 1x2x2 or 4 degrees of freedom for estimation. 
Higher order interactions consume most of the information provided by a full 
factorial design but rarely provide any useful information [69]. An alternative, Bayesian 
approach [70] to the investigation of complex design spaces is based illustrated in Figure 
5.4. The Bayesian approach is similar to the classical approach to experimentation in 
which screening designs based on fractional factorials precede attempts to optimize the 
system. An advantage of the Bayesian approach, however, is that designs can be 
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constructed specifically to meet the objectives of a particular experiment using Bayesian 
D-optimal design [71]. 
Bayesian D-optimal design is computer-aided approach to experimentation, 
similar to standard D-optimal design. For “main effect” or linear models, the two design 
methods are equivalent. But when information concerning higher order terms is required, 
Bayesian D-optimal designs are more effective than standard D-optimal designs [72-73]. 
The diagram in Figure 5.4 illustrates how a project would be conducted with a 
Bayesian approach. In the screening phase, a design would be constructed to obtain 
maximum information concerning main effects and two-factor interactions. 
A Bayesian D-optimal second order design is a suitable initial platform for 
screening and is equivalent to a “Resolution 5” design in classical experimentation [69] 
with respect to its ability to estimate main-effects and two-factor interactions without 
confounding or aliasing of main effects and two-factor interactions. Bayesian D-optimal 
screening experiments have a proven foundation in other disciplines, and were 
successfully employed to reduce the resource requirements of an industrial high 
throughput screening program [74].  
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Figure 5.4 Bayesian Approach to a Complex Factor Space 
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As opposed to classical factorial experiments, Bayesian designs are not 
orthogonal arrays, and model terms are not truly independent. Therefore, confirmation 
trials are usually required to validate the inferences obtained from the screening stage. A 
special advantage of the Bayesian technique is that the designs can be augmented easily 
with additional trials to resolve ambiguities of interpretation. Although specific programs 
have been described in the literature to construct Bayesian D-optimal designs [75], the 
method can be implemented entirely with commercial software, such as JMP version 8 
[58]. 
The experimental space described by Table 5.3 represents an excellent candidate 
for investigation using the Bayesian approach. Simulation represents a low risk 
environment in which trials can easily be added, if necessary, to expand a model to 
resolve ambiguities. The information contained in Table 5.4 suggests that a design exists 
with the capability to estimate the main effects and two-factor interactions for this factor 
space with 31 degrees of freedom, or 32 trials. 
JMP 8.0 was used to construct the 32 trial Bayesian D-optimal design presented in 
Table 5.5. The experiment described in Table 5.5 represents a carefully chosen subset 
from the full factorial design sufficient to estimate all main effects and second order 
interactions, as confirmed by analyzing the matrix with simulated data from JMP. 
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 Table 5.5 Bayesian D-optimal Screening Design  
Run CV S3 Attribute Tolerance level CV X<Q S2 CV X<Q S3
1 1 80% 2 6
2 1 90% 3 6
3 1 90% 2 off
4 1 70% 3 6
5 2 90% 2 6
6 1 70% 3 4
7 1 80% 2 off
8 2 80% 2 4
9 2 90% 3 4
10 1 90% off 6
11 1 80% 3 off
12 2 off 3 4
13 2 80% off off
14 2 70% off 6
15 1 off off 6
16 2 90% 3 off
17 2 off 2 6
18 2 80% off 6
19 2 70% 2 4
20 2 90% off off
21 2 70% off 4
22 2 80% 3 6
23 1 off off 4
24 1 70% 2 off
25 1 off 3 off
26 1 80% off 4
27 1 70% off off
28 2 off 2 off
29 1 90% 2 4
30 2 70% 3 off
31 2 off off off
32 1 off 2 4  
 
The first column of the experiment represents the trial order, which was 
randomized as part of the design procedure. The second column details the proposed 
modification to the stage 3 Q-15% attribute test, whereas the third column represents the 
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tolerance test. The final two columns represent the attribute coverage test for stages 2 and 
3, respectively. 
Factor levels labeled as “off” are indicators to revert the test to the existing USP 
procedure, if applicable. In the case of the tolerance test, this indicates simple comparison 
of the stage averages to the mean, whereas in the attribute coverage tests, it represents 
total elimination of the comparison. Trial 31 thus represents the existing USP procedure, 
a deliberate intention of the design to provide a benchmark for comparison. 
The experiment in Table 5.5 is a fully saturated design, meaning that there is no 
independent estimate of experimental error. The strategy behind this initial design is that 
some of the two-factor interactions or even main effects would not be significant, 
providing an opportunity to interpret the results through advanced screening tools 
contained in JMP, such as half normal plots [76]. 
 
 
5.5 Project Plan 
 
The project plan for this study is presented in Figure 5.5. Three types of 
distributions were selected for the development of a robust alternative to USP <711>, 
including beta (skewed), normal and uniform distributions. The beta distribution was 
chosen for the initial screening design using the screening design of Table 5.5, since it 
represented a compromise between the extremes of the normal and uniform patterns. 
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Figure 5.5 Project Plan for Improving USP <711> 
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The initial screening study would also serve the purpose of providing feedback of 
the adequacy of the design. This provided a “stop loss” opportunity to correct the matrix 
for inadequacies prior to committing to large scale simulation with normal and uniform 
distributions. 
Upon completion of the simulations with the beta distribution, the revised 
screening experiment would be conducted with normal and uniform distributions. The 
results of all three experimental designs would be analyzed as a single system to select a 
robust candidate or candidates from the factor space as an alternative to the existing USP 
procedure. The candidate trials would be validated against a series of uniform, beta and 
normal distributions and compared to the USP procedure. 
Once a final version of a revised procedure was selected, it would be validated 
against a final series of bimodal distributions. The goal upon completion of this phase of 
the project was to offer a non-parametric, robust alternative to the USP <711> dissolution 
test. 
 
 
5.6 Design Standard and Responses for Optimization 
 
A necessary pre-condition for the success of the project plan was a concise 
performance goal for the revised method in terms of statistical power. Figure 5.6 
illustrates the distributions selected for the development of a revised protocol. 
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Each of the distributions in Figure 5.6 contains approximately 30% of values less 
than the lower specification, Q=80%. Further, each was investigated previously as part of 
a familiarization trial or the actual investigation of the statistical power of USP <711>, 
and all consistently passed the existing procedure. 
The design goal chosen for this study was at 80% power for proportions of 
dissolutions less than Q of 30%. Specifically, any distribution containing 30% or more 
values less than Q should fail the revised protocol in 80% of all repeated testing. Ideally, 
a power curve for a good protocol would display a step function with respect to beta as 
the response as a function of the proportion of non-conforming product. The ideal 
protocol would pass 100% of lots under the coverage limit and fail 100% of lots 
exceeding this limit. Such a protocol is not possible, however, with limited samples sizes. 
This standard was chosen with the understanding that the method would begin to fail lots 
at some point before the proportion of values less than Q reach 30%, as evidenced by the 
power curves presented in Chapter 4. Furthermore, the standard is consistent with the 
behavior observed for the revised content uniformity test and represents a substantial 
improvement over the existing coverage standard for dissolution, 50% coverage at 50% 
confidence. 
The primary response for optimization was the “beta” or failure rate of the overall 
test. The failure rates at stages 1, 2, and 3 were also recorded to gain insight into the 
function of the modification to each test stage. Failure rates at stage 1 were collected for 
confirmation purposes only, since no modifications were proposed for this stage of the 
protocol. 
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5.7 Simulation Procedure 
 
The simulation tool discussed in Chapter 4 was the basis for the experimental 
designs. The original tool was modified to accept two spreadsheets, including one to 
represent the experimental design, and another to automatically link the conditions of the 
experiment to the simulation. Figures 5.2 and 5.3 were the blueprint for modifications to 
the compendial simulator.  
Stage 2 was modified to accept an input value for tolerance K and limits for the 
maximum number of values less than Q. Trials for which these values were set to the 
existing standard were issued values of K=0 and “12” for the maximum number of 
observations less than Q. Stage 3 was treated similarly, with values of K=0 and “24” for 
the maximum number of observations less than Q when existing USP standards were 
required for a trial. Stage 3 also received the appropriate value of “2” or “1” as the 
maximum number of observations less than Q-15% as required by the experimental 
design. 
These simulations were not conducted with lots of discrete values, but instead 
used the distribution functions in Crystal Ball, representing repeated sampling of lots of 
infinite size. The typical characteristics of the distributions are presented in Table 5.6. 
Note that these values only represent expected values. For a given trial, observations 
could appear anywhere within the upper and lower bounds set for the distribution. 
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 Table 5.6 Summary Characteristics of the Test Distributions. Q=80% 
Distribution Beta α=3 β=2
N o r m a l U n i f o r m
Minimum 50.00 0.00 74.00
Maximum 110.00 120.00 94.00
Mean 86.04 85.00 84.00
Standard Deviation 11.98 9.53 5.78
Proportion < Q 31.09 31.27 31.17
Proportion < Q-15% 4.98 5.14 0.00
Proportion < Q-25% 0.00 0.23 0.00
Proportion ≥ Q+5% 55.47 55.33 55.33  
 
Each simulation trial of the experimental designs was replicated 20,000 times. 
The results for each stage of the tests were tabulated in Crystal Ball and transferred to 
JMP version 8.0 for analysis. 
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5.8 Chapter Summary and Testable Hypotheses 
 
The testable hypotheses for Chapter 5 are: 
1. The existing USP dissolution protocol for immediate release solid dosage forms 
can be improved by increasing the coverage of the mean test at stages 2 and 3 and 
by decreasing the attribute coverage requirement for the stage 3 attribute test from 
at most 2 values less than Q<15% to at most 1. 
2. Both attribute coverage requirements, derived from the critical binomial 
distribution, or a continuous coverage test using a K factor would meet the 
improved coverage requirement. 
A Bayesian D-optimal design was constructed to test these hypotheses with simulation 
studies using continuous distributions of infinite size. The results of this study are 
presented in Chapter 6. 
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Chapter 6 
 
 
Presentation and Discussion of Results 
 
 
6.1 Screening Results with the Beta Distribution 
 
The results of the initial screening design with the beta distribution are presented 
in Table 6.1. Each response in Table 6.1 represents the cumulative failure rate or “beta” 
for 20,000 trials at each stage of the revised test protocols. The last four columns 
represent the failure rate of the trial conditions for each stage of the tests and the overall 
beta, which is labeled Power <711>. 
Trial 31 represents the existing USP test, which had an observed beta of 13%. 
This agrees reasonably well to an earlier trial performed with a discrete version of this 
same beta distribution, which was previously presented in Figure 4.3. Approximately 
20,000 replicate tests of that distribution with the USP <711> protocol resulted in an 
observed beta value of 13.63%. 
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Table 6.1 Results for the Beta Distribution 
Run
CV S3 
Attribute
Tolerance 
level
CV X<Q 
S2
CV X<Q 
S3 Power S1 Power S2 Power S3
Power 
<711>
1 1 80% 2 6 97.20 99.29 99.79 96.31
2 1 90% 3 6 97.22 99.95 100.00 97.17
3 1 90% 2 off 97.21 99.95 100.00 97.16
4 1 70% 3 6 97.13 94.85 96.68 89.07
5 2 90% 2 6 96.96 99.94 99.99 96.89
6 1 70% 3 4 97.06 95.38 97.65 90.40
7 1 80% 2 off 97.17 99.23 99.79 96.22
8 2 80% 2 4 97.12 99.32 99.71 96.18
9 2 90% 3 4 97.09 99.96 100.00 97.05
10 1 90% off 6 97.17 99.97 100.00 97.14
11 1 80% 3 off 97.10 99.25 99.80 96.18
12 2 off 3 4 97.00 70.09 96.88 65.87
13 2 80% off off 97.42 99.27 99.84 96.55
14 2 70% off 6 97.28 95.45 96.82 89.90
15 1 off off 6 97.16 47.22 87.16 39.99
16 2 90% 3 off 96.96 99.97 100.00 96.93
17 2 off 2 6 97.05 84.31 77.11 63.09
18 2 80% off 6 97.24 99.25 99.82 96.34
19 2 70% 2 4 97.09 95.64 97.80 90.81
20 2 90% off off 97.10 99.96 100.00 97.06
21 2 70% off 4 97.10 95.42 97.87 90.69
22 2 80% 3 6 97.02 99.29 99.82 96.16
23 1 off off 4 97.06 47.31 96.82 44.46
24 1 70% 2 off 97.17 95.18 96.63 89.37
25 1 off 3 off 97.09 71.24 46.13 31.91
26 1 80% off 4 97.12 99.27 99.80 96.21
27 1 70% off off 97.10 95.19 96.86 89.52
28 2 off 2 off 97.06 84.54 18.27 14.99
29 1 90% 2 4 97.28 99.96 100.00 97.23
30 2 70% 3 off 97.04 95.32 96.86 89.59
31 2 off off off 97.04 47.62 28.12 13.00
32 1 off 2 4 97.12 84.54 96.88 79.54  
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The characteristics of the stage 1 values are presented in Figure 6.1. The 
distribution of stage 1 values is skewed to the right, with an average value of 97.12% 
failure with a standard deviation of approximately 0.1%. The expected value for this 
distribution, based on the characteristics presented in Table 5.6 and the power model for 
stage 1 given by equation (4.8) is 97.09%. 
The standard error of the mean for these values is 0.017%, and provides a rough 
estimate for interpreting the effects observed for stages 2 and 3 in the absence of a true 
error term.
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Figure 6.1 Characteristics of the Stage 1 Results 
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The only response of relevance for this experimental design is the overall power 
contained in the last column of Table 6, since it is the only response that fully measures 
the overall impact of the proposed changes that comprise the experimental design. The 
responses at stage 2 and 3 are useful, however, for assessing the validity of the 32 trial 
Bayesian design. Only changes applied to stage 2 should impact the power at stage 2, and 
the remaining factorial effects should represent random error. Table 6.2 contains the 
results of the full model fit applied to the stage 2 power data. 
Table 6.2 Application of Full Model to Stage 2 Beta Results 
Source Nparm DF Sum of Squares F Ratio Prob > F
Tolerance level 3 3 3808.6324 . .
Tolerance level*CV X<Q S2 6 6 1262.754 . .
CV X<Q S2 2 2 259.3975 . .
Tolerance level*CV X<Q S3 6 6 0.4422 . .
CV S3 Attribute*Tolerance level 3 3 0.1893 . .
CV X<Q S3 2 2 0.1118 . .
CV X<Q S2*CV X<Q S3 4 4 0.0831 . .
CV S3 Attribute*CV X<Q S3 2 2 0.0818 . .
CV S3 Attribute 1 1 0.0365 . .
CV S3 Attribute*CV X<Q S2 2 2 0.0042 . .
 
 
The results of this table can only be interpreted intuitively, since the quantitative 
measures of statistical significance, the F ratio and associated probability value, cannot be 
estimated from the data of Table 6.1. In such cases, the relative magnitudes of the sum of 
squares, which represents the total variation associated with a factor, provides a rough 
estimate of the impact of each effect. Clearly, only effects associated with changes made 
to stage 2, which include the tolerance interval and the attribute test based on a critical 
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value, show any significant contribution to the total variability. In comparison, the 
remaining factors associated with stage 3 represent only noise or random variation. 
The corresponding results of the full model applied to the stage 3 beta results are 
presented in Table 6.3. Changes applied at stage 2 can impact the results of stage 3 due to 
the conditional probabilities involved in the test interpretation. The results of the stage 3 
analysis, however, suggest that the factors relevant to stage 3 dominate the results, with 
the tolerance level and attribute coverage tests accounting for most of the observed 
variation in terms of total sum of squares. 
Table 6.3 Application of Full Model to Stage 3 Beta Results 
Source Nparm DF Sum of Squares F Ratio Prob > F
Tolerance level*CV X<Q S3 6 6 2941.47 . .
Tolerance level 3 3 2915.80 . .
CV X<Q S3 2 2 1185.42 . .
CV S3 Attribute*Tolerance level 3 3 61.41 . .
Tolerance level*CV X<Q S2 6 6 54.55 . .
CV X<Q S2 2 2 48.12 . .
CV S3 Attribute 1 1 39.54 . .
CV X<Q S2*CV X<Q S3 4 4 22.36 . .
CV S3 Attribute*CV X<Q S2 2 2 13.96 . .
CV S3 Attribute*CV X<Q S3 2 2 13.02 . .  
 
The results of Table 6.3 suggest that the proposed modifications indeed interact to 
impact the power at the stage. This is a significant finding, considering that changes to 
compendial methods are typically proposed with only one factor considered at a time. 
The assumption underlying this approach is that the factors are totally independent and 
do not interact appreciably. 
Another interesting result related to this consideration is that the change of the 
critical value for the maximum number of observations less than Q-15% at stage 3 from 
“2” to “1” through the variable “CV S3 Attribute” was a relatively minor effect 
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(hypothesis 2 of Chapter 5). Familiarization trials conducted with a discrete version of 
this same distribution, presented in Table 6.4, had suggested that this change had a 
significant impact when considered alone. 
 Table 6.4 Application of Proposed Stage 3 Modification for Q-15%  
Standard Test Stage 3 Modified
USP Stage Fail % Pass % Fail % Pass %
1 97.19 2.81 97.22 2.78
2 Q-15 47.39 52.61 47.21 52.80
2 Mean 4.55 95.45 4.51 95.49
2 47.94 52.06 47.68 52.33
3 Q-15 24.20 75.80 60.08 39.92
3 Q-25 8.21 91.79 8.56 91.44
3 Mean 1.64 98.36 1.53 98.47
3 29.26 70.74 61.86 38.14
Overall 13.63 86.37 28.67 71.33  
 
The comparison presented in Table 6.4 represents the results obtained from 
approximately 20,000 trials in which the proposed Q-15% modification was compared to 
the standard USP method for a discrete version of the beta test distribution, originally 
presented as Figure 4.3. The modification, which considered individually, increased the 
statistical power of the stage 3 Q-15% attribute test from 24.2% to approximately 60.1%, 
or a factor of 2.48. The apparent impact on the beta of the overall test was an increase in 
power from 13.63% to 28.67%, or approximately a factor of 2. 
The results at stage 3 were further explored to investigate the suggested 
interactions between factors and the apparent lack of significance of the Q-15% main 
effect. The power results for stage 3 were transformed using a Box-Cox transform [67] 
represented by the expression: 
85.173
13
3
2 

PowerS
XPowerS        (6.1) 
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The transformed data were fitted against a reduced model, which included only 
terms representing factor changes at stage 3. The analysis of variance for the reduced 
model is presented in Table 6.5. 
Table 6.5 Reduced Model for Transformed Stage 3 Power 
Source Nparm DF 
Sum of 
Squares F Ratio Prob > F 
Tolerance level 3 3 3085.25 476.43 <.0001 
CV X<Q S3 2 2 734.99 170.25 <.0001 
Tolerance level*CV X<Q S3 6 6 2168.62 167.44 <.0001 
CV S3 Attribute*Tolerance level 3 3 50.24 7.76 0.0027 
CV S3 Attribute 1 1 13.98 6.48 0.0233 
CV S3 Attribute*CV X<Q S3 2 2 9.69 2.24 0.1428 
 
The reduced model, which accounted for more than 99% of the observed variation 
in terms of the adjusted “R Squared,” suggests that the Q-15% modification is 
statistically significant at the 95% confidence level but is relatively minor in comparison 
to the coverage tests and their interaction. This confirms the necessity of using design of 
experiments (DoE) to the consideration of protocol changes, as results based on 
successive single-factor changes could prove highly misleading. 
A promising result for stage 3 was discovered by examining the interaction 
between the tolerance level and stage 3 critical value for coverage based on attribute 
testing, represented by the third term in Table 6.5. The interaction is illustrated in Figure 
6.2. This interaction suggests that the power of the attribute test for coverage based on a 
maximum value of 4 approaches the power of the continuous tolerance tests. 
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Figure 6.2 Characteristics of the Stage 1 Results 
 
The transformed value of power displayed by the critical value of 4, 
approximately 53%, represents an actual power of 96% based on equation (6.1). A 
powerful test based on attributes offers the advantage of being truly non-parametric, as 
opposed to the tolerance test, which assumes a normal distribution. 
Note that the interaction only affects the current tolerance level of the USP test, or 
50% coverage. The parallel slope of the lines for 70%, 80% and 90% tolerance indicate 
that these tolerance levels are independent of the attribute coverage factor, CV X<Q S3. 
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6.2 Overall Power of the Beta Distribution 
 
The overall impact of the proposed changes to the USP protocol can only be 
observed from the overall power results, which appear in the final column of Table 6.1. 
The application of the full model to the overall power results is presented in Table 6.6. 
Table 6.6 Application of the Full Model to Observed Power 
Source Nparm DF Sum of Squares F Ratio Prob > F
Tolerance level 3 3 8529.88 . .
Tolerance level*CV X<Q S3 6 6 1200.73 . .
CV X<Q S3 2 2 655.75 . .
Tolerance level*CV X<Q S2 6 6 505.93 . .
CV X<Q S2*CV X<Q S3 4 4 184.26 . .
CV S3 Attribute*CV X<Q S2 2 2 152.53 . .
CV S3 Attribute*CV X<Q S3 2 2 84.23 . .
CV X<Q S2 2 2 62.90 . .
CV S3 Attribute 1 1 23.19 . .
CV S3 Attribute*Tolerance level 3 3 2.82 . .
 
 
In the absence of a true, independent error term, alternative techniques must be 
employed to interpret the observed results. A scree plot of the “Sum of Squares” is 
presented in Figure 6.3. A scree plot is analogous to a Pareto plot, with the magnitude of 
the sum of squares plotted in descending order representing the relative impact of a factor 
effect. Based on this analysis, the first four or five factor effects appear to be significant. 
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Figure 6.3 Scree Plot of the Analysis of Variance, Overall Power 
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A more sensitive analysis of the data was obtained through application of a half 
normal plot to a transformed version of the data [76]. In this case, a logarithmic 
transformation was applied to the overall power results to reduce the scale effect 
introduced by the extreme range of observed values [69]. The half normal plot is 
presented in Figure 6.4. 
This analysis distributes the total variation for multiple-level factors into 
individual components or contrasts. The relative significance of an effect is assessed by 
its distance above the normal quantile reference line. According to this analysis, the 
single most important effect is the 70% level of the tolerance factor, followed by the 80% 
and 90% levels. The next most significant effects are the attribute coverage at stage 3 and 
the interaction of this effect with the tolerance level. 
A reduced model based on the top seven significant effects from Table 6.6 is 
presented in Table 6.7. These results were also based on the logarithmically transformed 
power response. The results suggest that the top four effects are significant up to the 95% 
confidence level. 
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Figure 6.4 Half Normal Plot for Overall Power 
 
The statistical significance of these results must be interpreted cautiously, since 
the error term used to assess significance is a proxy value created by pooling the sums of 
squares of the four least significant effects from Table 6.6. 
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Table 6.7 Reduced Model for LOG Power 
 
 
 
Figure 6.5 illustrates the details of the highly significant tolerance effect. Note 
that the level “50%*” represents the current USP level, although only at 50% confidence 
as opposed to the 95% level of the other levels. The results support the inference from the 
half normal plot in Figure 6.3, that the effect of implementing the 70% tolerance interval 
represents the most significant effect in the experiment. Statistical power improved as 
tolerance increased beyond the 70% level, but only marginally. 
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Figure 6.5 Main Effect of Tolerance Level 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Tolerance level 3 3 3.47 66.75 <.0001
Tolerance level*CV X<Q S3 6 6 1.71 16.46 0.0008
CV X<Q S3 2 2 0.60 17.25 0.0020
Tolerance level*CV X<Q S2 6 6 0.40 3.85 0.0504
CV X<Q S2 2 2 0.10 2.85 0.1243
CV S3 Attribute 1 1 0.04 2.03 0.1972
CV X<Q S2*CV X<Q S3 4 4 0.07 1.08 0.4348
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The tolerance factor interacts strongly with the stage 3 attribute coverage test, 
thus requiring that these factors be considered jointly. Figure 6.6 illustrates this 
interaction. The interpretation of this effect is straightforward. In the absence of an 
enhanced tolerance level, the implementation of coverage based on attribute testing 
improves the power of the protocol, although to a much less effective level in comparison 
to the tolerance method. A statistical test based on Student’s t for least significant mean 
differences detected no difference between the critical values of “6” and “4” as maximum 
number of values less than Q at 50% tolerance. 
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Figure 6.6 Interaction between Tolerance Level and Stage 3 Attribute Coverage 
 
 
The same inference was obtained from the analysis of the main effect of the stage 
3 attribute factor, presented in Figure 6.7. The inferences from this analysis are that 
implementation of an attribute coverage test improves the overall beta, and further, that 
maximum values of 6 and 4 yield equivalent results. 
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Figure 6.7 Main Effect of Stage 3 Attribute Coverage Test 
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The final inferences of interest represent the main effect of the attribute coverage 
test at stage 2, and the modification of the Q-15% attribute test at stage 3, both of which 
were found to be statistically insignificant. These effects are presented jointly in Figure 
6.8. Analysis of least significant differences confirmed that all levels of these factors are 
equivalent at 95% confidence.  
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Figure 6.8 Main Effects of Stage 2 Attribute Coverage and the Q-15% Stage 3 Modification 
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6.3 Confirmation Trials Based on the Screening Design 
 
The screening design produced some conflicting results concerning certain factor 
effects, particularly with respect to the attribute coverage test at stage 3. The strong 
interaction observed at stage 3, that suggested the maximum value of 4 observations less 
than Q would provide equal power as compared to the 70% tolerance test, was not 
observed in the overall power results. Table 6.8 contains a set of confirmation trials, 
listed as runs 33-36, designed to resolve this ambiguity. 
Expected values for the confirmation trials were calculated from the model in 
Table 6.7 using the general linear model in JMP 8.0. The model does not contain a true 
error term, so confidence levels on the expected values are not useful. Based on the 
random error of the stage 1 power results, however, the model results should be within 
approximately a 3% range of the values in Table 6.8. 
Table 6.8 Confirmation Trials with Expected Values for the Beta Distribution 
 
Run 
CV S3 
Attribute Tolerance level 
CV 
X<Q S2 
CV X<Q 
S3 
Prediction 
Formula 
Power,% 
33 2 50%* 3 6 75.726 
34 2 50%* 2 4 65.728 
35 1 50%* 3 6 81.973 
36 2 70% off off 86.882 
 
 
The results from the first screening design suggest that a tolerance level of 70% 
would produce the desired power for an improved version of USP <711>. The results 
also suggest that the strongest attribute coverage combination, run 34, would fall short of 
  
  176 
the goal of 80% power. Runs 33 and 35 were included since they approach the desired 
coverage level and provide more detail about the attribute test modifications. 
The confirmation trials were added to the USP simulation tool and replicated 
20,000 times for the beta distribution. The results of these additional trials are presented 
in Table 6.9. With the exception of trial 36, the overall observed power (“Power <711>”) 
and predicted values do not agree and represent a deficiency in the original design. 
  
Table 6.9 Results for the Confirmation Trials for the Beta Distribution 
Run 
CV S3 
Attribute 
Tolerance 
level 
CV 
X<Q 
S2 
CV 
X<Q 
S3 
Power 
S1 
Power 
S2 
Power 
S3 
Power 
<711> 
Prediction 
Formula 
Power % 
33 2 50%* 3 6 97.075 70.585 81.735 56.005 75.726 
34 2 50%* 2 4 97.025 84.638 96.536 79.275 65.728 
35 1 50%* 3 6 97.160 70.507 86.534 59.280 81.973 
36 2 70% off off 97.040 95.662 96.779 89.840 86.882 
 
 
The observation that the actual results followed a direction contrary to what was 
expected suggests an unrecognized or poorly estimated interaction effect. Thus, a 
significant drop of 10% power was predicted for trials 33 and 34, whereas an increase of 
23% was observed. Similarly, a relatively small increase of power was expected from 
runs 35 and 36, but instead, a relatively large increase of ~30% was recorded. 
An advantage of the Bayesian approach to DoE is the ability to augment and 
revise an experiment as new data are obtained. The data from Table 6.9 were added as 
trials 33–36 to the original screening design, and the results were analyzed as a single 
experiment. The results of the revised analysis are presented in Table 6.10. 
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Table 6.10 Revised Model for the Beta Distribution 
RSquare 0.9962
RSquare Adj 0.9670
Root Mean Square Error 4.42
Mean of Response 80.65
Observations (or Sum Wgts) 36
Source Nparm DF Sum of Squares F Ratio Prob > F
Tolerance level 3 3 12377.41 211.31 <.0001
CV X<Q S3 2 2 687.03 17.59 0.0104
Tolerance level*CV X<Q S3 6 6 1611.40 13.76 0.0120
Tolerance level*CV X<Q S2 6 6 560.13 4.78 0.0759
CV S3 Attribute*CV X<Q S3 2 2 110.66 2.83 0.1712
CV S3 Attribute*CV X<Q S2 2 2 101.38 2.60 0.1894
CV X<Q S2*CV X<Q S3 4 4 198.22 2.54 0.1945
CV X<Q S2 2 2 79.77 2.04 0.2447
CV S3 Attribute 1 1 22.11 1.13 0.3472
CV S3 Attribute*Tolerance level 3 3 14.59 0.25 0.8586  
 
The addition of the data for runs 33-36 significantly improved the model in terms 
of agreement to observed results, but did not significantly impact the original 
conclusions. The revised model required no transformation of the response data and 
apparently improved the precision of the factor effects.  
The revised table of results for the beta distribution, including the original and 
revised model predictions, is presented in Table 6.11. A plot of the predicted versus 
actual values for the original and revised models appears in Figure 6.9. 
The impact of the additional trials on the final model for the beta distribution is 
clear in Figure 6.9. The original model lacked accuracy in the mid-range of the power 
response, and precision at the extremes. The revised model based on 36 trials resolved 
this issue. One possible explanation for the superior performance of the 36 trials, as 
opposed to the original 32 trial design, is that the augmented design is a multiple or half-
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fraction of the 72 trial full factorial matrix. In any case, the augmented 36 trial 
experiment was adopted to investigate the uniform and normal distributions.
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Table 6.11 Revised Results for the Beta Distribution, Runs 1-18 
Run 
CV S3 
Attribute 
Tolerance 
level 
CV X<Q 
S2 
CV X<Q 
S3 
Power 
S1 
Power 
S2 Power S3 
Power 
<711> 
Prediction 
Formula 
Power % 
Revised Pred 
Formula Power 
<711> 
1 1 80% 2 6 97.200 99.285 99.793 96.305 104.216 97.019 
2 1 90% 3 6 97.220 99.949 99.995 97.165 100.228 98.828 
3 1 90% 2 off 97.205 99.954 99.995 97.155 92.615 97.249 
4 1 70% 3 6 97.130 94.847 96.684 89.070 92.193 89.722 
5 2 90% 2 6 96.960 99.938 99.990 96.890 92.947 96.890 
6 1 70% 3 4 97.060 95.379 97.645 90.395 87.644 89.094 
7 1 80% 2 off 97.165 99.228 99.793 96.215 91.049 94.365 
8 2 80% 2 4 97.120 99.315 99.710 96.175 93.917 97.312 
9 2 90% 3 4 97.085 99.964 99.995 97.045 88.746 97.139 
10 1 90% off 6 97.170 99.969 99.995 97.135 98.162 95.472 
11 1 80% 3 off 97.100 99.253 99.798 96.180 102.690 98.453 
12 2 50%* 3 4 97.000 70.088 96.882 65.865 74.285 67.072 
13 2 80% off off 97.415 99.266 99.840 96.545 95.555 96.122 
14 2 70% off 6 97.275 95.451 96.817 89.895 86.850 89.243 
15 1 50%* off 6 97.155 47.218 87.160 39.985 41.509 40.740 
16 2 90% 3 off 96.955 99.974 99.995 96.925 102.751 95.168 
17 2 50%* 2 6 97.050 84.307 77.108 63.090 60.774 62.376 
18 2 80% off 6 97.240 99.254 99.819 96.340 95.053 97.899 
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Table 6.11, continued. Revised Results for the Beta Distribution, Runs 19-36 
Run 
CV S3 
Attribute 
Tolerance 
level 
CV X<Q 
S2 
CV X<Q 
S3 
Power 
S1 
Power 
S2 Power S3 
Power 
<711> 
Prediction 
Formula 
Power % 
Revised Pred 
Formula Power 
<711> 
19 2 70% 2 4 97.085 95.643 97.798 90.810 95.066 91.590 
20 2 90% off off 97.100 99.959 100.000 97.060 96.045 98.723 
21 2 70% off 4 97.100 95.422 97.874 90.685 89.344 91.206 
22 2 80% 3 6 97.015 99.294 99.824 96.160 90.064 93.887 
23 1 50%* off 4 97.060 47.306 96.820 44.455 44.063 45.070 
24 1 70% 2 off 97.170 95.179 96.626 89.365 85.364 88.585 
25 1 50%* 3 off 97.090 71.238 46.129 31.905 28.288 30.739 
26 1 80% off 4 97.115 99.269 99.798 96.210 98.523 95.073 
27 1 70% off off 97.095 95.190 96.857 89.520 94.050 90.949 
28 2 50%* 2 off 97.060 84.540 18.268 14.990 17.396 17.526 
29 1 90% 2 4 97.275 99.959 99.995 97.230 106.323 97.136 
30 2 70% 3 off 97.035 95.316 96.859 89.585 89.267 90.234 
31 2 50%* off off 97.035 47.622 28.120 12.995 12.629 11.625 
32 1 50%* 2 4 97.120 84.540 96.876 79.540 71.151 81.456 
33 2 50%* 3 6 97.075 70.585 81.735 56.005 75.726 58.085 
34 2 50%* 2 4 97.025 84.638 96.536 79.275 65.728 75.537 
35 1 50%* 3 6 97.160 70.507 86.534 59.280 81.973 57.159 
36 2 70% off off 97.040 95.662 96.779 89.840 86.882 88.542 
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Figure 6.9 Actual versus Predicted Values for the Beta Distribution 
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6.4 Simulations with Normal and Uniform Distributions 
 
The compendial simulator was used to investigate the normal and uniform 
distributions of Table 5.6 using the revised 36 trial Bayesian D-optimal design. Each 
simulation study was replicated 20,000 times using the continuous distribution functions 
contained in Crystal Ball.  
The results of the simulations for the normal and uniform distributions are 
presented in Tables 6.12 and 6.13, respectively. These results were not analyzed 
separately, but instead were combined with the beta distribution results to produce a 108 
trial experimental design with a new nominal factor, “Distribution.” As a combined 
database, the resulting experimental design can be employed to investigate all two-factor 
interactions between the modifications and the distribution types. 
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Table 6.12 Simulation Results for the Normal Distribution 
Run
CV S3 
Attribute
Tolerance 
level
CV X<Q 
S2
CV X<Q 
S3
Power 
S1
Power 
S2
Power 
S3
Power 
<711>
1 1 80% 2 6 98.38 99.29 99.87 97.56
2 1 90% 3 6 98.32 99.96 100.00 98.28
3 1 90% 2 off 98.59 99.99 100.00 98.57
4 1 70% 3 6 98.46 95.57 96.91 91.19
5 2 90% 2 6 98.56 99.99 100.00 98.55
6 1 70% 3 4 98.36 95.68 97.42 91.68
7 1 80% 2 off 98.49 99.37 99.83 97.70
8 2 80% 2 4 98.48 99.40 99.86 97.75
9 2 90% 3 4 98.55 99.96 100.00 98.51
10 1 90% off 6 98.32 99.99 100.00 98.30
11 1 80% 3 off 98.58 99.48 99.87 97.94
12 2 50%* 3 4 98.41 58.00 97.92 55.89
13 2 80% off off 98.29 99.34 99.82 97.46
14 2 70% off 6 98.51 95.62 96.94 91.31
15 1 50%* off 6 98.52 21.10 79.53 16.53
16 2 90% 3 off 98.44 99.98 100.00 98.41
17 2 50%* 2 6 98.42 77.83 73.75 56.49
18 2 80% off 6 98.47 99.37 99.84 97.69
19 2 70% 2 4 98.41 95.62 97.42 91.67
20 2 90% off off 98.36 99.96 100.00 98.32
21 2 70% off 4 98.28 95.43 97.37 91.31
22 2 80% 3 6 98.49 99.38 99.77 97.65
23 1 50%* off 4 98.37 21.00 95.81 19.79
24 1 70% 2 off 98.29 95.76 96.67 90.99
25 1 50%* 3 off 98.41 58.09 12.64 7.23
26 1 80% off 4 98.55 99.39 99.87 97.82
27 1 70% off off 98.42 95.56 96.62 90.87
28 2 50%* 2 off 98.47 77.39 3.88 2.96
29 1 90% 2 4 98.59 99.96 100.00 98.55
30 2 70% 3 off 98.32 95.59 96.44 90.63
31 2 50%* off off 98.32 21.01 10.22 2.11
32 1 50%* 2 4 98.45 77.38 96.25 73.32
33 2 50%* 3 6 98.41 57.38 81.41 45.97
34 2 50%* 2 4 98.33 78.27 96.28 74.10
35 1 50%* 3 6 98.40 58.95 82.67 47.95
36 2 70% off off 98.49 95.45 96.52 90.74  
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Table 6.13 Simulation Results for the Uniform Distribution 
Run
CV S3 
Attribute
Tolerance 
level
CV X<Q 
S2
CV X<Q 
S3 Power S1 Power S2 Power S3
Power 
<711>
1 1 80% 2 6 99.08 98.36 99.28 96.75
2 1 90% 3 6 99.04 99.83 99.99 98.87
3 1 90% 2 off 99.25 99.82 99.99 99.06
4 1 70% 3 6 99.13 90.64 90.09 80.95
5 2 90% 2 6 99.17 99.82 99.99 98.99
6 1 70% 3 4 99.22 90.80 94.46 85.10
7 1 80% 2 off 99.13 98.38 99.36 96.90
8 2 80% 2 4 99.20 98.40 99.40 97.03
9 2 90% 3 4 99.12 99.82 100.00 98.93
10 1 90% off 6 99.15 99.84 99.99 98.98
11 1 80% 3 off 99.16 98.45 99.40 97.04
12 2 50%* 3 4 99.25 51.21 99.47 50.56
13 2 80% off off 99.15 98.47 99.37 97.02
14 2 70% off 6 99.07 91.07 90.72 81.85
15 1 50%* off 6 99.18 0.79 99.36 0.78
16 2 90% 3 off 99.26 99.82 99.99 99.07
17 2 50%* 2 6 99.12 75.30 74.30 55.46
18 2 80% off 6 99.16 98.48 99.29 96.96
19 2 70% 2 4 99.27 91.73 94.57 86.11
20 2 90% off off 99.15 99.90 99.99 99.04
21 2 70% off 4 99.08 91.01 94.54 85.25
22 2 80% 3 6 99.19 98.37 99.39 96.98
23 1 50%* off 4 99.11 0.72 100.00 0.71
24 1 70% 2 off 99.16 91.64 90.02 81.80
25 1 50%* 3 off 99.18 51.23 0.04 0.02
26 1 80% off 4 99.19 98.43 99.25 96.90
27 1 70% off off 99.16 91.12 90.28 81.57
28 2 50%* 2 off 99.19 75.03 0.04 0.03
29 1 90% 2 4 99.19 99.79 100.00 98.98
30 2 70% 3 off 99.13 91.07 90.31 81.53
31 2 50%* off off 99.23 0.76 0.67 0.01
32 1 50%* 2 4 99.28 74.65 96.66 71.64
33 2 50%* 3 6 99.01 50.62 85.05 42.63
34 2 50%* 2 4 99.05 74.80 96.91 71.80
35 1 50%* 3 6 99.18 51.28 85.63 43.55
36 2 70% off off 99.16 91.31 90.27 81.73  
  
  185 
 
 
6.5 Analysis and Interpretation of the Combined Results 
 
The database created by folding the experiments for each distribution resulted in a 
matrix with highly desirable properties for analysis. Table 6.14 describes the analysis 
requirements for this experiment in terms of main effects and second order interactions. 
 Table 6.14 Resource Requirements for estimation of a Second Order Model 
Source DF
CV S3 Attribute 1
CV S3 Attribute*CV X<Q S2 2
CV S3 Attribute*CV X<Q S3 2
CV S3 Attribute*Tolerance level 3
CV X<Q S2 2
CV X<Q S2*CV X<Q S3 4
CV X<Q S3 2
Distribution Type 2
Distribution Type*CV S3 Attribute 2
Distribution Type*CV X<Q S2 4
Distribution Type*CV X<Q S3 4
Distribution Type*Tolerance level 6
Tolerance level 3
Tolerance level*CV X<Q S2 6
Tolerance level*CV X<Q S3 6
Total 49  
 
Estimation of all main effects and two-factor interactions, including interactions 
with the newly introduced “Distribution” factor, requires 49 degrees of freedom. The 
expanded design matrix contains 107 degrees of freedom, most of which represent third 
order interactions among the distribution factor and the protocol variables. The 
assumption that higher order interactions are likely inconsequential renders 58 degrees of 
freedom for estimation of experimental error. Therefore, the expanded matrix is 
essentially self-standing in terms of its ability to identify significant effects. 
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The model form of Table 6.14 was applied to the overall power response using 
the general linear model platform in JMP version 8.0. Table 6.15 lists the analysis of 
variance and summary of fit characteristics of the resulting model. A plot of the actual 
versus predicted values is presented in Figure 6.10. 
 Table 6.15 Analysis of Variance Details for the Combined Data  
RSquare 0.9886
RSquare Adj 0.9789
Root Mean Square Error 4.3471
Mean of Response 77.2732
Observations (or Sum Wgts) 108
Source DF Sum of Squares Mean Square F Ratio Prob > F
Model 49 94891.17 1936.55 102.48 <.0001
Error 58 1096.06 18.90
C. Total 107 95987.23
 
 
A slightly better fit of the data (RSquare Adjusted >0.99) could be obtained 
through a Box-Cox transformation of the power response, similar to that of equation 
(6.1). The transformation did not add value, however, in terms of interpreting the model 
effects. Thus, the original model was considered to be the final version.  
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Figure 6.10 Actual versus Predicted Values for the Combined Data 
 
The adjusted RSquare value of 0.98 indicates that the original model accounts for 
approximately 98% of the variation of the combined data. The slight improvement 
obtained through transformation was concluded to be simply a scale effect due to the 
extreme range of the observations over the power scale, which spans from 0% to 100%. 
Note that the quality of the model fit justifies the assumption of the third-order interaction 
terms as an estimate of experimental error. 
A detailed analysis of variance for the power model, with effects sorted in 
descending order of importance, is presented in Table 6.16. The most important effects 
are the “Tolerance level” factor, and its interactions with the attribute coverage tests. The 
“Distribution Type” factor was also statistically significant, but not nearly to the same 
  
  188 
extent as the first five effects in Table 6.16. The results also suggest that the distribution 
type interacts with the tolerance level. 
Table 6.16 Detailed Analysis of Variance for the Final Model 
Source Nparm DF Sum of Squares F Ratio Prob > F 
Tolerance level 3 3 56427.14 995.32 0.00000 
CV X<Q S3 2 2 2775.02 73.42 0.00000 
Tolerance level*CV X<Q S3 6 6 5313.02 46.86 0.00000 
Tolerance level*CV X<Q S2 6 6 3102.75 27.36 0.00000 
CV S3 Attribute*CV X<Q S2 2 2 825.53 21.84 0.00000 
Distribution Type 2 2 643.36 17.02 0.00000 
CV X<Q S2 2 2 547.31 14.48 0.00001 
Distribution Type*Tolerance level 6 6 1623.26 14.32 0.00000 
CV X<Q S2*CV X<Q S3 4 4 1060.24 14.03 0.00000 
CV S3 Attribute*CV X<Q S3 2 2 419.38 11.10 0.00008 
Distribution Type*CV S3 Attribute 2 2 127.27 3.37 0.04134 
CV S3 Attribute*Tolerance level 3 3 151.18 2.67 0.05610 
Distribution Type*CV X<Q S2 4 4 154.42 2.04 0.10022 
CV S3 Attribute 1 1 12.16 0.64 0.42564 
Distribution Type*CV X<Q S3 4 4 3.61 0.05 0.99558 
 
 
A detailed list of parameter estimates for the model appears in Table 6.17. This 
table includes all parameters necessary to construct reduced models or reproduce the 
predicted values. All parameters have been listed for completeness, including those for 
non-statistically significant effects. 
All terms of this model are nominal or ordinal, so the parameter estimates are 
simply added to the intercept to estimate a particular combination of factors. The overall 
power observed across the factor space produced an average power of 78.729%, 
represented by the intercept in Table 6.17. The effect of applying the current USP 
coverage standard, 50% coverage at 50% confidence, drops the power by 42.236%. 
Increasing the tolerance level to 70% coverage at 95% increases the power over the 
average value by 7.56%. 
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Note that if the coverage level of 50% is dropped from the model, the remaining 
levels of the tolerance factor, which represent 95% confidence, could be reclassified as a 
continuous factor. This would be useful for determining an exact level of coverage for a 
desired power or beta. The results produced by this experimental design, however, 
already contain sufficient information to achieve the original goal of this project, which 
was 80% power for 30% coverage. 
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Table 6.17 Parameter Estimates for the Combined Model 
Term Estimate 
Std 
Error t Ratio Prob>|t| 
Intercept 78.729 0.483 163.067 0.00000 
Tolerance level[50%] -42.236 0.782 -53.983 0.00000 
Tolerance level[80%] 17.053 0.882 19.342 0.00000 
Tolerance level[50%]*CV X<Q S3[off] -17.476 1.234 -14.157 0.00000 
CV X<Q S3[off] -8.473 0.699 -12.113 0.00000 
Tolerance level[50%]*CV X<Q S2[off] -12.230 1.129 -10.835 0.00000 
Tolerance level[70%] 7.560 0.883 8.558 0.00000 
Distribution Type[Beta]*Tolerance level[50%] 8.307 0.974 8.527 0.00000 
Tolerance level[50%]*CV X<Q S3[6] 6.652 1.052 6.324 0.00000 
Tolerance level[80%]*CV X<Q S2[off] 7.317 1.280 5.716 0.00000 
CV X<Q S2[off] -4.164 0.776 -5.363 0.00000 
CV S3 Attribute[1]*CV X<Q S2[off] -4.696 0.904 -5.197 0.00000 
CV X<Q S3[6] 3.253 0.677 4.808 0.00001 
Tolerance level[70%]*CV X<Q S3[off] 6.546 1.376 4.756 0.00001 
Distribution Type[Beta] 2.781 0.599 4.639 0.00002 
CV X<Q S2[off]*CV X<Q S3[off] 5.887 1.280 4.599 0.00002 
CV S3 Attribute[1]*CV X<Q S3[off] 4.443 1.019 4.361 0.00005 
Tolerance level[80%]*CV X<Q S3[6] -5.759 1.461 -3.941 0.00022 
Distribution Type[Beta]*Tolerance level[80%] -3.486 1.078 -3.234 0.00201 
Tolerance level[80%]*CV X<Q S3[off] 3.980 1.241 3.207 0.00219 
Tolerance level[70%]*CV X<Q S3[6] -4.519 1.414 -3.195 0.00226 
CV X<Q S2[3] 2.217 0.704 3.150 0.00258 
Distribution Type[Normal]*Tolerance 
level[50%] 
-2.901 0.974 -2.978 0.00423 
Distribution Type[Normal]*Tolerance 
level[70%] 
2.798 1.053 2.658 0.01014 
CV S3 Attribute[1]*Tolerance level[80%] 2.877 1.098 2.620 0.01121 
Distribution Type[Beta]*CV S3 Attribute[1] 1.358 0.595 2.281 0.02624 
Distribution Type[Beta]*CV X<Q S2[off] 1.890 0.855 2.212 0.03095 
CV S3 Attribute[1]*CV X<Q S2[3] -2.018 0.983 -2.053 0.04459 
Tolerance level[70%]*CV X<Q S2[3] 2.801 1.575 1.778 0.08058 
CV S3 Attribute[1]*Tolerance level[50%] -1.344 0.898 -1.497 0.13978 
Distribution Type[Beta]*Tolerance level[70%] -1.184 1.053 -1.124 0.26547 
Tolerance level[70%]*CV X<Q S2[off] 1.484 1.363 1.089 0.28061 
CV S3 Attribute[1]*CV X<Q S3[6] -0.829 0.872 -0.951 0.34569 
Tolerance level[50%]*CV X<Q S2[3] -1.120 1.294 -0.865 0.39041 
CV X<Q S2[off]*CV X<Q S3[6] -0.931 1.109 -0.840 0.40449 
CV S3 Attribute[1] 0.416 0.518 0.802 0.42564 
Distribution Type[Normal] 0.447 0.599 0.745 0.45927 
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Table 6.17, continued. Parameter Estimates for the Combined Model 
Term Estimate 
Std 
Error t Ratio Prob>|t| 
CV X<Q S2[3]*CV X<Q S3[6] 0.621 1.068 0.582 0.56288 
Tolerance level[80%]*CV X<Q S2[3] -0.772 1.481 -0.521 0.60427 
CV X<Q S2[3]*CV X<Q S3[off] 0.631 1.212 0.521 0.60456 
Distribution Type[Beta]*CV X<Q S3[off] 0.291 0.831 0.350 0.72729 
Distribution Type[Normal]*CV X<Q S3[off] -0.285 0.831 -0.343 0.73298 
Distribution Type[Beta]*CV X<Q S3[6] -0.272 0.858 -0.317 0.75268 
Distribution Type[Normal]*Tolerance 
level[80%] 
0.273 1.078 0.253 0.80080 
Distribution Type[Normal]*CV X<Q S3[6] 0.188 0.858 0.220 0.82684 
Distribution Type[Normal]*CV X<Q S2[3] -0.138 0.849 -0.163 0.87120 
Distribution Type[Normal]*CV S3 
Attribute[1] 
-0.041 0.595 -0.069 0.94561 
CV S3 Attribute[1]*Tolerance level[70%] -0.060 1.198 -0.050 0.95999 
Distribution Type[Normal]*CV X<Q S2[off] -0.030 0.855 -0.035 0.97190 
Distribution Type[Beta]*CV X<Q S2[3] -0.002 0.849 -0.003 0.99769 
 
 
 
6.6 Detailed Interpretation of Significant Factor Effects 
 
Although the detailed list of significant effects is expansive, the overall 
interpretation of this experiment can be simplified to a discussion of several important 
factors and interactions. Figure 6.11 illustrates the main effect of the highly significant 
tolerance factor. 
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Figure 6.11 Main Effect of Tolerance Level 
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The accompanying table presents the results of individual pair-wise comparisons 
of least squares means in the model using Student's t-tests at 95% confidence. The results 
indicate that the 70% tolerance level is not equivalent to the 80% and 90% levels, as was 
suggested previous results with the beta distribution. The 70% level, however, is a 
significant improvement over the existing 50% level of the USP method. 
These results suggest that a tolerance level of 70% would produce at least 80% 
power across a range of likely distributions for the 30% coverage specification. If 
increased power were desired, the 80% level would increase the power to over 90%. The 
70% level, however, has the advantage that it would be less sensitive to the assumption of 
normality [60]. 
The interaction between the tolerance level and distribution types for this 
experiment is presented in Figure 6.12. These results suggest that the current USP 
specification of 50% tolerance is the most sensitive to the shape of the distribution, a 
finding that was confirmed through a Student’s t-test of least square means.  
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Figure 6.12 Tolerance Level x Distribution Type Interaction 
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The results of the least mean square analysis based on paired comparisons 
analysis for 95% confidence are presented in Table 6.18. Levels not connected by the 
same letter in Table 6.18 are statistically different. Thus, all levels of the 80% and 90% 
tolerance levels are equivalent across all distributions, whereas the means for the beta and 
normal distribution are equivalent for 70% tolerance. But all levels for 50% tolerance are 
significantly different, indicating that this specification is the most affected by the shape 
of the underlying distribution. 
Table 6.18 Significant Factor levels for the Distribution Type by Tolerance Interaction 
Level Least Sq Mean
Uniform,90% A 96.933
Normal,90% A 96.629
Normal,80% A 96.502
Uniform,80% A 95.767
Beta,90% A 95.496
Beta,80% A 95.077
Normal,70% B 89.533
Beta,70% B 87.886
Uniform,70% C 81.447
Beta,50% D 47.581
Normal,50% E 34.039
Uniform,50% F 27.859  
 
This characteristic is probably related to the fact that all tolerance levels greater 
than 50% account for the variability of the data at both stages 2 and 3 of the test. The 
effect is weakest for the 70% level, which has the lowest K values. Nevertheless, the 
results of Table 6.18 suggest that a 70% tolerance level would provide 80% across a 
range of possible distributions. 
The remaining significant effects of interest concern the attribute coverage tests 
and their interaction with the tolerance levels. The interaction between the tolerance level 
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and attribute coverage test at stage 2 is presented in Figure 6.13. Prior to this 
investigation, it was thought that a particular combination of tolerance level and attribute 
coverage might enhance power, particularly with non-normal distributions. But the 
results of this investigation suggest that attribute coverage does not enhance the power of 
the tolerance factor. 
The results for the interaction plot in Figure 6.13 indicates that in the absence of a 
K factor, or 50% tolerance, application of a coverage test in attribute terms enhances the 
power of the existing USP method. Yet, even the maximum strength of this test, 
represented by a value of “2” for the maximum number of observations less than Q, never 
approaches the power of the tolerance factor when applied to stage 2. 
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Figure 6.13 Tolerance Level x Attribute Coverage Interaction at Stage 2 
The same arguments apply to the corresponding interaction for stage 3, presented 
in Figure 6.14. The interaction is due to the introduction of attribute coverage to 
supplement the current USP method, represented by the “off” level at 50% tolerance. 
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Figure 6.14 Tolerance Level x Attribute Coverage Interaction at Stage 2 
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Note that whereas the attribute factor does enhance the statistical power as 
compared to the pure USP test, it does not approach the power of the tolerance factor 
when considered alone. According to the results in Table 6.16, however, the attribute 
coverage tests at stages 2 and 3 interact, and therefore, must be interpreted jointly. The 
interaction between the attribute coverage tests at stages 2 and 3 is presented in Figure 
6.15. 
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Figure 6.15 Interaction between Attribute Coverage Tests at Stages 2 & 3 
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The parallel plots describe the power of the of the stage 3 attribute coverage test 
for the 3 levels of the stage 2 coverage test, listed in the legend at the far right of the plot. 
The results suggest that the combination of a coverage value of “4” at stage 3 when 
combined with a value of “2” at stage 2 produces an increase in power than would be 
expected from consideration of main effects alone. 
The results of paired t-tests for the least square means, listed in table 6.19 confirm 
this inference at 95% confidence. Least square means not connected to the same letter in 
Table 6.19 are statistically different, and the highest level “A” corresponds to the highest 
combination observed in Figure 6.15. 
Table 6.19 Paired Comparisons of the Attribute Coverage Interaction 
Stage 2 Critical 
Value
Stage 3 Critical 
Value
Least Sq 
Mean
2 4 A 92.10
3 4 B 84.91
3 6 B 84.82
2 6 B 84.24
off 6 C 76.89
off 4 C D 74.83
3 off C D 73.10
off off D 71.98
2 off E 65.68  
 
The inference from this analysis is that a combination a critical values of “2” and 
“4” for the maximum number of observations less than Q at stages 2 and 3, respectively, 
could increase the power of the existing USP by 20% in the absence of a tolerance factor, 
K. Note that this trial was previously observed as “run 34” of the confirmations trials.  
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6.7 Conclusions  
 
The results of the experimental designs employed in this support the following 
conclusions. 
1. The results of these experiments confirm hypothesis 1 of Chapter 5, that the coverage 
of the existing USP test could be improved either by attribute coverage requirements 
or through application of a tolerance factor, K. 
2. The experiments did not produce any results to confirm hypothesis 2 of Chapter 5. 
Reducing the maximum number of values less than Q-15% at stage 3 from a 
“maximum of 2” to “at most 1” did not improve the power of the test. 
3. The original 32 trial Bayesian D-optimal design identified significant main effects 
and produced evidence for two-factor interactions but suffered lack of fit in the 
middle range of the factor space. 
4. Augmentation of the original design with four additional trials resolved the lack of fit 
issue and produced an acceptable model for the beta distribution. 
5. Replication of the 36 trial augmented design with uniform and normal distributions 
resulted in a factor space with an additional nominal factor, “Distribution Type.” The 
third-order interactions of the distribution factor with two-factor interactions of 
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interest from the proposed modifications provided a suitable term for estimation of 
experimental error. 
6. The complete factor space of the combined experiments was successfully modeled 
and interpreted without transformation of the power response. 
7. The model suggested that practically all modifications of the USP <711> procedure 
were successful, as evidenced by the fact that the trial representing the USP method 
(run 31) produced the lowest power of all combinations observed for the test 
distributions. 
8. The overwhelmingly significant effect in this experiment was the “Tolerance Level” 
factor and its interactions with the independent attribute coverage tests and 
distribution factor. 
9. Although the tolerance factor assumes a normal distribution of the observations, it 
was less sensitive to departures from a normal distribution than the existing USP 
coverage test.  
10. The inference from analysis of the tolerance factor suggests that a tolerance level of 
70% would provide 80% power for any likely product distribution with a portion of 
values less than Q greater than or equal to 0.30. 
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11. Increased coverage requirements could be realized through increasing the tolerance 
level, but this would also likely increase the sensitivity of the method to the 
assumption of normality. 
12. An alternative to the 70% tolerance test at stages 2 and 3 is an attribute coverage 
specification with critical values of “2” and “4” as the maximum number of 
observations less than Q. The attribute alternative is not as powerful as the tolerance 
test, but has the advantage that it is a non-parametric test. 
Based on the conclusions, three trials from the factor space were selected for 
extended confirmation and validation trials. These runs included trial 34, the attribute 
coverage alternative, trial 36, the tolerance level recommendation, and trial 31, the USP 
baseline. The testable hypothesis for Chapter 7 is that the alternatives to the current 
procedure, trial 34 and 36, will enhance the coverage capability of the method when 
tested against materials with the mean approaching Q. 
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Chapter 7 
 
 
Validation of Proposed Alternatives to the Dissolution Test 
 
 
7.1 Introduction 
 
The results from the protocol modification study suggested that two alternatives 
for the current USP dissolution test would provide enhanced statistical power over the 
existing procedure. The alternative procedures are presented in Figures 7.1 and 7.2.  
  
 
2
0
5
 
Stage1
Stage 2
Stage 3
Obtain sample of 
6 
All values 
Q+5%
Obtain additional 
sample of 6
Min(x) > Q-15%
Avg. > Q
Max 2 values < Q
Obtain additional 
sample of 12
Min(x) > Q-25%
Avg. > Q
Max 2 values < Q-15%
Max 4 values < Q
Accept Lot
Accept Lot
Accept Lot
Reject Lot
Yes
No
Yes
No
Yes
No
>
 
Figure 7.1 Trial 34 Dissolution Test 
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Figure 7.2 Trial 36 Dissolution Test 
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These protocols were validated against a series of lots representing normal, 
uniform, and beta distributions using the simulation tool and distributions of infinite size. 
Each simulation was replicated 20,000 times. In most cases, the USP protocol (Trial 31) 
was also included to get a comparison of the methods. 
A final series of validation trials was executed using discrete lots of bimodal 
distributions containing 1.8 million dosage units. These simulations were also replicated 
20,000 times. 
 
 
7.2 Validations with Normal Distributions 
 
The results of the validation runs for Trial 34, representing attribute coverage, are 
presented in Table 7.1.The essential characteristics of the normal distributions tested are 
represented by columns 2 through 7 of Table 7.1, including the mean, standard deviation, 
and proportions of values less than the various test criteria, such as the proportion of 
values less than Q. 
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Table 7.1 Normal Validation Series, Trial 34 
Series   P<Q P<Q-15% P<Q-25% P>Q+5% 
Beta 
Stage 1 
Beta 
Stage 2 
Beta 
Stage 3 
Beta 
Overall 
Probability 
of 
Acceptance 
Trial 34 
1 82.42 9.53 0.400 0.034 0.002 0.393 0.9958 0.9278 0.9957 0.9200 0.0801 
2 83.67 9.53 0.350 0.025 0.001 0.445 0.9924 0.8733 0.9859 0.8544 0.1456 
3 85.00 9.53 0.300 0.018 0.001 0.500 0.9907 0.8103 0.9656 0.7752 0.2249 
4 85.70 9.53 0.275 0.015 0.001 0.529 0.9785 0.7207 0.9434 0.6652 0.3348 
5 86.43 9.53 0.250 0.012 0.000 0.560 0.9678 0.6469 0.9084 0.5687 0.4313 
6 88.02 9.53 0.200 0.008 0.000 0.624 0.9383 0.4923 0.8004 0.3698 0.6303 
7 89.88 9.53 0.150 0.005 0.000 0.696 0.8879 0.3177 0.6403 0.1806 0.8194 
8 92.22 9.53 0.100 0.002 0.000 0.775 0.7810 0.1586 0.4213 0.0522 0.9478 
9 95.68 9.53 0.050 0.001 0.000 0.869 0.5687 0.0436 0.1169 0.0029 0.9971 
10 115.46 9.53 0.000 0.000 0.000 0.999 0.0039 0.0000 0.0000 0.0000 1.0000 
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The performance of the revised protocol is represented by the columns labeled 
“Beta,” which describe the power or failure rate of the various stages of the test. The 
probability of acceptance is presented in the final column of Table 7.1, and is the 
complement of the overall test power. 
The design objective was to achieve 80% failure as P<Q approached 0.30, or 
30%. Figure 7.3 details the performance of the individual stages and overall test for Trial 
34. These results demonstrate that stage 2 controls the outcome of this proposed 
dissolution test. Ideally, stage 2 would be more difficult to pass than stage 3. The 
protocol, however, does achieve the goal of 80% power with P<Q within the range of 
0.30 to 0.35. 
The problem with an attribute classification, particularly at stage 2, is that there is 
limited flexibility in choosing a coverage criterion, since the values must be integers. 
This was discussed previously in Chapter 5 in the selection of coverage values based on 
the critical values for the binomial distribution.
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Figure 7.3 Detailed Results for Trial 34, Normal Series 
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The results for this normal series for the protocol based on a 70% tolerance 
interval, Trial 36, are presented in Table 7.2. Visual inspection of Table 7.2 suggests that 
the coverage achieved at stages 2 and 3 are consistent, i.e., stage 3 is always more 
powerful than stage 2. This is an expected outcome for the tolerance interval, which 
adjusts the value of K as the sample size is increased from 12 at stage 2 to 24 at stage 3. 
The results for all stages are illustrated in Figure 7.4. Note that the desired power 
is achieved at some point prior to P<Q equal to 0.30. This observation justifies the 70% 
coverage specification as opposed to a more stringent criterion, such as 90% coverage. 
Lots begin to fail once P<Q exceeds 10%, and at approximately P<Q equal to 20%, the 
lot only has a 50% chance of passing the revised test. 
  
 
2
1
2
 
Table 7.2 Normal Validation Series, Trial 36. 
Series   P<Q P<Q-15% P<Q-25% P>Q+5%
Beta 
Stage 1
Beta 
Stage 2
Beta 
Stage 3
Beta 
Overall
Probability of 
Acceptance 
Trial 36
1 82.42 9.53 0.400 0.034 0.002 0.393 0.9968 0.9921 0.9979 0.9869 0.0132
2 83.67 9.53 0.350 0.025 0.001 0.445 0.9917 0.9804 0.9921 0.9646 0.0355
3 85.00 9.53 0.300 0.018 0.001 0.500 0.9843 0.9522 0.9653 0.9047 0.0954
4 85.70 9.53 0.275 0.015 0.001 0.529 0.9774 0.9339 0.9411 0.8590 0.1411
5 86.43 9.53 0.250 0.012 0.000 0.560 0.9702 0.9046 0.8987 0.7887 0.2114
6 88.02 9.53 0.200 0.008 0.000 0.624 0.9440 0.8093 0.7451 0.5693 0.4308
7 89.88 9.53 0.150 0.005 0.000 0.696 0.8865 0.6566 0.4817 0.2804 0.7197
8 92.22 9.53 0.100 0.002 0.000 0.775 0.7830 0.4272 0.1821 0.0609 0.9391
9 95.68 9.53 0.050 0.001 0.000 0.869 0.5701 0.1558 0.0203 0.0018 0.9982
10 115.46 9.53 0.000 0.000 0.000 0.999 0.0038 0.0000 0.0000 0.0000 1.0000  
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Figure 7.4 Detailed Results for Trial 36, Normal Series 
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This entire series was not repeated for Trial 31, USP <711>, since previous 
experience suggested that this series would pass the protocol in practically 100% of all 
cases. Instead, the series was expanded to make a comparison of the protocols. The 
results for the expanded series are presented in Table 7.3.  
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Table 7.3 Normal Validation Expanded Series, USP <711>, Trial 31. 
Series   P<Q P<Q-15% P<Q-25% P>Q+5%
Beta 
Stage 1
Beta 
Stage 2
Beta 
Stage 3
Beta 
Overall
Probability 
of 
Acceptance 
Trial 31
11 76.33 9.53 0.650 0.117 0.013 0.181 1.0000 0.9442 0.9861 0.9311 0.0690
12 77.59 9.53 0.600 0.093 0.009 0.218 0.9998 0.8803 0.9427 0.8298 0.1703
13 78.80 9.53 0.550 0.074 0.006 0.258 0.9999 0.7799 0.8477 0.6611 0.3390
14 80.00 9.53 0.500 0.058 0.004 0.300 0.9993 0.6707 0.6860 0.4597 0.5403
11 81.20 9.53 0.450 0.045 0.003 0.345 0.9984 0.5337 0.5010 0.2670 0.7331
1 82.42 9.53 0.400 0.034 0.002 0.393 0.9960 0.4146 0.3012 0.1244 0.8757
2 83.67 9.53 0.350 0.025 0.001 0.445 0.9925 0.2984 0.1710 0.0507 0.9494
3 85.00 9.53 0.300 0.018 0.001 0.500 0.9829 0.2038 0.1076 0.0216 0.9785  
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The results for the individual stages and overall power are presented in Figure 7.5. 
In this series, stage 2 controls the overall result once the percentage of values less than Q 
exceeds 45%. The test does not attain 80% power until the proportion less than Q 
approaches 0.55, a result that is consistent with its design specification. 
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Figure 7.5 Detailed Results for Trial 31, Expanded Normal Series 
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A comparison of the three protocols in terms of probability of acceptance as a 
function of coverage is presented in Figure 7.6. These results were obtained from the 
corresponding table for each trial under the column “probability of acceptance.” The 
results clearly demonstrate that each proposed protocol represents a significant 
improvement over the USP procedure. Excellent performance against normal 
distributions, however, is not sufficient justification to recommend a method, since the 
tolerance procedure assumes a normal distribution. Therefore, simulations with non-
normal distributions were also conducted.
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Figure 7.6 Comparisons of Protocols for Power, Normal Series 
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7.3 Validations with Uniform Distributions 
 
Table 7.4 contains the results for a series of uniform distributions intended to 
investigate the robustness of the coverage criteria represented by attribute and tolerance 
alternatives. The results in Table 7.4 were based on 20,000 replicate trials with 
distributions of infinite size using the protocol of Trial 34. 
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Table 7.4 Uniform Validation Series, Trial 34 
Distribution Series Q Pct < Q
Lower 
Bound
Upper 
Bound P > Q+5
Beta 
Stage 1
Beta 
Stage 2
Beta 
Stage 3
Beta 
Overall
Probability of 
Acceptance 
Trial 34
Uniform k 80 0.00 80.00 100.00 0.75 0.8268 0.0000 . 0.0000 1.0000
Uniform j 80 0.05 79.99 99.99 0.75 0.8837 0.0207 0.1562 0.0029 0.9972
Uniform i 80 0.10 79.98 99.98 0.75 0.9275 0.1214 0.4442 0.0500 0.9500
Uniform h 80 0.15 79.97 99.97 0.75 0.9540 0.2753 0.6750 0.1773 0.8227
Uniform g 80 0.20 79.96 99.96 0.75 0.9755 0.4530 0.8322 0.3677 0.6323
Uniform f 80 0.25 79.95 99.95 0.75 0.9848 0.6117 0.9250 0.5572 0.4428
Uniform e 80 0.30 79.94 99.94 0.75 0.9910 0.7500 0.9690 0.7202 0.2798
Uniform d 80 0.35 79.93 99.93 0.75 0.9956 0.8508 0.9891 0.8379 0.1621
Uniform c 80 0.40 79.92 99.92 0.75 0.9977 0.9199 0.9965 0.9146 0.0855
Uniform b 80 0.45 79.91 99.91 0.75 0.9992 0.9586 0.9991 0.9570 0.0431
Uniform a 80 0.50 79.90 99.90 0.75 0.9998 0.9822 0.9999 0.9819 0.0182  
  
  222 
Visual inspection of the results suggests a similarity to the normal series with 
respect to the relative power of the stages. As illustrated in Figure 7.7, stage 2 controls 
the overall power of the test. The stage 1 results were not included on this graph for 
clarity of presentation. 
Trial 34 performed almost identically for the uniform series as it did for the 
normal distribution. This confirms the non-parametric asset of a coverage test, that its 
performance is strictly a function of the proportion of values less than Q, and is not 
affected by the shape of the distribution. As observed previously for the normal series, 
the design objective of 80% is realized in the interval between 0 and 0.3 with respect to 
the proportion of values less than Q. 
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Figure 7.7 Detailed Results for Trial 34, Uniform Series 
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The corresponding results for this series for Trial 36 are presented in Table 7.5. 
The justification for the selection of 70% tolerance is that it would be robust to the 
assumption of normality as compared to higher tolerances. The results from Table 7.5, 
presented graphically in Figure 7.8, support this assumption.  
Stage 3 consistently controls the overall result for Trial 36 until the proportion 
P<Q approaches 0.30. Beyond this point, the two stages are essentially equal with respect 
to power. The goal of 80% power, however, is not realized until P<Q reaches 0.30, 
indicating a loss of sensitivity as compared to the normal series results. 
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Table 7.5 Uniform Validation Series, Trial 36 
Series   P<Q P<Q-15% P<Q-25% P>Q+5%
Beta 
Stage 1
Beta 
Stage 2
Beta 
Stage 3
Beta 
Overall
Probability of 
Acceptance 
Trial 36
1 82.42 9.53 0.400 0.034 0.002 0.393 0.9968 0.9921 0.9979 0.9869 0.0132
2 83.67 9.53 0.350 0.025 0.001 0.445 0.9917 0.9804 0.9921 0.9646 0.0355
3 85.00 9.53 0.300 0.018 0.001 0.500 0.9843 0.9522 0.9653 0.9047 0.0954
4 85.70 9.53 0.275 0.015 0.001 0.529 0.9774 0.9339 0.9411 0.8590 0.1411
5 86.43 9.53 0.250 0.012 0.000 0.560 0.9702 0.9046 0.8987 0.7887 0.2114
6 88.02 9.53 0.200 0.008 0.000 0.624 0.9440 0.8093 0.7451 0.5693 0.4308
7 89.88 9.53 0.150 0.005 0.000 0.696 0.8865 0.6566 0.4817 0.2804 0.7197
8 92.22 9.53 0.100 0.002 0.000 0.775 0.7830 0.4272 0.1821 0.0609 0.9391
9 95.68 9.53 0.050 0.001 0.000 0.869 0.5701 0.1558 0.0203 0.0018 0.9982
10 115.46 9.53 0.000 0.000 0.000 0.999 0.0038 0.0000 0.0000 0.0000 1.0000  
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Figure 7.8 Detailed Results for Trial 36, Uniform Series 
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Table 7.6 includes the results for Trial 31, or USP <711>, for an expanded version 
of this series that overlaps the series investigated for Trials 34 and 36. Expansion of the 
series was necessary to compensate for the relative lack of sensitivity of the USP protocol 
as compared to the alternatives. 
The results for individual stages of the USP for power are illustrated in Figure 7.9. 
Note that the power curves are similar to the results of attribute coverage test, Trial 34. 
Stage 2 controls the overall outcome of the test until throughout the observed range. 
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Table 7.6 Expanded Uniform Series, Trial 31, USP <711> 
Distribution Series Q P<Q
Lower 
Bound
Upper 
Bound P>Q+5%
Beta 
Stage 1
Beta 
Stage 2
Beta 
Stage 3
Beta 
Overall
Probability of 
Acceptance 
USP <711>
Uniform f 80 0.25 79.95 99.95 0.75 0.9840 0.0005 0.0000 0.0000 1.0000
Uniform g 80 0.20 79.96 99.96 0.75 0.9712 0.0000 0.0000 0.0000 1.0000
Uniform h 80 0.15 79.97 99.97 0.75 0.9550 0.0000 0.0000 0.0000 1.0000
Uniform e 80 0.30 79.94 99.94 0.75 0.9919 0.0072 0.0490 0.0004 0.9997
Uniform d 80 0.35 79.93 99.93 0.75 0.9955 0.0366 0.0713 0.0026 0.9974
Uniform c 80 0.40 79.92 99.92 0.75 0.9991 0.1192 0.2406 0.0287 0.9714
Uniform b 80 0.45 79.91 99.91 0.75 0.9993 0.2735 0.5061 0.1384 0.8617
Uniform a 80 0.50 79.90 99.90 0.75 0.9998 0.5014 0.7511 0.3765 0.6235
Uniform l 80 0.53 69.50 89.50 0.23 1.0000 0.6161 0.8458 0.5211 0.4789
Uniform m 80 0.55 69.00 89.00 0.20 1.0000 0.7211 0.9169 0.6612 0.3389
Uniform n 80 0.60 68.00 88.00 0.15 1.0000 0.8899 0.9807 0.8727 0.1273
Uniform o 80 0.65 67.00 87.00 0.10 1.0000 0.9654 0.9980 0.9635 0.0366
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Figure 7.9 Detailed Results for Trial 31, Uniform Series 
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The results of the three protocols in terms of probability of acceptance as a 
function of P<Q are compared in Figure 7.10. Based upon this comparison, Trial 36 is 
slightly more sensitive than the attribute alternative (Trial 34), as evidenced by the 
steepness of the slope of the power curve. Further, both methods are a significant 
improvement over the current USP test (Trial 31). 
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Figure 7.10 Comparisons of Protocols for Power 
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7.4 Validation Trials with Beta Distributions 
 
The previous validations were intended to assess the coverage provided by the 
alternative attribute and tolerance approaches. Additional simulations were required to 
test the behavior of these coverage tests in combination with the current tests for outliers 
at stages 2 and 3, which were not modified. Table 7.7 presents the results of simulations 
conducted with beta distributions of infinite size for Trial 34. 
The characteristics of the lots tested in Table 7.7 include characteristics that 
would activate all test components, including proportions of values in the outlier test 
ranges. Detailed results for Trial 34 are presented in Figure 7.11.  
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Table 7.7 Beta Validation Series, Trial 34 
Series Min Max   P<Q 
P< 
Q-15% 
P< 
Q-25% P>Q+5% Stage 1 Stage 2 Stage 3 Overall 
Probability 
of 
Acceptance 
Trial 34 
-10% 40.0 100.0   0.5927 0.1995 0.0504 0.2639 0.9999 0.9981 0.9999 0.9979 0.0022 
-7.5% 42.5 102.5   0.5217 0.1526 0.0306 0.3313 0.9991 0.9926 0.9999 0.9917 0.0083 
-5% 45.0 105.0   0.4479 0.1114 0.0159 0.4039 0.9955 0.9753 0.9984 0.9693 0.0307 
-3% 47.0 107.0   0.3905 0.0824 0.0080 0.4676 0.9906 0.9421 0.9929 0.9266 0.0735 
-2.5% 47.5 107.5   0.3762 0.0777 0.0071 0.4814 0.9892 0.9302 0.9903 0.9112 0.0888 
Design 50.0 110.0   0.3133 0.0510 0.0020 0.5536 0.9720 0.8371 0.9636 0.7841 0.2160 
+2.5% 52.5 112.5   0.2533 0.0307 0.0003 0.6217 0.9431 0.7152 0.8928 0.6022 0.3978 
+3% 53.0 113.0   0.2426 0.0266 0.0001 0.6355 0.9342 0.6727 0.8774 0.5514 0.4487 
+5% 55.0 115.0   0.2009 0.0167 0.0000 0.6852 0.8934 0.5366 0.7873 0.3775 0.6226 
+7.5% 57.5 117.5   0.1499 0.0071 0.0000 0.7485 0.8262 0.3605 0.6313 0.1880 0.8120 
+10% 60.0 120.0   0.1102 0.0021 0.0000 0.8028 0.7343 0.2021 0.4714 0.0700 0.9301 
+15% 65.0 125.0   0.0506 0.0000 0.0000 0.8868 0.5065 0.0371 0.1463 0.0028 0.9973 
+30% 80.0 140.0   0.0000 0.0000 0.0000 0.9979 0.0132 0.0000 . 0.0000 1.0000 
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Figure 7.11 Detailed Test results, Trial 34, Beta Series 
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These results are similar to those observed previously for normal and uniform 
distributions. Stage 2 controls the overall power of the test, which approaches 80% as the 
proportion less than Q approaches 0.30, or 30%. The corresponding results for Trials 36 
and 31 are presented in Tables 7.8 and 7.9, respectively. 
The beta distributions did not require an expansion of the series for the current 
USP procedure. Inspection of Table 7.9, however, reveals that the final few series passed 
the USP in essentially 100% of all 20,000 trials. 
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Table 7.8 Beta Validation Series, Trial 36 
Series Min Max  
P< 
Q 
P< 
Q-15% 
P< 
Q-25% 
P> 
Q+5% 
Beta 
Stage 1 
Beta 
Stage 
2 
Beta 
Stage 
3 
Beta 
Overall 
Probability 
of 
Acceptance 
Trial 36 
-10% 40.0 100.0   0.5927 0.1995 0.0504 0.2639 0.9997 1.0000 1.0000 0.9996 0.0004 
-7.5% 42.5 102.5   0.5217 0.1526 0.0306 0.3313 0.9987 0.9996 1.0000 0.9983 0.0017 
-5% 45.0 105.0   0.4479 0.1114 0.0159 0.4039 0.9948 0.9959 0.9996 0.9903 0.0097 
-3% 47.0 107.0   0.3905 0.0824 0.0080 0.4676 0.9905 0.9894 0.9974 0.9773 0.0227 
-2.5% 47.5 107.5   0.3762 0.0777 0.0071 0.4814 0.9867 0.9849 0.9948 0.9668 0.0333 
Design 50.0 110.0   0.3133 0.0510 0.0020 0.5536 0.9713 0.9523 0.9671 0.8945 0.1055 
+2.5% 52.5 112.5   0.2533 0.0307 0.0003 0.6217 0.9388 0.8864 0.8679 0.7223 0.2778 
+3% 53.0 113.0   0.2426 0.0266 0.0001 0.6355 0.9327 0.8677 0.8425 0.6819 0.3182 
+5% 55.0 115.0   0.2009 0.0167 0.0000 0.6852 0.8960 0.7799 0.6593 0.4607 0.5393 
+7.5% 57.5 117.5   0.1499 0.0071 0.0000 0.7485 0.8271 0.6175 0.3850 0.1966 0.8034 
+10% 60.0 120.0   0.1102 0.0021 0.0000 0.8028 0.7319 0.4197 0.1488 0.0457 0.9543 
+15% 65.0 125.0   0.0506 0.0000 0.0000 0.8868 0.5102 0.1071 0.0027 0.0002 0.9999 
+30% 80.0 140.0   0.0000 0.0000 0.0000 0.9979 0.0117 0.0000 . 0.0000 1.0000 
 
 
  
 
2
3
7
 
Table 7.9 Beta Validation Series, Trial 31 
Series Min Max   P<Q 
P < 
Q-15% 
P< 
Q-25% P>Q+5% Stage 1 Stage 2 Stage 3 Overall 
Probability 
of 
Acceptance 
Trial 31 
-10% 40.0 100.0   0.5927 0.1995 0.0504 0.2639 0.9998 0.9602 0.9838 0.9445 0.0556 
-7.5% 42.5 102.5   0.5217 0.1526 0.0306 0.3313 0.9988 0.8927 0.9152 0.8160 0.1840 
-5% 45.0 105.0   0.4479 0.1114 0.0159 0.4039 0.9957 0.7759 0.7515 0.5806 0.4194 
-3% 47.0 107.0   0.3905 0.0824 0.0080 0.4676 0.9900 0.6728 0.5551 0.3697 0.6303 
-2.5% 47.5 107.5   0.3762 0.0777 0.0071 0.4814 0.9873 0.6400 0.5140 0.3248 0.6752 
Design 50.0 110.0   0.3133 0.0510 0.0020 0.5536 0.9740 0.4759 0.2784 0.1291 0.8710 
+2.5% 52.5 112.5   0.2533 0.0307 0.0003 0.6217 0.9399 0.3242 0.1164 0.0355 0.9646 
+3% 53.0 113.0   0.2426 0.0266 0.0001 0.6355 0.9365 0.2953 0.0962 0.0266 0.9734 
+5% 55.0 115.0   0.2009 0.0167 0.0000 0.6852 0.9008 0.1896 0.0305 0.0052 0.9948 
+7.5% 57.5 117.5   0.1499 0.0071 0.0000 0.7485 0.8306 0.0957 0.0038 0.0003 0.9997 
+10% 60.0 120.0   0.1102 0.0021 0.0000 0.8028 0.7364 0.0293 0.0000 0.0000 1.0000 
+15% 65.0 125.0   0.0506 0.0000 0.0000 0.8868 0.4997 0.0000 - 0.0000 1.0000 
+30% 80.0 140.0   0.0000 0.0000 0.0000 0.9979 0.0130 0.0000 - 0.0000 1.0000 
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The individual stage results for Trial 36 are presented in Figure 7.12. The results 
are similar to what was observed for the corresponding normal distributions, with stage 3 
determining the overall outcome as P<Q approaches 0.20, after which stages 2 and 3 
become equally effective. A power of 80% was observed at P<Q equal to approximately 
0.25. 
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Figure 7.12 Detailed Test results, Trial 36, Beta Series 
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Figure 7.13 Detailed Test results, Trial 31, Beta Series 
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The results for the USP procedure, illustrated in Figure 7.13, show a striking 
similarity to the behavior observed for Trial 34. The difference observed between these 
tests is the power as a function of P<Q. The USP procedure in Figure 7.13 does not 
achieve 80% power until P<Q approaches 0.50, as compared to 0.30 for the non-
parametric alternative. 
The three protocols are compared with respect to probability of acceptance as a 
function of P<Q in Figure 7.14. These results provide further evidence that although the 
tolerance procedure is slightly more sensitive than the attribute coverage test, either 
would be a notable improvement over USP <711> for the same sample size. 
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Figure 7.14 Comparisons of Protocols for Power 
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7.5 Validation Trials with Bimodal Distributions 
 
The final series for validation purposes were based on discrete bimodal 
distributions. Since this was the final validation exercise, discrete lots of 1,800,000 
dissolution values were created with the characteristics listed in Table 7.10. The 
simulations were executed using the procedure previously described in Chapter 2 for 
large, discrete lots. Each simulation was attempted 20,000 times, but only those trials 
producing valid samples (no repeated sample numbers) were subjected to testing. 
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Table 7.10 Discrete Lot Characteristics, Bimodal Distributions 
Series μ1 μ2  Min Max   P<Q P<Q-15% P<Q-25% P>Q+5% 
BD75.0 85.0 s3 75.0 85.0 3.0 46.4 101.1   0.4500 0.0002 0.0000 0.2500 
BD75.5 85.5 s3 75.5 85.5 3.0 46.9 101.6   0.4835 0.0001 0.0000 0.2835 
BD76.5 86.5 s3 76.5 86.5 3.0 47.9 102.6   0.4469 0.0001 0.0000 0.3465 
BD80.0 90.0 s3 80.0 90.0 3.0 51.4 106.1   0.2504 0.0000 0.0000 0.4998 
BD81.5 91.5 s3 81.5 91.5 3.0 52.9 107.6   0.1548 0.0000 0.0000 0.5530 
BD82.0 92.0 s3 82.0 92.0 3.0 53.4 108.1   0.1268 0.0000 0.0000 0.5741 
BD83.0 93.0 s3 83.0 93.0 3.0 54.4 109.1   0.0798 0.0000 0.0000 0.6238 
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The basis of selection for these lots appears in Table 7.11, which details the 
results for the current USP procedure, represented in the experimental design as Trial 31. 
Note that all of these distributions, with the exception of the first, readily pass the current 
USP procedure. The final column of Table 7.11 and following tables represent the 
number of successful trials out of 20,000 attempts. 
Table 7.11 Validation Results for USP <711>, Bimodal Distributions. 
Series
Beta 
Stage 1
Beta 
Stage 2
Beta 
Stage 3
Beta 
Overall
Probability of 
Acceptance 
Trial 31 N
BD75.0 85.0 s3 0.9999 0.4992 0.7496 0.3742 0.6258 19,997
BD75.5 85.5 s3 0.9995 0.3825 0.6304 0.2410 0.7590 19,995
BD76.5 86.5 s3 0.9984 0.1885 0.3918 0.0738 0.9262 19,997
BD80.0 90.0 s3 0.9846 0.0015 0.1034 0.0002 0.9999 19,994
BD81.5 91.5 s3 0.9707 0.0001 . 0.0001 1.0000 19,999
BD82.0 92.0 s3 0.9676 0.0002 . 0.0002 0.9998 19,997
BD83.0 93.0 s3 0.9202 0.0004 . 0.0002 0.9998 19,997  
 
The results in Table 7.11 demonstrate the most serious weaknesses of the existing 
USP protocol. Any combination of discrete values producing an overall mean grater than 
or equal to Q, will likely pass the test, as long as the proportion of outliers is not too 
excessive. 
Table 7.12 presents the results obtained for the same distributions when attribute 
coverage tests are introduced at stages 2 and 3 according to the protocol defined by Trial 
34. The results from these distributions are too complex to be compared against a single 
lot characteristic, but visual inspection reveals a dramatic increase in power with respect 
to the original test.  
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Table 7.12 Validation Results for Trial 34, Bimodal Distributions 
Series
Beta 
Stage 1
Beta 
Stage 2
Beta 
Stage 3
Beta 
Overall
Probability of 
Acceptance 
Trial 34 N
BD75.0 85.0 s3 0.9997 0.9813 0.9998 0.9808 0.0193 19,997
BD75.5 85.5 s3 0.9997 0.9752 0.9997 0.9747 0.0254 19,999
BD76.5 86.5 s3 0.9981 0.9536 0.9990 0.9508 0.0492 19,996
BD80.0 90.0 s3 0.9845 0.6215 0.9260 0.5665 0.4335 19,999
BD81.5 91.5 s3 0.9725 0.2906 0.7002 0.1979 0.8021 19,993
BD82.0 92.0 s3 0.9672 0.1924 0.5773 0.1074 0.8926 19,997
BD83.0 93.0 s3 0.9398 0.0624 0.3205 0.0188 0.9812 19,996
 
 
Table 7.13 present the results obtained for Trial 36 with this series. The results 
indicate increased sensitivity with respect to Trial 34 for the first three populations, but 
are essentially equivalent for the remaining lots. The increased sensitivity is due to the 
inclusion of an estimate of the standard deviation in the tolerance procedure, which is 
absent from the attribute coverage protocol. Bimodal and multimodal distributions 
typically display increased variation as compared to the individual populations 
comprising the whole. The finding, however, that Trials 34 and 36 produced comparable 
results is significant, given that the protocols are based on contrasting probability 
considerations and assumptions. 
Table 7.13 Validation Results for Trial 36, Bimodal Distributions 
Series
Beta Stage 
1
Beta Stage 
2
Beta 
Stage 3
Beta 
Overall
Probability of 
Acceptance 
Trial 36 N
BD75.0 85.0 s3 0.9997 0.9998 0.9999 0.9979 0.0021 19,998
BD75.5 85.5 s3 0.9992 0.9968 0.9996 0.9956 0.0044 19,999
BD76.5 86.5 s3 0.9982 0.9899 0.9882 0.9863 0.0138 19,996
BD80.0 90.0 s3 0.9841 0.8260 0.7383 0.6003 0.3997 19,996
BD81.5 91.5 s3 0.9728 0.5862 0.3445 0.1965 0.8035 19,997
BD82.0 92.0 s3 0.9635 0.4868 0.2173 0.1019 0.8981 19,995
BD83.0 93.0 s3 0.9407 0.2808 0.0729 0.0193 0.9808 19,996  
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7.6 Conclusions 
 
The inferences from the Bayesian experimental identified two candidates to 
improve the coverage of the USP dissolution test using the existing format. The first 
candidate trial added an attribute test, expressed as counts of observations less than the 
specification Q, to the second and third stages of the USP protocol. The second 
alternative was based on the concept of tolerance analysis and modified the current USP 
procedure by increasing the coverage requirement at stages 2 and 3 from the current 50% 
coverage with 50% confidence to 70% coverage with 95% confidence. 
The test based on attributes has the theoretical advantage that the test is truly non-
parametric, and should perform equally well for any type of product distribution. The 
tolerance test assumes a normal distribution, but is consistent with and analogous to the 
revised content uniformity test examined in Chapter 3. Further, the assumption of 
normality for this test is not critical at the 70% tolerance level, and the method likely 
would benefit from the central limit theorem.  
Both methods performed well in trials with a range of distributions. The tolerance 
approach demonstrated consistency of statistical power across the stages and was slightly 
more sensitive than the attribute alternative. The attribute test behaved analogously to the 
USP test, with the exception that it substantially improved the coverage. 
Sufficient justification exists to publish and offer these methods as alternatives to 
the USP procedure. Future studies could be directed towards a final assessment of these 
approaches. 
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Chapter 8 
 
 
Conclusions and Recommendations for Future Work 
 
 
8.1 Summary 
 
The null hypothesis formed in Chapter 1, that existing USP compendial tests for 
content uniformity and dissolution would detect counterfeit and substandard drugs for 
those cases in which basic qualitative and quantitative field tests were inconclusive, was 
rejected. Simulation studies with artificial populations designed to mimic the 
characteristics of substandard, immediate release solid oral dosage forms suggested that 
both the revised content uniformity test and the dissolution test would repeatedly pass 
drugs of poor quality. 
 
 
8.2 Summary Findings and Recommendations for Content Uniformity 
 
The revised USP content uniformity test is relatively insensitive to detecting non-
conforming material. In test simulations with various distributions of dosage forms with 
increasing proportions of non-conforming product, the revised compendial standard did 
not demonstrate reasonable discrimination power until the defect percentage exceeded 
20%. 
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The insensitivity of the test was attributed to the following characteristics of the 
test stages: 
1. The stage 1 sample size of 10 is too small to obtain a reasonable estimate of the 
population standard deviation, σ.  
2. A failure at stage 1 always results in a second opportunity to pass at stage 2.  
3. Stage 2 ultimately passed an unacceptable number of defective lots.  
The limited power of the sample size of 10 was confirmed by tabulating the 
sample estimates of the values and comparing them to the true estimate during the 
simulation. Considering the insensitivity of stage 1, a more reasonable procedure would 
be to stop testing if the lot failed at this point, as opposed to proceeding to stage 2.  
The insensitivity of stage 2 to high defect percentages was a surprising result, 
since the procedure utilizes all 30 values, a sample size that proved highly effective with 
Bergum’s method. The problem appears to be that the calculated tolerance interval is too 
broad.  
4. The revised USP content uniformity test increases robustness with respect to the 
underlying product distribution. 
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Although the method was relatively insensitive, it performed consistently 
regardless of the shape of the underlying distribution. Thus, the tolerance interval concept 
was definitely effective in this respect. 
5. The Bergum method was highly effective in identifying defective materials. 
Although the method was too sensitive to the assumption of normality, as 
observed in the results for bimodal and uniform distributions, the method performed 
consistently well. In certain lots with high defect percentages, the test did not produce a 
single incorrect inference in over 11,000 simulation trials. 
As opposed to a singlet test that could theoretically performed repeatedly until a 
failing result is produced, a modification of Bergum’s method might be useful as a single 
test that would only be performed once to definitely assess material acceptability. 
Conceivably, other values for P or the confidence interval (such as 90% and 95%, 
respectively) would moderate the effect of the assumption of normality. 
In summary, the tolerance concept is a proven method to make valid inferences 
about a population of interest and forms the basis of many standard statistical tests, such 
as statistical process control. The sample size employed in stage 1 of the content 
uniformity test is too small to effectively estimate the population standard deviation and 
thus increases the Type II or consumers’ risk. 
Bergum’s method provides a prediction of how a lot would do against repeated 
content uniformity testing. Thus, it represents a secondary standard that is more powerful 
than the parent protocol and is an effective tool for pre-assessment or post assessment of 
the fitness for use. 
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8.3 Summary Findings and Recommendations for Dissolution 
 
The results of this study support the following conclusions about the current USP 
dissolution procedure. 
6. The attribute tests of the method can be modeled as Bernoulli trials with binomial 
distributions, whereas the mean tests can be approximated using the sampling 
distribution for a normal distribution based on sample sizes of 12 and 24. 
7. The models can be applied to any distribution, but the normal approximation for the 
mean becomes increasingly biased as the mean of the distribution approaches the 
lower specification Q. 
8. The models predict excellent statistical power for the stage 1 attribute test. The 
distribution of values greater than Q+5% must exceed 90% to achieve an 80% 
probability of acceptance. 
9. The Q-15% attribute test has good statistical power at stage 2 but is significantly 
weaker at stage 3 until the proportion of values less than Q-15% exceeds 0.25. 
10. The attribute test Q-25% has acceptable power, but is not a reliable detector of 
outliers or extreme values. The proportion of values less than Q-25% must be greater 
than 0.02 for less than 80% acceptance. 
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11. The attribute tests at stage 3 interact in the sense that values less than Q-25% are also 
likely to fail the Q-15% criterion. 
12. The coverage tests at stages 2 and 3 provide 50% coverage at 50% confidence and 
favor lots with high variability For any given value of the mean less than Q, a higher 
variance will increase the probability of acceptance. A likely consequence of these 
findings is a Type II error at stage 2, i.e., lots that would fail at stage 3 will pass at 
stage 2 due to a lack of sensitivity, as was observed in these simulations. 
13. The coverage tests interact to provide an increased failure rate as the mean 
approaches Q. 
14. The Bergum method is not acceptable as a secondary standard for dissolution. 
Briefly stated, simple predictive models were confirmed to successfully model the 
statistical power of the existing USP dissolution test. The model suggested that the 
coverage specification of the USP dissolution test for immediate release solid oral dosage 
forms was 50% coverage at 50% confidence. This level of coverage would pass any 
substandard material as long as the overall mean of the lot was close to Q, an inference 
that was confirmed in this investigation through controlled simulations.  
Inasmuch as the basic dissolution test was flawed, the use of the Bergum method 
as an alternative to the USP is not acceptable as an alternative.  
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8.4 Alternative Procedure for Dissolution 
 
The central hypothesis of Chapters 5 and 6 was that the existing dissolution test 
could be improved by modifications to improve its coverage at stages 2 and 3 and outlier 
detection capability at stage 3. An experimental design based on Bayesian design 
techniques was introduced to test these hypotheses. The stepwise execution of these 
experiments produced the following results:  
15. The originally proposed 32 trial Bayesian D-optimal design identified significant 
main effects and produced evidence for two-factor interactions but suffered lack of fit 
in the middle range of the factor space. 
16. Augmentation of the original design with four additional trials resolved the lack of fit 
issue and produced an acceptable model for the beta distribution. 
17. Replication of the 36 trial augmented design with uniform and normal distributions 
resulted in a factor space with an additional nominal factor, “Distribution Type.” The 
third-order interactions of the distribution factor with two-factor interactions of 
interest from the proposed modifications provided a suitable term for estimation of 
experimental error. 
18. The complete factor space of the combined experiments was successfully modeled 
and interpreted without transformation of the power response. 
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19. The model suggested that practically all modifications of the USP <711> procedure 
were successful, as evidenced by the fact that the trial representing the USP method 
produced the lowest power of all combinations observed for the test distributions. 
20. The overwhelmingly significant effect in this experiment was the “Tolerance Level” 
factor and its interactions with the independent attribute coverage tests and 
distribution factor. 
21. Although the tolerance factor assumes a normal distribution of the observations, it 
was less sensitive to departures from a normal distribution than the existing USP 
coverage test.  
22. The inference from analysis of the tolerance factor suggests that a tolerance level of 
70% would provide 80% power for any likely product distribution with a portion of 
values less than Q greater than or equal to 0.30. 
23. Increased coverage requirements could be realized through increasing the tolerance 
level, but this would also likely increase the sensitivity of the method to the 
assumption of normality. 
24. An alternative to the 70% tolerance test at stages 2 and 3 is an attribute coverage 
specification with critical values of “2” and “4” as the maximum number of 
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observations less than Q. The attribute alternative is not as powerful as the tolerance 
test, but has the advantage that it is a non-parametric test. 
 
 
8.5 Validation Trials 
 
The testable hypothesis of Chapter 7 was that two modifications of the current 
dissolution procedure, one based on attribute coverage with the second alternative based 
on the continuous tolerance concept, would substantially improve the performance of the 
dissolution test with respect to substandard drug products. The alternative procedures 
were tested against each other as well as to the existing USP test for immediate release 
solid oral dosage forms through confirmation trials using simulated normal, beta, uniform 
and bimodal distributions. The results of these experiments confirmed that: 
25.  Both methods demonstrated excellent statistical power and substantially 
outperformed the USP test. 
26. The tolerance approach demonstrated consistency of statistical power across the 
stages and was slightly more sensitive than the attribute alternative.  
27. The attribute test behaved analogously to the USP test with respect to the shape of the 
power curves, with the exception that it substantially improved the coverage. 
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8.6 Recommendations for Method Introduction 
 
This work has demonstrated that the public health would benefit from the 
implementation of the Bergum method for content uniformity and either of the two 
alternative tests for dissolution. The FDA is already promoting the use of Bergum’s 
method for content uniformity [45, 47-48]. Additional efforts will be required to 
encourage application of one of the alternatives to the dissolution test. 
Additional testing of the alternatives against simulated and actual lots, particularly 
with data from known substandard drug products, would facilitate the acceptance of these 
methods. The non-profit organizations currently assessing the quality of drug products in 
Asia and Africa would be good candidate sources of substandard drugs for testing. 
Promoting the dissolution alternatives with the pharmaceutical industry could be 
accomplished through publications in peer-reviewed journals. It should be emphasized 
that the current compedial test is a special case of the proposed alternative based on 
tolerance intervals. Thus, in effect, one of these alternatives is already in use, but at a 
level that provides unnecessary risk to the public, i.e., 50% coverage at 50% confidence. 
Clearly, no reputable pharmaceutical manufacturer would accept that level of 
performance from its supplier base. 
 
 
8.7 Recommendations for Future Work 
 
The proposed dissolution tests, in their current form, are limited to testing 
immediate release solid oral dosage forms, which have a single lower specification limit 
for release after a specified time period under standardized conditions of media, 
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temperature and solid-liquid interface. Although this covers a broad range of oral drug 
products, the methods would not be directly applicable to modified release solid dosage 
forms, such as extended release or delayed release dosage forms. 
These dosage forms are typically tested at three time points, including an initial 
period to ensure effective release against a lower specification, an intermediate interval to 
assure against potentially dangerous dose dumping, and a third point after an extended 
time to ensure that the drug is quantitatively released. Whereas the first and third 
sampling points are equivalent to the single lower specification applied to immediate 
release forms, the second point would require both lower and upper specification limits. 
The dissolution alternative based on the tolerance concept could be modified to 
apply to upper and lower specification limits. The required modification would require 
specification of the desired coverage and statistical confidence between the upper and 
lower specification limits, followed by calculation of the tolerance factor K for two-sided 
tolerance limits. Development and refinement of the method could proceed through 
simulation experiments using statistical experimental designs analogous to those applied 
in this work. 
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Appendix 
 
 
Tables of the Results of the Bergum’s Method for the 
Distributions of Chapter 4 at 90% and 95% confidence 
levels for Stage 1 (N=6), Stage 2 (N=12) and Stage 3 
(N=24) with corresponding USP <711> results. 
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Table A1.1 Bergum Results Normal Series I 
Mean
Standard 
deviation
Proportion
<Q-25
Proportion
<Q-15
Proportion 
< Q
Proportion
>Q+5
Prob. of 
Acceptance 
USP<711>
Pass 
Bergum 
95% 
n=24
Pass 
Bergum 
90% 
n=24
Pass 
Bergum 
95% 
n=12
Pass 
Bergum 
90% 
n=12
Pass 
Bergum 
95% 
n=6
Pass 
Bergum 
90% 
n=6
85.0 1.00 0.00 0.00 0.00 0.502 1.000 1.000 1.000 1.000 1.000 1.000 1.000
84.0 1.00 0.00 0.00 0.00 0.159 1.000 1.000 1.000 1.000 1.000 0.993 0.998
83.0 1.00 0.00 0.00 0.00 0.022 1.000 1.000 1.000 0.999 0.999 0.903 0.941
82.0 1.00 0.00 0.00 0.02 0.024 1.000 0.999 0.999 0.974 0.990 0.512 0.592
81.0 1.00 0.00 0.00 0.16 0.000 1.000 0.709 0.834 0.300 0.402 0.102 0.128
80.5 1.00 0.00 0.00 0.31 0.000 0.995 0.056 0.113 0.028 0.047 0.017 0.025
80.3 1.00 0.00 0.00 0.40 0.000 0.926 0.004 0.011 0.006 0.010 0.007 0.009
80.0 1.00 0.00 0.00 0.50 0.000 0.622 0.000 0.001 0.001 0.001 0.001 0.002
79.8 1.00 0.00 0.00 0.60 0.000 0.225 0.000 0.000 0.000 0.000 0.000 0.000
79.5 1.00 0.00 0.00 0.69 0.000 0.045 0.000 0.000 0.000 0.000 0.000 0.000
79.0 1.00 0.00 0.00 0.84 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000  
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7
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Table A1.2 Bergum Results Normal Series II 
Mean
Standard 
deviation
Proportion
<Q-25
Proportion
<Q-15
Proportion 
< Q
Proportion
>Q+5
Prob. of 
Acceptance 
USP<711>
Pass 
Bergum 
95% 
n=24
Pass 
Bergum 
90% 
n=24
Pass 
Bergum 
95% 
n=12
Pass 
Bergum 
90% 
n=12
Pass 
Bergum 
95% n=6
Pass 
Bergum 
90% n=6
87.0 2.01 0.00 0.00 0.00 0.840 1.000 1.000 1.000 0.999 0.999 0.969 0.984
85.0 2.00 0.00 0.00 0.01 0.503 1.000 1.000 1.000 0.999 1.000 0.762 0.826
84.0 2.01 0.00 0.00 0.02 0.309 1.000 0.999 0.999 0.973 0.989 0.524 0.603
83.0 2.01 0.00 0.00 0.07 0.159 1.000 0.994 0.997 0.754 0.845 0.273 0.331
82.0 2.01 0.00 0.00 0.16 0.066 1.000 0.691 0.824 0.288 0.386 0.090 0.118
81.0 2.01 0.00 0.00 0.31 0.022 0.995 0.057 0.113 0.029 0.049 0.019 0.026
80.5 2.00 0.00 0.00 0.39 0.013 0.936 0.006 0.014 0.006 0.011 0.007 0.009
80.3 2.00 0.00 0.00 0.45 0.008 0.816 0.001 0.003 0.002 0.003 0.004 0.005
80.3 2.01 0.00 0.00 0.45 0.009 0.801 0.001 0.002 0.002 0.004 0.004 0.005
80.0 2.01 0.00 0.00 0.50 0.006 0.619 0.000 0.000 0.001 0.001 0.002 0.003
79.8 2.01 0.00 0.00 0.55 0.004 0.414 0.000 0.000 0.000 0.000 0.001 0.001
79.5 2.01 0.000 0.000 0.597 0.003 0.226 0.000 0.000 0.000 0.000 0.000 0.001
79.0 2.01 0.00 0.00 0.69 0.001 0.046 0.000 0.000 0.000 0.000 0.000 0.000
78.0 2.01 0.00 0.00 0.84 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000  
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Table A1.3 Bergum Results Final Series of Normal Distribution 
Mean
Standard 
deviation
Proportion
<Q-25
Proportion
<Q-15
Proportion 
< Q
Proportion
>Q+5
Prob. of 
Acceptance 
USP<711>
Pass 
Bergum 
95% 
n=24
Pass 
Bergum 
90% 
n=24
Pass 
Bergum 
95% 
n=12
Pass 
Bergum 
90% 
n=12
Pass 
Bergum 
95% 
n=6
Pass 
Bergum 
90% 
n=6
84.0 1.0 0.000 0.000 0.000 0.159 1.000 1.000 1.000 1.000 1.000 0.993 0.998
80.5 1.0 0.000 0.000 0.311 0.000 0.995 0.056 0.113 0.028 0.047 0.017 0.025
84.0 2.0 0.000 0.000 0.023 0.309 1.000 0.999 0.999 0.973 0.989 0.524 0.603
84.0 5.0 0.000 0.000 0.213 0.422 0.999 0.368 0.524 0.140 0.202 0.052 0.067
80.5 5.0 0.000 0.001 0.462 0.183 0.771 0.001 0.002 0.002 0.004 0.002 0.004
84.0 10.0 0.002 0.029 0.348 0.459 0.935 0.005 0.010 0.006 0.010 0.009 0.011
80.5 10.0 0.006 0.062 0.482 0.328 0.588 0.000 0.000 0.000 0.001 0.003 0.003
84.0 12.6 0.011 0.065 0.376 0.467 0.712 0.001 0.001 0.001 0.002 0.005 0.006
83.9 15.1 0.027 0.104 0.397 0.472 0.449 0.000 0.000 0.001 0.001 0.002 0.003
80.5 12.6 0.021 0.109 0.486 0.361 0.382 0.000 0.000 0.000 0.000 0.001 0.002
80.4 15.1 0.046 0.152 0.488 0.384 0.212 0.000 0.000 0.000 0.000 0.001 0.001
83.9 20.1 0.075 0.172 0.423 0.479 0.158 0.000 0.000 0.000 0.000 0.001 0.001
80.4 20.1 0.102 0.220 0.491 0.413 0.070 0.000 0.000 0.000 0.000 0.001 0.001  
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Table A1.4 Bergum Results for Uniform Distributions 
Distribution Mean Standard deviation Proportion<Q-25 Proportion<Q-15 Proportion < Q Proportion>Q+5 
UD8010000 89.99 5.78 0.000 0.000 0.000 0.750 
UD8010005 88.82 7.74 0.002 0.021 0.050 0.711 
UD801007,5 88.24 8.55 0.003 0.033 0.075 0.694 
UD8010010 87.67 9.24 0.004 0.044 0.100 0.675 
UD8010015 86.47 10.31 0.006 0.066 0.150 0.639 
UD8010020 85.29 11.22 0.009 0.089 0.200 0.601 
UD8010030 82.92 12.47 0.012 0.133 0.300 0.522 
UD8010040 80.60 13.15 0.016 0.176 0.400 0.451 
UD8010050 78.24 13.43 0.042 0.220 0.500 0.307 
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Table A1.4, continued. Bergum Results for Uniform Distributions 
Distribution 
Prob. of 
Acceptance 
USP<711> 
Pass 
Bergum 95% 
n=24 
Pass 
Bergum 
90% 
n=24 
Pass Bergum 
95% 
n=12 
Pass Bergum 
90% 
n=12 
Pass Bergum 
95% 
n=6 
Pass Bergum 
90% 
n=6 
UD8010000 1.000 1.000 1.000 0.774 0.887 0.184 0.228 
UD8010005 0.966 0.542 0.619 0.439 0.513 0.130 0.161 
UD801007,5 0.927 0.375 0.449 0.325 0.383 0.112 0.138 
UD8010010 0.882 0.244 0.307 0.232 0.276 0.095 0.120 
UD8010015 0.768 0.107 0.143 0.125 0.154 0.067 0.083 
UD8010020 0.624 0.037 0.053 0.062 0.078 0.047 0.059 
UD8010030 0.376 0.003 0.006 0.014 0.019 0.021 0.027 
UD8010040 0.198 0.000 0.000 0.002 0.003 0.008 0.011 
UD8010050 0.081 0.000 0.000 0.000 0.000 0.003 0.004 
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Table A1.5 Bergum Results for Bimodal Distributions  
Distribution Mean
Standard 
deviation
Proportion 
< Q-25
Proportion 
< Q
Proportion 
< Q-15
Prob. of 
Acceptance 
USP<711>
Pass 
Bergum 
95% 
n=24
Pass 
Bergum 
90% 
n=24
Pass 
Bergum 
95% 
n=12
Pass 
Bergum 
90% n=12
Pass 
Bergum 
95% 
n=6
Pass 
Bergum 
90% 
n=6
BD75853 80.00 5.83 0.0000 0.4695 0.0003 0.628 0.000 0.001 0.002 0.003 0.006 0.007
BD74863 79.99 6.71 0.0000 0.5008 0.0006 0.628 0.000 0.000 0.002 0.002 0.008 0.009
BD72883 80.01 8.54 0.0000 0.4999 0.0045 0.623 0.000 0.000 0.001 0.002 0.013 0.014
BD73873 79.99 7.61 0.0000 0.5000 0.0019 0.620 0.000 0.001 0.001 0.002 0.012 0.013
BD734873 79.99 7.84 0.0000 0.4859 0.0114 0.617 0.000 0.001 0.002 0.003 0.011 0.012
BD713883 79.49 9.01 0.0000 0.5013 0.0114 0.517 0.000 0.000 0.001 0.002 0.012 0.013
BD703883 78.99 9.48 0.0000 0.5018 0.0245 0.422 0.000 0.000 0.001 0.001 0.013 0.014
BD693883 78.49 9.96 0.0000 0.5019 0.0468 0.322 0.000 0.000 0.000 0.001 0.013 0.013
BD683883 77.99 10.44 0.0000 0.5020 0.0798 0.162 0.000 0.000 0.001 0.001 0.013 0.014
BD673883 77.50 10.93 0.0000 0.5023 0.1263 0.103 0.000 0.000 0.000 0.000 0.012 0.013
BD643883 75.99 12.37 0.0005 0.5020 0.3127 0.019 0.000 0.000 0.000 0.000 0.012 0.013
 
